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Modulation of innate immune cells by the NAD
+
 pathway 
Abbas Jawad Al-Shabany 
Abstract 
NAD
+
 has previously been shown to regulate TNF-α synthesis and TNF-α has been shown to 
regulate NAD
+
 homeostasis, thus providing a link between a pro-inflammatory response and 
redox status. Despite the well-established link between TNF-α and NAD+, the mechanism as to 
how NAD
+
 modulates TNF-α release is not fully understood. To achieve this, this link was 
investigated using THP-1 cell line-derived M1-like (pro-inflammatory) and M2-like (anti-
inflammatory) macrophages using PMA and vitamin D3, respectively. NAD
+
 levels differed 
markedly between M1-like and M2-like macrophages, with M1-like having much higher basal 
levels. LPS increases NAD
+
 levels and TNF-α secretion in M1-like but not M2-like cells. In an 
effort to investigate the source of the NAD
+
 levels and the association with TNF-α release, three 
inhibitors (FK866, DPI and 1D-MT) were used. Following stimulation, NAD
+
 is produced 
partially via NADH oxidation and partially through NAD
+
 synthesis. Both DPI and FK866 
reduced TNF-α secretion with DPI showing the largest effect. The two phenotypes showed 
differential profiles of NAD
+
 homeostasis gene expression compared with each other and with 
the progenitor THP-1 in both resting and activated states. While IDO expression was induced in 
both phenotypes, CD38 and NAMPT were upregulated in M1-like cells whereas CD157 was 
upregulated in M2-like cells. LPS induced M1-like cells to up-regulate CD38 and CD157 and 
down-regulate NAMPT unlike M2-like cells which up-regulated NAMPT and CD38 and down-
regulated CD157. M1s increased glycolysis activity whereas conversely, decreased oxidative 
metabolism during LPS stimulation confirming previous findings showing that classical M1s are 
predominantly glycolytic. Collectively, these data suggest that the relationship between NAD
+
 
levels and pro-/anti-inflammatory responses is complex and may be regulated via a combination 
of pathways. These findings open the possibility of pharmacological manipulation of NAD
+
 
synthesis as a way of selectively modulating macrophage responses which may be beneficial for 
the development of therapeutics targeting inflammatory diseases. 
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CHAPTER 1 
GENERAL INTRODUCTION 
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1. Introduction 
1.1 Innate immune response and pathogen recognition 
The innate immune response constitutes the first line of the host defence and therefore it is 
responsible for triggering the pro-inflammatory response in the early phase of infection 
against an invading pathogen (Medzhitov and Janeway, 2000; Warrington et al., 2011). The 
innate response is comprised of several defensive barriers including mechanical, chemical, 
physiological and cellular barriers, against invading pathogens (Medzhitov and Janeway, 
2000; Basset et al., 2003). The chemical defence elements include cytokines, chemokines, 
anti-microbial peptides and pattern recognition receptors that could be soluble or cell-
associated (Medzhitov and Janeway, 2000; Basset et al., 2003). The mechanical elements 
represent the physical barriers including skin and mucosal secretions (by mucosal surfaces) 
along with physiological elements including cilia action (by ciliated respiratory cells), low 
pH and fever (Basset et al., 2003). The cellular defence mechanism is represented by 
epithelial cells, mast cells, antigen presenting cells (APCs) including dendritic cells (DCs), 
phagocytic granulocytes and macrophages (MФs; Matzinger, 2002; Basset et al., 2003; 
Iwasaki and Medzhitov, 2004). These cells play an important function in the innate immune 
response via (i) pathogen recognition (ii) recruiting effector cells to the site of inflammation 
via production of chemokines and finally (iii) phagocytosis to digest and engulf pathogens 
(Si-Tahar et al., 2009; Jounai et al., 2012). Indeed, the innate responses, are multi-cellular in 
all organisms, facilitating immune defence via recognition of a variety of microbial 
components known as pathogen associated molecular patterns (PAMPs), via a set of a 
specific pattern recognition receptors (PRRs) including Toll-like (TLRs) and NOD 
(nucleotide-binding oligomerization domain)-like receptors (NLRs; Iwasaki and Medzhitov, 
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2010; Jounai et al., 2012). PRRs play important functions in autophagy, phagocytosis and 
immune complements to limit and eliminate microbes early on during infection (Basset et al., 
2003). Examples of PRRs include TLRs and NLRs (Medzhitov, 2001; Gordon, 2003; Van 
Ginderachter et al., 2006; Kabelitz and Medzhitov, 2007; Iwasaki and Medzhitov, 2010; 
Jounai et al., 2012). TLRs consist of a group of 10 members (TLR 1 to 10) in humans 
(O’Neill et al., 2006), while the other family is composed of NODs, leucine-rich-repeat-
containing proteins, IL-1β-converting enzyme (ICE)-protease activating factor (IPAF) and 
neuronal apoptosis inhibitor factors (NAIPs) (Ting et al., 2006). Each of these family 
receptors is triggered by specific microbial structures initiating a series of complex signalling 
reactions that lead to activation of a range of immune cells that help in orchestrating specific 
and non-specific responses. One of these cell types is the macrophage (Forman and Torres, 
2001). Activated macrophages are able to produce pro-inflammatory cytokines, chemokines, 
and reactive oxygen and nitrogen species (ROS/RNS; Si-Tahar et al., 2009). While the 
immune response is essential for host protection, an improper response can cause damage to 
the host itself (Joos and Tamm, 2005). Given that macrophages play a key role in developing 
optimal response, it is crucial to control the inflammatory responses of macrophages. 
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1.1.1. Macrophages 
Macrophages are heterogeneous populations of APCs that exist in most tissues and are 
involved in the recognition and elimination of invading pathogens and toxic molecules. MФs 
first were described by Elie Metchnikoff in 1882, and may be described as mononuclear 
phagocytic immune cells that represent a crucial component of initial and adaptive immune 
responses (Cavaillon, 2011). MФs originate mainly from the circulating monocyte precursors 
which migrate from the blood vessels and through the endothelium; once they arrive in the 
tissue they differentiate into macrophages in response to infection and/ or inflammatory 
stimuli (Hume, 2006). Indeed, it is considered that the main role of monocyte precursors is to 
renew tissue macrophage. Tissue MФs represent a subpopulation of specialised-tissue 
resident macrophages that are distributed throughout the body, involved in homeostatic 
function, such as Kupfer cells in the liver, alveolar MФs in the lung, microglial MФs in the 
brain and osteoclasts in bone (Table 1.1; Gordon and Taylor, 2005; Lambrecht, 2006; 
Strauss-Ayali et al., 2007; Mosser and Edwards, 2008). Given that macrophages exist almost 
in every tissue and organ in the body, it is perhaps not surprising that they are involved in 
combatting a variety of chronic diseases. An example of macrophage influence in pathology 
is cancer, where MФs are recruited to the tumour microenvironment. Here they are referred 
to tumour associated macrophages (TAMs). It has been shown that TAMs play key roles in 
promoting tumour progression and malignancy, for instance, in promoting angiogenesis 
(Bingle et al., 2006; Mantovani et al., 2006). Indeed, there is a correlation between TAMs 
and poor prognosis in almost 80% of cancer cases in humans (Bingle et al, 2002). Other 
examples of their involvement in autoimmune diseases include (i) Crohn's disease, an 
infectious inflammatory autoimmune disease, which is associated with the upregulation of 
pro-inflammatory cytokines, IL (interleukin)-12 and IFN (interferons) -γ, which is linked to 
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the pro-inflammatory M1-like environment (Bouma and Strober, 2003; Foey, 2015) and (ii) 
MФs are also correlated with progression of acute and chronic rheumatoid arthritis (RA), 
sterile inflammatory autoimmune disease, where MФs are activated in numerous inflamed 
synovial membranes (Mulherin et al., 1996; Kinne et al., 2000). Indeed, pro-inflammatory 
M1s have been shown to play a pivotal role in the pathology of RA via TNF-α regulated ROS 
production (Miesel et al., 1996). Therefore, pharmacological modulation of MФ immune 
function might be a useful strategy for targeting disease-associated inflammation, for 
instance, rheumatoid arthritis. Thus, the diversity of macrophage specialization and 
distribution reflects the heterogeneity of macrophage subsets allowing a wide variety of 
relevant homeostatic functions (Gordon and Taylor, 2005). Indeed, MФs are involved in a 
range of protective and pathogenic mechanisms from microbial killing, inflammatory (anti-
tumoral responses), anti-inflammatory process (pro-tumoral responses), and wound healing to 
tissue repair, as well as antigen processing and presentation (Vega and Corbí, 2006). The 
variety in these functions is defined by a range of distinct macrophage subpopulations which 
has been suggested to be determined by the impact of several factors including heterogeneity, 
reprogramming, differentiation and microenvironment (Foey, 2015). In general, macrophages 
are categorized by two distinct forms, that reflect the activation and differentiation state, 
known as M1 (classical) and M2 (alternative) macrophages which are paradigm of Th1/Th2 
(T helper 1/2) polarization (Mills et al., 2000). Given macrophage heterogeneity, it is not 
surprising that macrophages show plasticity and fluidity, and hence, give rise to a sliding 
scale of functionally polarized subsets in response to environmental stimuli (Mantovani et al., 
2004). 
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Tissue  Macrophage  Function 
Bone Osteoclast  Bone remodelling and providing a stem cell 
niche 
Bone marrow  Erythropoiesis 
Intestine Crypt macrophage Immune surveillance 
Ovary Macrophage  Steroid hormone production and ovulation 
Pancreas Macrophage Islet development 
Eye Macrophage Vascular remodelling 
Epidermis Langerhans cell Immune surveillance 
Lung Alveolar  Immune surveillance 
Brain Microglial Neuronal survival and repair after injury 
Uterus Uterine DC Angiogenesis and decasualization 
macrophage Cervical ripening 
 
Table 1.1 Tissue resident macrophages (MФs). MФs are found in different tissues whereby they can 
participate in a broad range of specialised functions according to tissue localisation. Adapted and 
modified from Pollard (2009). 
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1.1.2. Macrophage polarisation 
Macrophages belong to a heterogeneous myelomonocytic lineage that can be polarised in 
response to a variety of local environmental signals (Mantovani et al., 2004). These include 
cytokines, bacterial components and chemokines that have been recognised to play a major 
role in the orchestration of the activation of functional effector phenotypes. Based on this, 
M1s, referred to as classical activation, are induced by IFN-γ alone or in combination with 
classical stimuli, such as lipopolysaccharide (LPS), a component of Gram-negative bacteria, 
or with TNF-α. In addition, classical M1s can also be induced when interaction occurs with 
phorbol myristate acetate, PMA (Kielian and Cohn, 1981; Green and Phillips, 1994). 
Granulocyte macrophage colony stimulation factor (GM-CSF) is another factor which was 
also shown to enhance the differentiation of M1s in a model of human monocytes (Finnin et 
al., 1999). On the other hand, M2s are induced by IL-4 in concert with IL-13 signal that is 
collectively known to derive M2-like mediated tumour growth and progression (Anderson 
and Mosser, 2002; Mantovani et al., 2002; Gordon, 2003; Mosser and Edwards, 2008).  
M1s reveal enhanced anti-microbial capacity and secrete large quantities of pro-inflammatory 
cytokines (TNF-α, IL-1β, IL-6, IL-18 and IL-23), and express chemokines (CXCL 1, 2, 3, 5, 
8, 10, CCL3, 4, 5, 11, 17 and 22; Figure 1.1). M1s are also characterized by the expression of 
inducible nitric oxide synthase (iNOS) which is involved in L-arginine catabolism resulting 
in nitric oxide (NO) production that is known as a major mediator of macrophage cytotoxicity 
(Nathan and Hibbs, 1991). Indeed, iNOS expression was shown to be correlated with the 
antimicrobial activity effects of NO (Granger et al., 1988). Interestingly, iNOS mRNA 
translation was inhibited by the induction of arginase-mediated arginine depletion (Lee et al., 
2003). In addition, macrophages are known to enhance production of ROS such as 
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superoxide anions and hydroxyl radicals (Sindrilaru et al., 2011). Toxic intermediates and 
ROS are considered to be important markers of classical activation and M1s use them to 
increase their killing activity during the early response against an invading pathogen. It has 
been suggested that TLRs, in particular TLR 2, 4 and 5, which directly link to NF-B 
(nuclear factor-kappa B) activation and pro-inflammatory cytokine secretion, represent a 
distinct features in LPS-induced M1s (Bosisio et al., 2002; Van Ginderachter et al., 2006; 
Foey, 2015) On the other hand, IL-13 and IL-4 mediation of M2 activation was shown to 
counteract these receptors (Bosisio et al., 2002; Nau et al., 2002; Gordon, 2003; Van 
Ginderachter et al., 2006). Both of the family receptors (TLRs/NLRs) constitute a key role in 
the recruitment of immune cells such as neutrophils and macrophages (Fukata et al., 2009). 
M1 activation is also characterised by upregulation of the expression of MHC II (HLA-DR, 
surface molecule), co-stimulatory B-7.2 (CD 86; cluster differentiation 86) and IL-12 
enhanced the ability to activate Th1-mediated responses to resident pathogens and to develop 
anti-tumour protection (Louis et al., 1998; Holscher et al., 2001; Mosser, 2003). This 
upregulation in expression accompanied by IL-23, which is produced by M1s, supports the 
differentiation and function of Th17 cells (Stockinger and Veldhoen, 2007). In general, M1s 
can be identified by the expression of matrix metalloproteinases (MMP-1,-2,-7,-9 and -12) 
under inflammatory conditions (Gibbs et al., 1999; Van Ginderachter et al., 2006). Finally, 
M1 polarisation can also be defined by transcription factors such as STAT1 and NF-B 
involved in the induction of pro-inflammatory cytokine expression (Liu et al., 2008). 
Functionally, classically activated macrophages participate in micro pathogen killing, tissue 
damage and pro-inflammatory responses via deriving Th1 response (Mills et al., 1992&2000; 
Krausgruber et al., 2011). 
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Conversely, M2s (alternative activation), are characterised by their immune regulatory, anti-
inflammatory and tissue repair abilities as well as tumour promotion and angiogenesis via 
inhibition of Th1 inflammatory responses and stimulation of the Th2-mediated anti-
inflammatory response (Anderson and Mosser, 2002; Lopez-Castejon et al., 2011; Takeuch 
and Akira, 2011). It has been shown that M2s exhibit a distinct activation profile with 
abundant expression (Mantovani et al., 2002; Gordon, 2003) of mannose receptor (MR, 
CD206) as a distinct marker of the anti-inflammatory phenotype (Figurer 1.1). Upon 
activation with IL-4, other important markers (arginase I, Arg
+
 I) have been shown to be 
upregulated in M2s (Gordon, 2003; Gordon and Taylor, 2005) resulting in L-arginine 
degradation into ornithine and urea which is further catabolised into polyamines and proline 
(Gordon, 2003; Gordon and Taylor, 2005; Classen et al., 2009). Arginase has been shown to 
be involved in tumour invasion via producing myeloid immune suppressor cells in cancer 
patients (Zea et al., 2005). These play a key role in protection against diseases allowing 
immune inhibitory mechanism (Highfill et al., 2010). Additionally, the cytokine profile has 
also been recognised as a marker of macrophage polarization. As such, M1s are characterised 
by IL-12
high
 and IL-10
low
 whereas M2 macrophages, dampen pro-inflammatory cytokines and 
thus they are characterised by IL-10
high
 and IL-12
low
 (Mantovani et al., 2004). In similar way 
to 1L-4 and 1L-13, alternative activation is shaped by exposure to IL-10, M-CSF, 
glucocorticoids or other steroid (vitamin D3) signals (Goerdt and Orfanos, 1999; Mantovani 
et al., 2004). Finally, considering the plasticity of M2 macrophages which have been 
described to be polarised by activator stimuli and differentiation factors, alternative M2s can 
be subdivided into three forms: M2a are induced by exposure to IL-4 or IL-13 and secretes 
TGF-β (tumour growth factor- β), IL-1R and IL-1ra, while expressing CCL-17, 18, 22 and 24 
(in Figure 1.1). In contrast, M2b macrophages are induced by immune complexes (IC) and 
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agonists of TLRs or IL-1β receptors, secrete cytokines such as TNF-α, IL-8 and IL-1β and 
express CCL-1 (Figure 1.1). Finally immunosuppressive M2c are induced by IL-10 and TGF-
β or glucocorticoids, secrete TGF-β and IL-23lo and express CCL-16 and 18, as well as CXC-
18. In addition, M2b and M2c have been described as regulatory macrophages as in figure 1.1 
(Gordon, 2003; Martinez et al., 2009). 
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Figure 1.1 Differentiated macrophages exhibit differential profiles of cytokine gene expression, receptor markers and immune function. Proposed model of 
differentiation macrophages in which a range of functional phenotypes effector subsets exist. M1s are induced by LPS and IFN-γ or TNF-α and differentiated 
by M-CSF, whereas regulatory or anti-inflammatory M2 phenotypes are subdivided to accommodate similarities and differences between interleukin-4 (IL-
4/1L-13): (M2a), immune complex/TLR ligands (M2b), and IL-10/glucocorticoids (M2c). This diagram is adapted and modified as required from Liu and 
Yang (2013) and Foey (2015). 
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1.1.3. Macrophages and TNF-α signalling pathways 
Macrophages are considered to be the major producer of a potent pleiotropic pro-
inflammatory cytokine, TNF-α and, somewhat conversely, they are themselves highly 
sensitive to it (Vassalli et al., 1992; Parameswaran and Patial, 2010). Indeed, TNF-α has been 
shown to play a central role in regulating the inflammatory responses of macrophages 
(Parameswaran and Patial, 2010). In general, activation of macrophages and TNF-α 
production occur via a range of activatory signals one of which is the LPS-mediated 
signalling pathway (Sweet and Hume, 1996; van der Bruggen et al., 1999). LPS signalling 
occurs via LPS-binding protein (LBP) in plasma (Ulevitch and Tobias, 1995), thus, the 
LBP/LPS complex binds the surface bound receptor of 14 (CD14) on monocyte/macrophage, 
as shown in figure 1.2 (Tobias et al., 1993; Delude et al., 1994). LPS is then delivered to a 
signalling transmembrane molecule, TLR4 (Beutler and Rietschel, 2003). The TLR4/LPS 
binding leads to the activation of various intracellular pathways such as the NF-B pathway 
that is activated via MyD88 and IRAK, which mediates the phosphorylation and 
ubiquitination of IBα. As a consequence, IBα is degraded and the NFB is released (Chen, 
2005; Kawai and Akira, 2007; Karin, 2009). The active NF-B (p50/p65) is finally 
translocated into the nucleus (Sun and Ley, 2008; Vallabhapurapu and Karin, 2009). 
Consequently, LPS-induced NF-B activation enhances TNF-α gene expression in 
macrophages (Shakhov et al., 1990). After these signalling events, a pro forma type II 
transmembrane TNF-α with a molecular mass of 26 KDa is produced (Beutler and Cerami, 
1989). This form exists as a membrane bound precursor that can be proteolyticaly cleaved by 
TACE (TNF-alpha-converting enzyme), a disintegrins and metalloproteinases (ADAMs), to 
yield a secreted 17 KDa mature TNF-α (Beutler and Cerami, 1989; Black et al., 1997; Moss 
et al., 1997; Peschon et al., 1998). In addition, the induction of TNF-α expression is also 
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triggered via networks of signalling pathways such mitogen-activated protein kinase (MAPK) 
pathways involving extracellular signal-regulated kinases (ERK 1, 2), p38 and c-Jun N-
terminal kinase (JNKs) as well as other transcription factor such as activated protein-1 (AP-1; 
Tsushima and Mori, 2001; Beutler and Rietschel, 2003; Sun and Ley, 2008). Activation of 
JNKs (Swantek et al., 1997), P38 and ERK1, 2 (Geppert et al., 1994; Lee and Young, 1996) 
in RAW 264.7 is required for LPS-induced TNF-α production. Additionally, the NF-B can 
also be activated independently of the MyD88 activation pathway via protein kinases C (PKC 
α and β) in response to LPS and PMA stimulation (Martin et al., 2003; Foey and Brennan, 
2004). Despite this, TNF-α is crucial for macrophage immune function and host defence, 
with uncontrolled TNF-α production sometimes leading to damaging to host tissue 
(Parameswaran and Patial, 2010). For instance, excessive production for TNF-α was shown 
to have a negative impact on the pathology of inflammatory conditions as in autoimmune 
disease as prolonged TNF-α secretion lead to tissue damage in rheumatoid arthritis (Drexler 
et al., 2008) or excessive response to infectious agents in sepsis (Conte et al., 2006; Smith et 
al., 2006). Therefore, a regulatory mechanism must evolve to dampen the excessive 
production of pro-inflammatory TNF-α which may help in creating therapeutic options for 
the disease-associated inflammation. 
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Figure 1.2 The TNF-α signalling pathway. This diagram shows the recognition process of the 
bacterial component LPS and the subsequent release of TNF-α that follows LPS stimulation. LPS 
sensing occurrs via LPS-binding protein (LBP) and the monocytic receptor, CD14. This binding, in 
turn, triggers signalling pathways for induction of the gene encoding TNF-α (nuclear factor-kappaB, 
NF-B) and protein kinases, resulting in regulation of TNF-α synthesis. IKBα is phosphorylated and 
ubiquitinated by IKB kinase. IKBα is then degraded to release NF-kB that is finally translocated into 
the nucleus. TLR4, toll-like receptor; IKK, Ikappa B kinase, LPS, lipopolysaccharide; MAPK, 
mitogen-activated protein kinase; ERK 1 and 2, extracellular signal-regulated kinases; JNKs, c-Jun N-
terminal kinase, AP-1; activator protein-1. This diagram was adapted and modified as required from 
Beutler and Rietschel (2003). 
 
 
 15 
 
1.2 NAD
+
 homoeostatic enzymes and the inflammatory response 
It is well known that inflammatory responses are tightly linked to NAD
+
 homeostasis 
pathways. NAD
+
 homeostasis is a complex system including many proteins mediating the 
biosynthesis and consumption of NAD
+
 (nicotinamide adeninedinucleotide; Houtkooper et 
al., 2010). In fact, NAD
+
 and its related proteins are considered as key elements of a variety 
of signalling pathways (Berger et al., 2004; Belenky et al., 2007; Magni et al., 2008; 
Houtkooper et al., 2010). Although NAD
+
 has long been known to play an important role as 
redox cofactor in oxidation-reduction reactions (Ziegler, 2000), it is also involved in immune 
transcriptional and translational regulation due to its co-enzymatic activity (Chiarugi et al., 
2012). In innate immune cells, for example, NAD
+
 mediates control of TNF-α production via 
NAD
+
-dependent sirtuin (SIRT) deacetylase activity (van Gool et al., 2009). Furthermore, it 
has been shown that the phosphorylation of NAD
+
 via NAD kinase (NADK) activity results 
in the generation of NADP
+
 (nicotinamide adeninedinucleotide phosphate) which is 
important for the production of ROS and oxidative burst for immune defence (Chiarugi et al., 
2012). In addition, NAD
+
 is vital not only for signalling-mediated immune function, but also 
for energy production. Thus, NAD
+
 serves as a cofactor for redox reactions involved in 
glycolysis, the trichloroacetic acid cycle (TCA), OXPHOS (oxidative phosphorylation) and 
the catabolism of carbohydrates and fat (Bogan and Brenner 2008; Garten et al., 2009). 
Therefore, NAD
+
 has emerged as an important link between regulatory processes and cellular 
bioenergetics redox metabolism (Chiarugi et al., 2012). Since NAD
+
 is required for metabolic 
pathways, it is perhaps not surprising that NAD
+
 levels have also been linked to immune 
function in macrophages. Also, NAD
+
 can serve as a metabolic factor for other cellular 
processes, including protein transcription, DNA repair, G-protein coupled and intracellular 
calcium signalling (Bogan and Brenner 2008; Garten et al., 2009). It is now accepted that 
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there is a link between NAD
+
 homeostasis, metabolism and immune response. Given this 
link, an interest in the pharmacological modulation of NAD
+
 has grown as a method for 
regulating the NAD
+
 levels. In particular, focus has grown on the modulation of NAD
+
 
homeostasis as a way of decreasing intracellular NAD
+
 levels, thus reducing the activity of 
NAD
+
-dependent immune function, particularly, in MФs. In general, intracellular NAD+ can 
be produced and consumed via networks of different pathways. For NAD
+
 generation, three 
different pathways and precursors are involved: nicotinamide (Nam) and nicotinic acid (NA) 
via NAMPT (nicotinamide phosphoribosyl transferase) the salvage pathway (Jacobson et al., 
1995; Rongvaux et al., 2003; Magni et al., 2008), nicotinamide riboside (NR) via 
nicotinamide riboside kinase pathway (NRK; Bieganowski and Brenner, 2004) and finally 
tryptophan (TRP) via the indole amine 2,3-dioxygenase (IDO) pathway (de novo pathway; 
Yamazaki et al., 1985; Kudo and Boyd, 2000). These are shown in figure 1.3. 
1.2.1 NAD
+
 recycling pathways and the inflammatory response 
Replenishment of NAD
+
 is essential to maintain appropriate immune responses with NAD
+
 
generation enzymes playing key roles in immune regulatory processes, in particular, in the 
regulation of TNF-α synthesis (van Gool et al, 2009). Indeed, the depletion of NAD+ pool, 
via suppression NAMPT-mediated NAD
+
 biosynthesis by FK866, a well-known inhibitor of 
the NAD
+
 recycling pathway, decreased TNF-α levels in THP-1 cells, human monocyte and 
macrophages (Nau et al., 2002; Hasmann and Schemainda, 2003; Iqbal and Zaidi, 2006; Li et 
al., 2008; Friebe et al., 2011; Schilling et al., 2012) during LPS stimulation. Since adequate 
NAD
+
 levels are required for optimal TNF-α production (van Gool et al., 2009), the immune 
cells need to maintain the NAD
+
 pool in order to support immune signalling pathways as well 
as other NAD
+
-dependent signalling pathways. To achieve this, NAD
+
 can be synthesised, 
via the salvage pathway, using a range of dietary precursors including NA, NAM and/ or 
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nucleosides, NR and NAR (NA riboside). Also, NAD
+
 can be synthesised de novo from 
tryptophan via the IDO-kynurenine pathway (Braidy et al., 2011). The dietary deficiency of 
these precursors is associated with human diseases like pellagra; patients with pellagra 
ultimately die as a result of diarrhoea, dermatitis, and dementia (Hegyi et al., 2004), although 
the dietary supplementation of these precursors however can easily treat this disease, thus 
confirming their dietary importance (Houtkooper et al., 2010). It is worth noting that the 
conversion of tryptophan in NAD
+
 de novo biosynthesis is limited to the liver under 
conditions of stress and thus tryptophan alone is insufficient to maintain NAD
+
 levels (Magni 
et al., 2004). This could indicate that the salvage pathway from the two precursors (NAM and 
NA) is the main source of NAD
+
 generation in mammals. Unlike NAM, NA content is low 
(Kirkland, 2009) in mammals, due to its rapid excretion, therefore the utilization of NA in 
NAD
+
 salvage pathway is limited compared to that of NAM. Indeed, in humans, NAM is the 
preferable metabolite in NAD
+
 synthesis (Olesen et al., 2008 & 2010; Watson et al., 2009). 
Intriguingly, NAM was found to act as anti-inflammatory agent via, in vitro, inhibiting the 
pro-inflammatory mediators such as TNF-α, IL-6 and IL-1β synthesis (Ungerstedt et al., 
2003). Also, NAM has been shown to inhibit intercellular adhesion molecule-1 (ICAM-1) 
expression in a model of cultured human thyroid cells (Hiromatsu et al., 1993) and also 
prevent IL-1β effect mediated nitric oxide (NO) production in rat islets of Langerhans 
(Andersen et al., 1994). The pathway starts with NAM, allowing NAD
+
 synthesis, which is 
catalysed by NAMPT, the rate limiting enzyme of NAD
+
 salvage pathway (Figure 1.3). 
NAMPT was first identified as pre-B cell colony-enhancing factor (PBEF), and it has this 
name due to its role in maturation of B-cell precursors (Nau et al., 2002). It has been 
documented that expression of NAMPT is induced in primary macrophages (Iqbal and Zaidi, 
2006). The induction of NAMPT expression was also shown during stimulation with 
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inflammatory stimuli in various immune cells including monocytes, neutrophils and dendritic 
cell  that is reported to rely mainly on the NAMPT salvage pathway for NAD
+
 generation 
(Van Beijnum et al., 2002; Revollo et al., 2004; Busso, 2008; Luk et al., 2008; Rongvaux et 
al., 2003&2008). 
The elevated levels of NAMPT expression might reflect a critical role for this enzyme in 
immune regulatory mechanisms, in activated immune cells, via the provision of a sufficient 
intracellular NAD
+
 pool required for NAD
+
-dependent enzyme-mediated immune signalling 
(van Gool et al., 2009). Thus, NAMPT has been suggested to induce myeloid differentiation 
(Skokowa et al., 2009), via up-regulation of the differentiation factor GM-CSF in a sirtuin-
dependent pathway. Similarly, NAMPT was also found to increase specific pro-inflammatory 
production of cytokines such as TNF-α. Decreasing NAD+ levels, through inhibition of 
NAMPT attenuates LPS-stimulated TNF-α levels in THP-1 cells and human monocytes 
(Busso et al., 2008; van Gool et al., 2009; Schilling et al., 2012). Furthermore, it has been 
reported that NAMPT inhibition led to a decrease in other inflammatory mediators such as 
TNF-α, IL-6 and IL-1β levels in different inflammatory settings (Busso et al., 2008; van Gool 
et al., 2009; Schilling et al., 2012). Together, these observations suggest that a link exists 
between NAD
+
 biosynthesis, intracellular NAD
+
 levels, and pro-inflammatory responses in 
macrophages, offering a potential therapeutic target for modulation of immune inflammatory 
effector functions. In addition to intracellular localization (iNAMPT), NAMPT has been 
found to reside extracellularly (eNAMPT) but with no enzymatic activity (Li et al., 2008; 
Hara et al., 2011). Also known as visfatin, eNAMPT is secreted into the extracellular 
environment by visceral fat tissues (Figure 1.3; Fukuhara et al., 2005). Interestingly, 
eNAMPT was shown to be highly expressed in diabetes and obesity with a role mimicking 
the hormonal insulin effect, as this protein is able to bind to the insulin receptor at a different 
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site to that of insulin (Arner, 2006; Stephens and Vidal-Puig, 2006). It seems that eNAMPT 
exhibits its immune regulatory functions as a cytokine, but not as an enzyme, as mentioned 
earlier for iNAMPT, by inducing pro-inflammatory responses in macrophages and 
neutrophils  
The other two niacin precursors are converted by two distinct salvage pathways. The first 
pathway of NAD
+
 biosynthesis, known as the Preiss-Handler pathway (Preiss and Handler, 
1958), is comprised of the conversion of NA into NAMN (NA mononucleotide) by nicotinic 
acid phosphoribosyl transferase (NAPRT). This pathway was shown to be well conserved 
and also highly active in bacteria (Preiss and Handler, 1958; Houtkooper et al., 2010). 
Recently, a second pathway, derived from nicotinamide riboside has also been described; it 
starts with the phosphorylation of NR to NMN (Figure 1.3), a process which is catalysed by 
NRK. This enzyme exists in two isoforms: the ubiquitously expressed NRK1 and the 
localized NRK2 (Bieganowski and Brenner, 2004). It has been suggested recently that this 
pathway appears to be highly conserved and active in both yeasts and humans (Bieganowski 
and Brenner, 2004). Beyond the salvage pathway, NAD
+
 can also be generated de novo from 
tryptophan via the IDO pathway (Figure 1.3). In this pathway, IDO is the rate-limiting 
enzyme that catalyses the oxidative catabolism of the essential amino acid tryptophan along 
the kynurenine (KYN) pathway, through a series of enzymatic reactions, into quinolinic acid 
(QA) which, in turn, is converted to NAD
+
 (Orabona et al., 2006; Pallotta et al., 2011). 
Similarly, the oxidative catabolism of TRP is also catalysed by the TRP dioxygenase (TDO) 
enzyme (Figure 1.3; Opitz et al., 2011b; Pilotte et al., 2012). While TDO is expressed in the 
liver, IDO is expressed in most body tissues (Revollo et al., 2004). IDO expression is induced 
by classical inflammatory stimuli molecules such as LPS in an autocrine dependent or a 
manner independent of IFN-γ regulated by NF-B (Grohmann et al., 2003; Mellor and Munn, 
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2004). This enzyme was shown to be highly upregulated by certain professional APCs, often 
macrophages and DCs, in response to pro-inflammatory stimuli, for which two related but 
distinct enzymes have been described, namely IDO1 and IDO2 (Ball et al., 2007; Metz et al., 
2007). IDO activity has been shown to modify both the innate and the adaptive immune 
system (Taylor and Feng, 1991) via two main mechanisms. The first proposed mechanism is 
centred around the fact that IDO-mediated tryptophan depletion results in starvation of the 
cell microenvironment (Orabona et al., 2006) via the action of IDO that might directly inhibit 
T-cell proliferation in different inflammatory settings (Mellor and Munn, 1999; Frumento et 
al., 2002). Several studies on DCs have revealed that IDO expression is required as a co-
stimulatory signal with B7 ligation leading to enhanced T regulatory cells (Treg) cells that is 
known to mediate immune modulatory effects (Grohmann et al., 2003). This might suggest 
an important role for IDO expression in regulating the ability of DCs to regulate T-cell 
associated immune responses (Mellor, 2005). Also, it is documented that IDO upregulation in 
DCs inhibits Th1 cell responses (Grohmann et al., 2003). Thus, others have reported that Th1 
cells are activated by inhibiting IDO function via the use of 1-methyl tryptophan as a potent 
inhibitor for IDO enzymatic activity (Kwidzinski et al., 2005). This might suggest that innate 
immune cells expressing IDO might have an impact on the balance of Th1/Th2 responses. 
The second proposed mechanism is the ability of IDO to produce downstream immune 
regulatory and cytotoxic intermediates (Stone and Darlington, 2002), such as kynurenine 
metabolites, which exert their effects on tissue microenvironments, suppressing cell 
activation and proliferation (Opitz et al., 2011b). IDO is highly expressed by a large range of 
tumour cells such as acute myeloid leukaemia (AML) cells and therefore tryptophan-
degradation mediates kynurenine production resulting in regulating T-cell responses in a way 
to enable effective tumour evasion of host immune defences (Watanabe et al., 1980). 
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Additionally, IDO plays a key role in mediating the flux between pathways that lead to pro-
/anti-inflammatory cytokine production (Pilotte et al., 2012). In general, the NAD
+
 
biosynthesis pathways, from all known precursors, share one major step which is common to 
all pathways, that is the formation of the mononucleotides, NMN or NAMN (Chiarugi et al., 
2012). This step is facilitated by nicotinamide mononucleotide adenylyl transferases 
(NMNAT), which mediate the reaction between AMP (adenosine monophosphate, the 
adenylate moiety of ATP, adenosine triphosphate ) and pyridine mononucleotide (Figure 1.3) 
allowing NAD
+
 generation from NMN or NA adenine dinucleotide (NAAD) from NAMN 
(Chiarugi et al., 2012). Interestingly, three mammalian NMNAT isoforms have been 
described, each having a distinct tissue distribution and cellular location (Berger et al., 2005; 
Lau and Ziegler, 2009). Of the three isoforms, only one resides in the mitochondria while the 
other two isoforms are exclusively located in the nucleus (NMNAT1) or cytosol (NMNAT2), 
respectively (Nikiforov et al., 2015). It has been reported that the distribution of these 
isoforms are pronounced in wide range of tissue including brain, heart, pancreasand skeletal 
muscle as well as, although to a lesser degree, the thymus and tumour tissues (Emanuelli et 
al, 2001; Lau and Ziegler, 2009). Given the key role of NMNAT in NAD
+
 formation, their 
pharmacological targeting could be relevant to NAD
+
-depleting therapeutic strategies 
(Chiarugi et al., 2012). Finally, the formation of NAD
+
 is carried out by NAD
+
 synthetase 
(NADs) via the amidation of the nicotinic acid moiety of NAAD using glutamine as a donor 
of NH2 groups (Nikiforov et al., 2015). It is now accepted that the involvement of NAD
+
 
biosynthesis in modulation of multiple immune regulatory responses might account for 
NAD
+
 availability. Indeed, NAD
+
 can act a substrate for a series of NAD
+
-consuming 
enzymes such as sirtuin and CD38 (ADP-ribosyl cyclase; Figure 1.3) which have important 
role in inflammatory response regulation in immune cells. 
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Figure 1.3 The NAD
+
 homeostasis pathways. Tryptophan (TRP), nicotinamide (NAM), nicotinic acid 
(NA), nucleosides NAM riboside (NR) and NA riboside (NAR), quinolinic acid (QA), NA 
mononucleotide (NAMN), nicotinamide mononucleotide (NMN), QA phospho ribosyl transferase 
(QAPRT), nicotinamide phospho ribosyl transferase (NAMPT), nicotinic acid phospho ribosyl 
transferase (NAPRT), extracellular NAMPT (eNAMPT), nicotinamide riboside kinases (NRK), NMN 
adenylyl transferases (NMNAT), NAD
+ 
synthetase (NADs), NAD kinase (NADK), O-acetyl-ADP 
ribose (OAcADPR), ploy ADP ribose polymerase (PARP). The diagram is adapted from Nikiforov et 
al. (2015). 
 23 
 
1.2.2 NAD
+
-dependent pathways and the inflammatory response 
Recent evidence has demonstrated that immune function is tightly regulated by a number of 
NAD
+
-dependent enzymes including ADP-ribose transferases (ARTs), cyclic ADP-ribose 
(cADPR) synthases (ADP-ribose cyclase) and protein-deacytlases (sirtuins) (Legutko et al., 
2009). Although these enzymes catalyse different types of reactions, the common feature for 
all these reactions is the transfer of the ADP-ribose (ADPR) moiety from NAD
+
 into a 
protein acceptor target with the concomitant release of NAM, which has been shown to not 
only affect the activity of NAD
+
-consuming enzymes but also to modulate inflammatory 
responses by acting as an end-product inhibitor (Sanders et al., 2007; van Gool et al., 2009; 
Chiarugi et al., 2012; Figure 1.4). Indeed, NAM was shown to non-competitively inhibit 
sirtuin activity with a subsequent impact on immune responses (Bitterman et al., 2002; 
Anderson et al., 2003; Ungerstedt et al., 2003). An increase in NAM was shown to inhibit 
sirtuin-mediated histone deacetylation activity, affecting NF-B activation (Fulco et al., 
2003; Yeung et al., 2004). These findings suggest a key role for NAD
+
-consuming enzymes 
in immune regulatory responses, for example histone de-acetylation enzymes, or sirtuins. 
Sirtuin belongs to the NAD
+
-dependent protein deacetylase family and it was originally 
described as homologous to the yeast silent information regulator 2 (Sir2; Landry et al., 
2000b; Smith et al., 2000; Sauve et al., 2006). In general, sirtuin uses NAD
+
 as substrate to 
catalyse the protein de-acylation reactions in which an acyl group, from the lysine residue on 
a target protein, is transferred onto an ADPR moiety on NAD
+ 
(Jackson and Denu, 2002). 
This is accompanied by NAM liberation resulting in 2ʹ, 3ʹ-O acetyl-ADP-ribose (OAADPR) 
generation as a by-product (Figure 1.5; Landry et al., 2000b). As a consequence, NAD
+
-
dependent de-acetylation leads to modulation of the stability and localization of target 
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proteins (Sauve et al., 2006; Haigis and Sinclair, 2010; Canto and Auwerx, 2012; 
Chalkiadaki and Guarente, 2012). 
 
Figure 1.4 The NAD
+
 consuming enzymes share one common step that uses NAD
+
 as a substrate for 
protein deacetylation, ribosylation and cyclic ADP ribose production, yielding de-acetylated protein 
and liberating nicotinamide (NAM) as the end product. The latter is converted back into NAD
+
 
through the activity of the salvage enzyme pathways including NAMPT, NMNAT and NR 
(Agnieszka, 2009; Chiarugi et al., 2012). 
The mammalian sirtuin family consists of seven conserved homologs namely SIRT 1-7 
(Michishita et al., 2005; Dali-Youcef et al, 2007; Michan and Sinclair, 2007) which are found 
in organisms ranging from bacteria to humans (Brachmann et al., 1995; Nikiforov et al., 
2015) and share one NAD
+
-catalytic domain comprised of 275 amino acids (Michan and 
Sinclair, 2007). SIRT1, 6 and 7 are found in the nucleolus, whereas SIRT 3-5 reside in 
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mitochondria. In contrast, SIRT 2 is mainly cytoplasmic, with an ability to shuttle from the 
cytoplasm to the nucleus to regulate gene expression by de-acetylating transcription factors 
(Michishita et al., 2005; Jing et al., 2007). The de-acetylation activity of sirtuins is highly 
sensitive to intracellular NAD
+
 levels (Magni et al., 2004) or to the redox ratio (NAD
+
/ 
NADH), thus sirtuins could act as sensors of the metabolic state of cells (Sauve et al., 2006; 
Chalkiadaki and Guarente, 2012) suggesting a direct link between metabolic bioenergetics, 
homeostasis and gene regulation (Chiarugi et al., 2012). Additionally, sirtuins can also 
control multiple cellular processes including gene silencing (Vaquero et al., 2004) and cell 
differentiation (Fulco et al., 2003). The best characterised mammalian sirtuin is SIRT1, and it 
has been shown to regulate the activity of a list of transcriptional regulators and co-
regulators, by modulating their acetylation status; these include the peroxisome proliferator-
activated receptor (PPAR), PPAR-coactivator-1 (PGC-1), p53 and NF-B (Picard et al., 
2004; Yeung et al., 2004) illustrating an important role for SIRT1 in the immune response via 
regulation of pro-inflammatory transcription factors. Indeed, Yeung and his team (2004) were 
the first to suggest that SIRT can modulate the de-acylation of NF-B via the de-acylation of 
the Rel A/p65 subunit of NF-B; this occurs when SIRT1 physically interacts with NF-B at 
lysine 310 resulting in inhibition of NF-B activity (Salminen et al, 2008), thereby regulating 
the expression of genes associated with innate immunity (Chen et al., 2005). Accordingly, 
SIRT1 has been shown to regulate pro-inflammatory transcriptional activity via repression of 
the transcriptional activity of AP-1, another transcription factor (Huang et al., 2004). On the 
other hand, a key role has been shown for SIRT6, as a NAD-dependent enzyme, in regulating 
TNF-α production by acting at a post-transcriptional level, therefore decreasing NAD+ levels 
and blocking the transcription of TNF-α (van Gool et al., 2009; Galli et al., 2010). These 
observations suggest an exciting link between the redox and thus metabolic state of cell and 
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pro-inflammatory responses. It seems that sirtuin plays an important immunomodulatory role 
based on its ability to control TNF-α secretion. However, the inflammatory response is also 
regulated via other mechanisms through the crosstalk between sirtuin and other NAD
+
 
utilizing enzymes such as CD38 (Aksoy et al., 2006a; Iqbal and Zaidi, 2006) via its ability to 
modulate NAD
+
 availability (Al-Abady et al., 2013). 
 
 
Figure 1.5 Sirtuin enzymatic reactions. Sirtuin members exhibit deacetylase activity in which NAD
+
 
is used as substrate to cleave acetyl groups from target proteins in a reaction that generates 2-O-
acetyl-ADP-ribose and NAM as an end product. Sirtuin also display ADP-ribosyl transferase (ARTs) 
activity in which the ADP-ribosyl moiety of NAD
+
 is transferred to a substrate protein. This figure is 
adapted from Houtkooper et al. (2010). 
OAADPR 
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In mammals, two members of the ADP-ribose cyclase family, CD38 and CD157, are known 
as lymphocyte antigens with the latter being approximately 25% identical to CD157 (Lee, 
2006). Both members are highly conserved ectoenzymes (Lee, 2006). They have been found 
in all organisms from sea slugs to mammals (Malavasi et al., 2006) and both proteins are 
ubiquitously expressed in most mammalian tissues (Lee, 2006). Importantly, the members of 
the ADP-ribose cyclase family use NAD
+
 as a substrate (Figure 1.6) to catalyse the 
generation of secondary enzyme messengers such as cADPR, nicotinic acid adenine 
dinucleotide phosphate (NAADP
+
) and ADP-ribose implicating ADP-ribose cyclase 
members in several complex processes (Lee, 2006) from calcium signalling (Fliegert et al., 
2007), cell activation to proliferation, hormone secretion and immune responses (Malavasi et 
al., 2008). In addition, these proteins have been shown to serve as receptors with enzyme-
dependent or independent signalling properties (Lund, 2006; Malavasi et al., 2006). 
 
Figure 1.6 The enzymatic activity of CD38. CD38 is involved in the generation of range of secondary 
messengers including nicotinic acid adenine dinucleotide phosphate (NAADP), cyclic ADP-ribose 
(cADPR), ADP-ribose (ADPR) and ADP-ribose-2’-phosphate (ADPRP), which are known to mediate 
intracellular calcium mobilization. The diagram is adapted from Lee (2006). 
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The most studied ADP-ribose member is CD38 which has been suggested to play a key role 
in immunity (Lund, 2006; Malavasi et al., 2006; Malavasi, et al., 2008). CD38 was described 
as a type II glycosylated protein with a single transmembrane domain near its N terminus 
(Lee, 2006). CD38 plays critical roles in immune cell differentiation, as it was found to be 
highly upregulated on cells that are committed to differentiation. In a study conducted on 
different cell lines, CD38 was upregulated in response to IFN-γ on myelomonocytic such as 
U937, THP-1 and Mono-Mac-6. However, it was unaffected in promyelocytic cells like HL-
60 (Drach et al., 1994). Similarly, CD38 was identified as marker for T and B lymphocyte 
activation and differentiation with activated lymphocytes and thymocytes mainly CD38
+
 
whereas resting T and B cells are CD38
-
 (Shubinsky and Schlesinger, 1997). 
In addition to these cells, CD38 is also constitutively expressed on other cells such as natural 
killer (NK) cells, monocytes and mature DCs (mDCs) (Mehta et al., 1996; Fedele et al., 
2004). It has been reported that CD38 is merely a maturation marker as it was shown to 
display a peculiar pattern of distribution during the differentiation stage. For instance, 
immature DCs (iDCs) seem to lose surface CD38 which is induced again on mature DCs in 
response to LPS stimulation (Fedele et al., 2004; Malavasi et al, 2008). The immune 
regulatory role of CD38 is reflected by the unique pattern of CD38 expression which is 
important for immune cell function. The CD38 is important for macrophage and monocytic 
cell lines, mediating their antigen-presenting ability as well as the ability to secrete pro-
inflammatory cytokines (Funaro et al., 1990; Lund et al., 1995). CD38 seems to critically 
regulate the expression of pro-inflammatory genes via an increase NF-B activation and 
inhibition of ERK1/2 phosphorylation in response to TNF-α, indicating that CD38 is required 
for the TNF-α signalling pathway (Iqbal and Zaidi, 2007). Conversely, CD38 can also 
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regulate anti-inflammatory mediators since CD38 was involved in IL-4 secretion in chronic 
lymphocytic leukaemia, via regulation of cellular Histone de-acylation (HDAC) activity 
(activity). Decreasing the HDAC activity via TNFα-induced CD38 upregulation, enhanced 
IL-4 secretion in chronic lymphocytic leukaemia (Levesque et al., 2006), suggesting an 
immune regulatory role for CD38 via limitation of NAD
+
 availability for sirtuin-mediated 
NAD
+
 consumption. Similarly, it has also been suggested that CD157 plays a role in 
inflammation as it was shown to be involved in B cell development and antibody production, 
and also in immune function and polarization of human neutrophils (Legutko et al., 2009). 
1.3 Metabolic pathways and immune responses 
Cellular energy metabolism is required for sustaining efficient immune cell functions and 
therefore metabolic regulation.  It may also be important for the control of metabolic 
reactions mediating immune cell responses. The degradation of nutrients via ATP-generating 
pathways leads to the production of chemically useful energy in the form of ATP (Delmastro-
Greenwood and Piganelli, 2013). Overall, ATP can be synthesised through aerobic 
respiration (oxidative phosphorylation) and anaerobic metabolism (glycolysis) in innate 
immune cells. By using these pathways, cells are able to produce 28 ATP molecules per 
glucose molecule, via mitochondrial respiration, while only 2 molecules of ATP are 
generated via glycolysis metabolism (Delmastro-Greenwood and Piganelli, 2013). ATP can 
then be utilized for various functional events including housekeeping, migration, 
differentiation, proliferation, phagocytosis and antigen processing/presentation (Buttgereit et 
al., 2000; Krauss et al., 2001). The diversity in immune functions is reflected by the 
differences that exist in the various known macrophage metabolism profiles. For example, 
classically activated macrophages (M1s) are mainly glycolytic. Although glycolysis 
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metabolism is less efficient for energy generation, it is critical for immune cells function, 
especially in a hypoxic environment (Delmastro-Greenwood and Piganelli, 2013). It is known 
that glycolysis can operate under anaerobic conditions for short periods of time such as those 
that may be found at sites of infection but is unsustainable in the long term due to lactate 
production, reflecting the role of M1s. In contrast, alternatively-activated macrophages (M2s) 
mainly utilize mitochondrial respiration (Lacy-Hulbert and Moore, 2006; Vats et al., 2006) as 
it is more efficient for energy generation and can sustain for longer. This is why M2s are 
involved in much longer term anti-inflammatory response/activity. Thus M2s are much more 
suited to aerobic oxidative metabolism of glucose and fatty acids oxidation. While slower 
than glycolysis, it produces more ATP and can be sustained for longer. Importantly, the 
reliance of immune cells on metabolic pathways, for their immune function, makes them 
good targets for immunometabolism regulatory approaches. 
1.3.1 Classical activation (M1 macrophages) and glycolysis 
The tight link between metabolic pathways and innate immune function is well established. 
This link is bidirectional with examples including changes in metabolism being required in 
order to mount responses and with immune mediators being able to modulate metabolism 
(Schertzer and Steinberg, 2014). Indeed, the metabolic switch, from OXPHOS to glycolysis 
(Rodriguez-Prados et al., 2010; Pearce et al., 2013a) is induced by a range of stimuli such as 
LPS (Krawczyk et al., 2010) and type I interferon (Pantel et al., 2014). The activated 
macrophages among the cells that represent the first line of the immune defence, which takes 
place within hours, and thus it is perhaps not surprising that macrophages quickly increase 
glycolysis, allowing rapid increase in ATP generation (Vazquez et al., 2010), required for the 
rapid production of pro-inflammatory cytokines (McGettrick and O'Neill, 2013; Galvan-Pena 
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and O'Neill, 2014). Following classical activation, M1s increase their glycolytic activity, 
allowing for rapid ATP production to meet the high energy demand, whereas TCA activity is 
inhibited (Galvan-Pena and O'Neill, 2014). TCA, via its accumulated metabolites, has been 
found to be involved in immunometabolism in activated MФs. Following MФ activation with 
LPS, the TCA cycle is broken, resulting in mitochondrial accumulation of TCA intermediates 
including citrate and succinate (Tannahill et al., 2013; Jha et al., 2015). Both of those 
metabolites have been proven to possess signalling capacity and to the immune response 
(Tannahill et al., 2013; Jha et al., 2015). Tannahill and his team have shown that succinate is 
an inflammatory signal that can enhance IL-1β production through stabilisation of the 
expression of HIF-1α. This, in turn, enhances glycolytic activity via induction of lactate 
dehydrogenase (LDH) expression. This converts pyruvate (required for acetyl-CoA 
production that feeds into TCA) into lactate thereby limiting TCA activity (Kim et al., 2006). 
HIF-1α expression has been shown to be regulated by NAD+-dependent sirtuin deacetylation 
which is also required for the regulation of TNF-α production (van Gool et al., 2009; Lim et 
al., 2010); these observations might strengthen the link between metabolism and immunity. 
Notably, HIF-1α has been shown to promote NAMPT-mediated NAD+ production supporting 
glycolysis (Benita et al., 2009). Since NAD
+
 is required for both glycolysis and TNF-α 
production, it seems that both NAD
+
 and accumulated succinate, via HIF-1α, are needed to 
support glycolysis-mediated M1s immune responses. Citrate, another TCA intermediate that 
accumulates in M1s, is preferentially transported from mitochondria into the cytosol via the 
citrate transporter. Once in the cytosol, citrate is cleaved by citrate lyase into acetyl- CoA and 
oxaloacetate to then be fed into pathways that generate nitric oxide, ROS and arachidonic 
acid, which is required for prostaglandin production. These are inflammatory mediators 
required for macrophage immune functions suggesting that citrate is an important player in 
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inflammation (reviewed in O'Neill et al., 2016). Additionally, Citrate can also feed into de 
novo synthesis of fatty acids, which in turn degrades into glucose, thus supporting the 
metabolic switch into glycolysis in DCs and MФs (reviewed in Kelly and O'Neill, 2015). 
Clearly, alteration of the TCA cycle plays an important role in the metabolic reprogramming 
in MФs/DCs and thus in promoting their immune functions. Several studies have shown that 
macrophages were able to increase glycolysis via an increase in glucose uptake, with most 
glucose being converted into lactate, with little being used for OXPHOS (Figure 1.7; 
Newsholme et al., 1987). Moreover, it was shown that the expression of the glycolytic 
enzymes, such as hexokinase is also increased in activated macrophages, indicating an 
increase in glycolytic activity in these cells (Newsholme et al., 1986). Furthermore, the 
increase in glycolysis is accompanied by the increase in the flux through pentose phosphate 
pathway (PPP) (Figure 1.7; Haschemi et al., 2012; Freemerman et al, 2014; Galvan-Pena and 
O'Neill, 2014). The PPP branches off glycolysis and is considered to be an important source 
of nicotinamide adenine dinucleotide phosphate (NADPH) required for NOS and NADPH 
oxidase, which mediates ROS production (Borregaard and Herlin, 1982; Aktan, 2004; Bedard 
and Krause, 2007). Owing to its ability to disturb redox balance, ROS production can cause 
serious damage to immune cells. This can be prevented via the action of anti-oxidant enzyme, 
glutathione (GSH) that detoxify ROS, and which requires NADPH as co-factor (Grant, 
2008). Indeed, GSH uses NADPH to regulate redox balance-mediated MФ activation by LPS 
(Wang et al., 1999). It has been suggested that this switch in the metabolic state is correlated 
with immune cell responses (McGettrick and O'Neill, 2013). Therefore, the inhibition of 
glycolysis with 2-deoxyglucose (2DG, a glucose analogue) resulted in a decrease the LPS-
induced production of inflammatory responses such as inhibition of the secretion of IL-1β 
(Tannahill et al., 2013). Also, 2-deoxy-glucose (2-DG) was able to block TNFα and IL-6 
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production via inhibition of NF-B signalling in primary microglia as a result of blocking 
glycolysis by inhibiting hexokinase activity (Wang et al., 2014). In contrast, the inhibition of 
mitochondrial respiration, via mitochondrial inhibitors, showed no effect, indicating that 
oxidative metabolism is already shut down under such conditions (Kellett, 1966). 
 
Figure 1.7 Metabolic profile of an M1 macrophage. Glycolytic metabolism is induced in classical 
activation (M1s) resulting in increased lactate production. HIF-1α is also induced in M1s allowing 
induction of pro-inflammatory cytokines. Meanwhile, the activity of PPP is initiated, allowing an 
increase in ROS production supporting the bacterial killing mechanism used in M1s. G6P, glucose-6-
phosphate; F6P, fructose-6-phosphate; R5P, ribose-5-phosphate; HIF-1α, Hypoxia inducible factor-1α; 
G3P, glyceraldehyde-3-phosphate; ROS, reactive-oxygen species. This diagram is adapted from 
Galvan-Pena and O'Neill (2014). 
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Additionally, LPS increases glycolytic activity in macrophages through an increase in the 
expression of iNOS (inducible nitric oxide synthase) that generates NO (nitric oxide), which 
inhibits mitochondrial activity via ROS production. This occurs via NO-mediated 
nitrosylation of iron-sulfur proteins present in electron transport chain complexes such as 
complex I (Drapier and Hibbs, 1988; Clementi, et al., 1998) as well as cytochrome-c oxidase 
(Cleeter et al., 1994). These observations suggest that a metabolic switch in macrophages 
might be dependent on iNOS and NO-mediated inhibition of mitochondrial metabolism. 
Indeed, it was shown that inhibition of iNOS was able to restore mitochondrial respiration 
activity during LPS stimulation (Kelly and O'Neill, 2015). Finally, LPS was shown to induce 
glycolytic activity via another mechanism, this being the induction of the hypoxia inducible 
factor (HIF-1α; Denko, 2008). HIF-1α promotes the switch to glycolysis so that these cells 
can continue to produce ATP when oxygen is limited (as oxygen is not required for 
glycolysis). HIF-1α facilitates this metabolic switch by binding to hypoxia response elements 
in target genes (Semenza et al., 1991; Mole et al., 2009) such as the glucose transporter 
(GLUT1; Chen et al., 2001) and glycolytic enzymes. For example, HIF-1α is involved in the 
induction of lactate dehydrogenase (LDH) expression (Semenza et al., 1996) which catalyses 
lactate production from pyruvate, thereby limiting the production of acetyl-CoA for the TCA 
cycle. HIF-1α also increases the expression of pyruvate dehydrogenase kinase (Kim et al., 
2006; Papandreou et al., 2006) which inhibits pyruvate dehydrogenase, an enzyme that 
catalyses the formation of acetyl-CoA from pyruvate (Cramer et al., 2003). Glycolysis seems 
to dominate in M1s during LPS stimulation, highlighting an important immune regulatory 
role for innate immune cells. 
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1.3.2 Alternative activation (M2s) and oxidative metabolism 
Alternative activation (M2s), unlike classical (M1) activation, displays a different metabolic 
profile. In activated M2s, the metabolism is shifted toward oxidative metabolism, while 
glycolysis is attenuated (McGettrick and O'Neill, 2013). This switch increases fatty acid 
utilization and decreases the PPP. The shift towards fatty acid oxidation occurs because M2 
stops ROS production and thus activates respiratory redox chain activity promoting fatty 
acids oxidation. Indeed, the oxidation of fatty acid has been shown to be anti-inflammatory 
(Steinberg and Schertzer, 2014), hence the metabolism unsurprisingly reflects the function of 
M2 macrophages. Indeed, the main functions of M2s are involved in wound healing and anti-
parasitic defence which last for longer term. Thus M2s utilize fatty acid and oxidative 
metabolism to obtain energy. While oxidative metabolism is slow, it can lead to the 
interconversion of more energy than glycolysis, and can be sustained for longer (Steinberg 
and Schertzer, 2014). Following activation, M2s increase the expression of the genes 
governing the electron transport chain allowing fully functional oxidative phosphorylation in 
addition to directing the pyruvate into the TCA cycle  instead of lactate production as in M1s 
(Figure 1.8). Forcing a switch from glycolysis to oxidative metabolism can lead to a 
transformation in phenotype. Thus, the inhibition of oxidative phosphorylation was found to 
not only inhibit the M2 phenotype but also to drive the macrophage into an M1 phenotype 
(Freemerman et al, 2014). In addition, forcing oxidative metabolism in an M1 macrophage 
potentiates the M2 phenotype (Tannahill et al., 2013; Freemerman et al, 2014). M2s are 
known to induce carbohydrate kinase-like protein (CARKL), a sedoheptulose kinase that 
catalyses the conversion of sedoheptulose into sedoheptulose-7-phosphate. The activity of 
CARLK leads to limitation of PPP activity and a consequent decrease in NADPH generation 
(Haschemi et al., 2012), while it activates the oxidative metabolism under activation 
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conditions. Interestingly, it has been observed that CARKL levels are increased during M2s 
while it decreased in M1s during LPS stimulation (Haschemi et al., 2012). The knockdown of 
CARLK enhances LPS-induced cytokine production as well as M1 macrophage polarization. 
However, overexpression of CARKL decreased LPS-induced IL-6 secretion (Haschemi et al., 
2012), suggesting a switch in phenotype effector functions.  
 
 
Figure 1.8 Metabolic profiles of an M2 macrophage. Alternative activation is via induced oxidative 
metabolism and β-oxidation activity. STAT6 and PGC-1β drive mitochondrial activity as well as the 
production of anti-inflammatory cytokines. This can also occur via the accompanying activity of 
AMPK, adenosine monophosphate activated protein kinase, and SIRT1. G6P, glucose-6-phosphate; 
G3P, glyceraldehyde-3-phosphate.This diagram is adapted from Galvan-Pena and O'Neill (2014). 
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In general, the oxidative metabolism of fatty acid in mitochondria is tightly controlled by, 
adenosine monophosphate activated protein kinase (AMPK) in M2s (Sag et al., 2008) via 
targeting the nuclear receptor, PPARs (Vats et al., 2006). The expression of PPARs has been 
found to be induced in response to the alternative stimulation signal (IL-4 and IL-13) 
resulting in increased expression of proteins involved in mitochondrial respiratory chain 
(Vats et al., 2006). In addition, the activity of fatty acid β-oxidation is also increased in 
macrophages via IL-4-mediated PPARs enzymatic activity (Odegaard et al., 2007). 
Additionally, AMPK is highly active in M2s and it is involved in the regulation the 
production of anti-inflammatory responses in M2s via the control of IL-10 production (Sag et 
al., 2008). These observations further confirm the link between the immune response and 
metabolism. Finally, activation of M2 with IL-4 resulted in an increase in oxidative 
metabolism via the activity of mechanistic target of rapamycin (mTOR), an atypical 
serine/threonine kinase which is the mechanistic target of rapamycin (Byles et al., 2013). 
Therefore, the inhibition of mTOR by rapamycin treatment (Land and Tee, 2007) can also 
lead to a decrease in HIF-1α levels and therefore could result in reduced HIF-1α-dependent 
glycolytic and inflammatory gene expression (Pawlus and Hu, 2013). 
1.4 NAD
+
 Homeostasis and metabolic pathways 
It is now acknowledged that NAD
+
-sensing energy bridges the metabolism shift with the 
reprogramming of effector phenotypes. By sensing NAD
+
, SIRT-1, 3 and 6-mediated de-
acetylation play important roles in regulating pro-inflammatory genes and metabolic enzymes 
used in glycolysis (Haigis and Sinclair, 2010; Wang et al., 2010). Thus, SIRT 6 can regulate 
glucose metabolism (Xiao et al., 2010) by reversing the trans-activating acetylation of genes 
involved in glycolysis, thus antagonising HIF1α-induced glycolysis (Wang et al., 2010; 
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Zhong et al., 2010). A recent study has shown that knockdown of SIRT6 causes mice to die 
due to hypoglycaemia (Xiao et al., 2010). Conversely, SIRT1, which is located in 
mitochondria, was found to regulate fatty acid oxidation via NAD
+
-sensing de-acetylation of 
multiple mitochondrial proteins, including members of the electron transport complexes I and 
III as well as isocitrate dehydrogenase, which supports the citric acid cycle, linking 
metabolism and inflammation (Lombard et al., 2007; Bell and Guarente, 2011). Importantly, 
SIRT1 plays a key role in regulating downstream phosphorylation and activation of AMPK 
(Lan et al., 2008). Once AMPK is activated, oxidative metabolism, which is associated with 
the anti-inflammatory state, is induced, whereas glycolysis, which is associated with 
inflammatory state, is inhibited (Beckers et al., 2006; Hawley et al., 2012). The link between 
SIRT1 and AMPK is well documented (Price et al., 2012). It has been found that SIRT1 
knockdown led to block AMPK activation indicating that the SIRT1 is required for AMPK 
activation (Price et al., 2012). Interestingly, the involvement of AMPK in modulating energy 
metabolism is well established, and AMPK is essential in order to maintain energy balance 
through promotion of catabolic and inhibiting energy consuming processes (Jones et al., 
2005). Conversely, it has been found that AMPK itself can activate SIRT1, probably via 
some sort of positive feedback loop (Canto et al., 2009), by inducing the expression of 
NAMPT and the subsequent increase in NAD
+
 (Canto et al., 2009). NAD
+
 levels can promote 
SIRT1 and the shift from the pro-inflammatory, (glycolytic) state to the anti-inflammatory, 
(oxidative) state, limiting inflammation (Pearce, 2010; Yang et al., 2010; Liu et al., 2012). 
This occurs via mediation of the suppression of PPARγ (a transcription factor) expression by 
SIRT 1, resulting in the regulation of multiples genes involved in fat storage (Wellen and 
Thompson, 2010). It has been show that NAD
+
 is essential for energy metabolism, and thus 
that a decrease in NAD
+
 levels via FK866-mrdiated NAMPT leads to the attenuation of 
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glycolysis at the glyceraldehyde 3-phosphate dehydrogenase step, in addition to limiting the 
pentose phosphate pathway activities (Tan et al., 2013). It has thus become clear that NAD
+
 
homeostasis is involved in both metabolism and pro-inflammatory responses. Therefore, a 
pharmacological approach must apply to control metabolism and to fine-tune appropriate 
immune inflammatory responses. 
1.5 The THP-1 cell line as model of macrophage differentiation 
It has been previously shown that the THP-1 cell line represents an appropriate model for 
native monocyte-derived macrophages (Tsuchiya et al. 1982; Reyes et al., 1999). Indeed, 
investigators have recently shown that THP-1 can be used as an accurate model to study the 
differentiation or maturation as well as the immune response of monocytes and macrophages 
in different conditions such as that of cardiovascular system (Tsuchiya et al. 1982; Auwerx, 
1991; Daigneault et al., 2010; Qin, 2012). THP-1 cells were first established by Tsuchiya et 
al. (1980), who isolated the cells from the peripheral blood of a one year old human male 
with acute monocytic leukaemia .Tsuchiya (1980) described THP-1 as single rounded cells 
that grow in suspension, and that do not adhere to a culture plate, with the ability to express 
monocytic markers such as Fc-γ receptors and C3b receptors (Tsuchiya et al. 1980; Fleit and 
Kobasiuk, 1991). Due to the difficulty in obtaining sufficient quantities of human primary 
monocytes/macrophages, as well as the inherent variation between subjects, it seems 
reasonable to use THP-1 as an in vitro substitute cell line. The main question being whether 
or not the cell line successfully mimics the primary cells derived from patient blood. 
Interestingly, THP-1s have become widely used to study monocyte-macrophages because of 
their similarity to the monocytes in peripheral blood mononuclear cells (PBMCs; Auwerx, 
1991; Sharif et al., 2007; Qin, 2008). Researchers have shown that THP-1, in a similar way to 
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PBMCs, can synthesize and secrete macrophage colony stimulation factor (M-CSF; Gaffney 
et al., 1986), IL-8 (Wang et al., 1996) and apolipoprotein E (Menju et al., 1989). In addition, 
it has been observed that THP-1 responses to LPS-induced gene expression are very similar 
to that of primary macrophages, even though they are a transformed and immortalised cell 
line (Verreck et al, 2006; Sharif et al., 2007). Sharif et al. (2007) observed that THP-1-
derived macrophage responses to LPS activation are comparable to that of PBMCs. 
Furthermore, it has been reported that THP-1 cells constitute a better model system for 
macrophage differentiation when compared to other monocytic cells line such as U937 cells, 
which have been reported to respond differently to LPS stimulation, with both cell types 
showed differential profiles of CD14 expression (Sharif et al., 2007). Therefore, it seems that 
THP-1 can be considered as a reliable and accurate in vitro model to study macrophage 
differentiation. 
Traditionally, THP-1 cells can be differentiated or activated via a range of agents, most 
commonly by PMA or vitamin D3 (1α, 25-dihydroxyvitamin D3; Auwerx, 1991; Schwende et 
al., 1996; Daigneault et al., 2010; Foey and Crean, 2013). Previous studies have reported that 
the monocyte differentiation is reflected by several criteria: (i) loss of proliferation, (ii) an 
increase in phagocytic ability and adherence, and (iii) changes in the cell morphology 
associated with irregular cell shape with obvious pseudopodia (Verreck et al., 2006; Sharif, et 
al. 2007). However, it is not clear whether these agents can induce macrophages that are 
comparable to tissue macrophages. A growing body of literature has shown that PMA is 
capable of inducing complete differentiation of THP-1 cells into macrophage-like cells 
although THP-1 is a monocytic cell line that has minimal receptor expression prior to 
exposure to PMA (Tsuchiya et al. 1982; Auwerx, 1991; Daigneault et al., 2010). Indeed, 
PMA treatment was found to activate macrophage differentiation that occurs via PKC, an 
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integral part of cellular signalling machinery. PMA was shown to induce differentiation, 
resembling diacylglycerol, which naturally mediates the differentiation process (Nishizuka, 
1995; Livneh and Fishman, 1997). Interestingly, the differentiation can be determined by 
observing (i) alterations in cell morphology as cells become adherent and adopt an irregular 
shape coupled with elongated pseudopodia, (ii) a loss of proliferation, and (iii) increased 
phagocytic markers. Additionally, macrophages induced by PMA are also associated with 
induced gene expression of adhesion molecules such as the Ig-related molecules CD54 
(ICAM-1), ICAM-2 and upregulated expression of complement receptors CR3 (CD18-
CD11b) and CR4 (CD18-CD11c) resembling a tissue macrophage like state (Prieto et al., 
1994; Traore et al., 2005). Furthermore, Daigneault et al. (2010) observed that PMA-derived 
THP-1 differentiation did not exhibit expression of CD206, a monocytic marker, when 
compared to monocyte-derived macrophages, suggesting that PMA-THP1 cells are very close 
to classical macrophages.  
Alternatively, THP-1 differentiation can be induced by vitamin D3, with the immune-
regulatory role of vitamin D3 on macrophages/monocytes being well recognised (Abe et al., 
1983). Phenotypically, macrophages induced by vitamin D3 mimic mature monocyte cells in 
that they exhibit upregulated CD14 expression, a surface antigen characteristic of mature 
mononuclear phagocytes (Fleit and Kobasiuk, 1991; Schwende et al., 1996; Hmama et al., 
1999; Daigneault et al., 2010). In fact, macrophages and monocytes express high levels of the 
vitamin D3 receptor (VDR) that causes those cells to be highly sensitized to the 
differentiation effect of vitamin D3 (Abe et al., 1983). In support of this, vitamin D3 was 
shown to attenuate the expression of TLR2 and TLR4 in a time-dependent manner in 
monocytes triggering a state of hypo-responsivity towards bacterial cell wall components in a 
VDR-dependent mechanism (Scherberich et al., 2005; Sadeghi et al., 2006). Sadeghi (2000) 
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showed that TLR2, 4 inhibition was associated with impaired NF-kB/RelA translocation to 
the nucleus, alongside p38 and p42/44 (extracellular signal-regulated kinase 1/2) 
phosphorylation. Recent studies reported by Coussens et al. (2009) showed that vitamin D3 
treatment inhibits the expression of some matrix metalloproteinases (MMP-7, 10) and 
secretion of MMP-7, as well as the secretion and activity of MMP-9 by M. tuberculosis-
infected PBMCs. In this study, the investigators also reported that the secretion of IL-10 and 
prostaglandin E2 were induced by vitamin D3 treatment from PBMCs (Coussens et al, 2009). 
Furthermore, vitamin D3 is known to induce the MAPK phosphatase-1 (MAPKP-1) 
expression which is highly controlled by AMPK (Wu et al., 2015), which plays a key role in 
supporting oxidative metabolism in M2s (Sag et al., 2008). Additionally, PMA and vitamin 
D3 modulatory effects are also reflected by the prevention of anti-inflammatory and pro-
inflammatory cytokine release, respectively (Alappat et al., 2010; Daigneault et al., 2010). 
Collectively, these observations suggest that PMA and vitamin D3 treated THP-1 cells is 
probably a valuable model to study macrophage immune-regulatory functions (Auwerx, 
1991). 
 
 
 
 
 
 
 43 
 
1.6 Aims of the current study 
This research study aimed to investigate the immune modulating effect of NAD
+ 
homeostasis 
on macrophage immune responses, particularly TNF-α by utilizing of the THP-1 cell line in 
generating macrophage-like subset as a model for the current study. Initially, the NAD
+
 
levels and NAD
+
 homeostasis gene expression was investigated in resting and activated 
macrophages generated from THP-1 cells differentiated with either PMA, to generate M1-
like macrophages, or vitamin D3, to generate M2-like macrophages (reported in Chapter 3). 
To understand more about the link between NAD
+ 
and TNF-α, the intention was to (1) 
investigate the source of NAD
+ 
generation using a pharmacological approach, (2) to 
investigate whether NAD
+ 
modulation can control LPS-induced TNF-α release and (3) to 
explore the mechanism(s) that underline how NAD
+ 
levels
 
are linked to TNF-α release in 
both subsets (Chapter 4). It is known that NAD
+ 
levels are required for glycolysis; therefore, 
the next aim was to investigate the metabolic profile in differentiated macrophages under 
LPS stimulation (Chapter 5). To understand whether NAD
+ 
manipulation can modulate 
metabolic flux, a pharmacological approach was taken and metallic flux was measured, as 
reported in chapter 5.  
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CHAPTER 2 
GENERAL MATERIALS & METHODS 
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2. General materials and methods 
2.1 Materials 
The cytokines, stimulants and antibodies used throughout this study, and their sources, are 
listed in table 2.1. Similarly, chemicals and buffers are shown in table 2.2, whilst table 2.3 
lists kits, inhibitors and other materials. In addition, a general overview of the experimental 
design employed during the course of this study is shown in Figure 2.8.  
Table 2.1 Cytokines, stimulants and antibodies used during this study and their suppliers 
Cytokines, stimulants, antibodies   
 
Supplier 
Recombinant human TNF-α  
 
Recombinant human IL-6  
BD Pharmingen, Oxford, UK 
Mouse anti-Hu TNF-α Mab1 IgG1 
 
Biotinylated mouse anti-Hu TNF-α Mab11 
 
Rat anti-human IL-6 Mab MQ2-13A5 IgG1 
 
Biotinylated Rat anti-Hu IL-6  
 
BD Pharmingen, Oxford, UK 
phorbol-12-myristate-13-acetate (PMA)  
 
1,25-(OH)2-Vitamin D3 (VD3) 
MTT(3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide) 
PES (5-ethylphenazinethylsulfate) 
ADH (alcohol dehydrogenase)  
NAD(H) 
Kynurenine  
Lactic acid  
Sigma-Aldrich, Poole, UK  
Bacterial lipopolysaccharide, Escherichia coli 
strain K12 (E.coli K12)  
Autogen-Bioclear Ltd., Wiltshire, UK 
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         Table 2.2 Chemicals and buffers used in the current study, and their suppliers 
Media and chemicals  
 
Supplier 
 
RPMI 1640 Lonza, Wokingham, UK 
TMB (3,3,5,5-Tetramethyl benzidine) Insight Biotechnology Ltd., Middlesex, 
UK 
Fetal bovine serum (FBS) Sera Laboratories International Ltd,  
Hull, UK  
Phosphate buffered saline (PBS) tablets  
Dulbecco’s PBS (DPBS) 
Melford Laboratories Ltd., Ipswich, 
U.K. 
Bovine serum albumin (BSA) 
Dimethyl sulfoxide (DMSO) 
Ethanol (general laboratory grade) 
Ethylenediaminetetracetic acid (EDTA) 
Trypan Blue (0.4%) 
Hydrochloric acid (HCl) (37%) 
Concentrated Sulphuric acid (H2SO4) 
Glacial acetic acid (100%) 
Sodium hydroxide (NaOH) 
Kynurenine (KYN) 
Ehrlich Reagent (p-dimethyl amino 
benzaldehyde) (DMAB) 
Trypsin 
Glutamine 
Penicillin-Streptomycin 
Protease inhibitor Cocktail 
Sigma-Aldrich, Poole, UK 
Streptavidin conjugate Horseradish peroxidise 
(HRP) 
Fisher Scientific U.K. Ltd., 
Loughborough, U.K. 
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Table 2.3 Inhibitors, reagent kits, plus other materials used, and their suppliers 
Inhibitors, reagent kits, Other materials  
 
Supplier 
Micro BCA
TM
 protein assay kit Thermo scientific, Waltham, USA 
Oligonucleotide primers Eurofins MWG Operon, Ebersberg, 
Germany 
Moloney Murine Leukaemia Virus (M-MLV) 
enzyme and buffer for cDNA synthesis  
Deoxynucleotides  
Gene Elute Mammalian Total RNA Mini Kit 
Random nonamers  
Ribonuclease Inhibitor 
SYBR® Green Jump Start Taq Ready Mix  
Sigma-Aldrich, Poole, UK 
FK866 (E-N-[4-(1-benzoyl piperidine)-4-yl) butyl] 
acrylamide-3-pryridin-3-yl)) 
1D-methyl tryptophan (1D-MT) 
Diphenylene iodonium chloride (DPI) 
2-deoxyglucose (2-DG) (Glycolysis inhibitor) 
Rotenone 
Antimycin 
Oligomycin 
Sigma-Aldrich, Poole, UK 
Sirtinol  (Sirtuin inhibitor) Santa Cruz Biotechnology Inc., Texas, 
U.S.A. 
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2.2. Methods 
2.2.1 Cell line maintenance and culture 
The human monocytic leukaemia cell line THP-1 (ECACC, Salisbury, Wiltshire, UK), was 
grown in suspension, was split every 3-4 days and was used routinely between passages 8 and 
24. The cells were maintained in RPMI 1640 complete growth medium supplemented with 
10% (v/v) heat inactivated fetal bovine serum, 2 mM L-glutamine, 100 U/ ml penicillin and 
100 µg/ ml streptomycin (P/S). The cells were kept at 37 ºC, under 5% CO2 in a humidified 
incubator. 
2.2.2 Cell differentiation with PMA or vitamin D3 (VD3) and stimulation with 
LPS-K12 
For THP-1 differentiation into macrophage-like subsets, the cells were plated (at a density of 
1 x 10
6 
cells/ ml) in complete medium (as described in the previous section) in six well tissue 
culture plates and incubated with either PMA (25 ng/ ml, three days; for differentiation into 
M1-like macrophages) or with 1,25-(OH)2-Vitamin D3 (10 nM, seven days; for 
differentiation into M2-like macrophages). PMA-treated THP-1 cells were washed after the 
initial three day stimulus, by replacing the PMA-containing media with fresh pre-warmed 
growth medium, and then incubated for further five days while VD3-THP1 enhanced 
(Daigneault et al., 2010). Differentiated cells were stimulated with 100 ng/ml 
lipopolysaccharide (LPS) derived from E.coli K12. Dead cells were aspirated while the 
supernatant were harvested following centrifugation at 200 x g for 5 min, before storage at -
20 ºC until the day of analysis. For cell counting, adherent cells (M1-like) were detached by 
trypsinization using 0.5% (v/v) of trypsin with 0.25% (v/v) EDTA and trypsinization stopped 
with fresh medium  
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2.2.3 Assessment of cell viability 
Viability assessment of suspended and adhered cells was carried out after differentiation. 
Viability was determined for all samples before they were used in each experiment. Ten 
microliters of cell suspension were mixed with 90 µl of 0.1% (v/v) Trypan blue. To 
determine the number of viable cells, 10 µl of this was placed into a Neubauer 
hemocytometer chamber and cell viability was visually determined. The viable cells had clear 
cytoplasm while non-viable cells had dark blue cytoplasm. 
2.2.4 Vitality assay 
Cell vitality measured using the MTT assay shows the ability of viable cells to reduce the 
yellow tetrazolium salt, MTT. Briefly, MTT is reduced by dehydrogenase enzymes, produced 
by viable cells, allowing the generation of reducing equivalents such as NADH and NADPH, 
and resulting in production of an insoluble purple formazan dye. The precipitated formazan is 
solubilized and spectrophotometrically quantified at 550 nm. The absorbance of the produced 
formazan signal is proportional to the number of viable cells.  
The cells were seeded at density 10
4
 cells/well in a 96-well microplate. The seeded cells were 
incubated for 2h at 37 ºC with an equal volume of assay medium containing thiazoyl blue 
tetrazolium (5 mg MTT in PBS). The resulting formazan crystals were solubilized in 100μl 
DMSO. The absorbance was read at 550 nm using the Versa Max plate reader (Molecular 
Devices, Sunny Vale, CA, USA) and the software processes the data was Soft max Pro 
version 2.4.1. 
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2.2.5 Preparation of cell extracts and protein quantification assay 
The differentiated macrophage cultures (six well plate) were washed twice with 5ml ice-cold 
Dulbecco’s modified phosphate buffered saline (DPBS), and the cells were removed from the 
plate using 0.25% (v/v) trypsin (for adherent cells) and aspiration (for suspension cells). Cell 
suspensions were centrifuged at 200 x g (Eppendorf 5418R, Hamburg, Germany) for 5 
minutes. The supernatant was aspirated and the pellets were re-suspended in 250 µl ice-cold 
lysis buffer that contained 100 mM Tris hydrochloride (pH 7.4), 50 mM NaCl and with 
freshly added a 1x protease inhibitor (AEBSF 104 mM, Aprotinin 80 μM, Bestatin 4 mM, E-
64 1.4 mM, Leupeptin 2 mM, Pepstatin A 1.5 mM). To aid cell lysis, samples were sonicated 
three times on ice for 10 s each time (SONICS Vibra cell, Newtown, USA). Following 
sonication, the extracts were centrifuged at 9000 x g (Eppendorf 5418R, Hamburg, Germany) 
for 10 mins at 4 ºC. The supernatants were stored at -20 ºC prior to NAD
+
, lactate and 
kynurenine analysis (see sections 2.6, 7 and 8). All steps were carried out at 4 ºC. All the 
measurements for total protein were performed using a commercially available bicinchoninic 
acid (BCA) protein assay micro
TM
 BCA kit, according to the manufacturer’s instructions 
(Smith et al., 1985). 
The BCA assay is a colorimetric assay which is linear with increasing protein concentrations 
over a range of 5 to 200 µg/ml. The standards were prepared from known BSA protein 
concentrations by 1/3 dilutions in assay buffer to create known standard concentrations (5-
200 µg/ ml; Figure 2.1, overleaf). 
 51 
 
 
Figure 2.1 The BSA protein standard curve. BSA was diluted in assay buffer to create standards of 
known concentrations and was quantified for protein estimation with BCA assay reagents. 
Absorbance was measured at 562 nm and plotted as a function of BSA concentration. 
Briefly, two microliters of sample were pipetted into a 96-well plate followed by 98µl assay 
buffer mixed with 10 x protease inhibitor. Next, an equal volume of BCA working reagent 
(Thermo Scientific # 23228) was added to each well. The reaction was performed at 37 ºC in 
a humidified incubator for 2 h. The absorbance was then read spectrophotometrically at 562 
nm using a plate reader (Versa Max, Molecular Devices, Sunny Vale, CA, USA) and the 
unknown samples were determined from a standard curve created using BSA (Figure 2.1). 
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2.2.6 NAD(H) Micro-cycling assay for the measurement of intracellular NAD
+
 
and NADH levels 
Intracellular NAD(H) concentrations were spectrophotometrically determined using a 
modified enzymatic cycling assay adapted for use in 96-well plates as previously described 
by Leonardo et al. (1996). The principle of this assay is based on the ADH cycling reaction. 
The reaction starts when ADH catalyzes the conversion of ethanol to acetaldehyde. This 
reduces all the available NAD
+
 to NADH. This, in turn, reduces MTT to a blue formazan dye. 
The absorbance is proportional to the amount of NAD(H) present. Also, the absorbance is 
linear with increasing concentrations of NAD(H) content over range (5-60 µM), and can be 
measured at a wavelength of 565nm (see Figure 2.2 for an example standard curve). After 
harvesting, the cells were centrifuged for 5 mins at 200 x g and split in two fractions. One 
fraction was used for NAD
+
 measurements while the other was used for measuring NADH. 
The cell pellets were then extracted with 250 µl 0.2 M HCl (or 250 µl 0.2M of NaOH for 
NADH measurement), and incubated at 100 ºC for 10 mins for NAD
+
 quantification. Extracts 
were centrifuged at 9000 x g for 5 mins and kept on ice. Supernatant was removed and stored 
in -20 ºC until analysis.  
The cycling assay was performed as follows. Forty nine microlitres of the acidic or alkaline 
extract was placed in each well, and 151 µl of cycling reagents, containing 98 mM sodium 
bicine buffer, pH 8.0, 1.626 mM of PES, 4.2 mM MTT, 9.8% (v/v) absolute ethanol, 3.92 
mM of EDTA pH 8.0 (adjusted with 1M HCl), and 5 µl of yeast ADH (400 U/mg) in 0.1 M 
sodium bicine buffer, pH 8.0, were added to each well, followed by 30 mins incubation in the 
dark at room temperature. The absorbance was measured at 565 nm on a plate reader (Versa 
Max, Molecular Devices, Sunny Vale, CA, and USA). NAD
+
 levels were expressed as 
pmol/10
6
 cells. The NAD
+ 
and NAD(H) concentrations were measured using the NADH 
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standard curve (Figure 2.2). All samples were corrected for the blank (without NAD
+
 and 
NADH) back ground activity and dilution factors before calculation. 
 
Figure 2.2 The NAD(H) standard curve, generated using the NAD(H) cycling assay. NADH was 
dissolved in PBS and diluted to known standard concentrations. The absorbance was measured 
spectrophotometrically at 565 nm and plotted as function of NAD(H) concentration.  
2.2.7 Determination of IDO-kynurenine activity in M1-like and M2-like 
macrophages 
Kynurenine was measured in culture supernatant for extracellular kynurenine while cells 
were lysed for intracellular kynurenine production. The Ehrlich colorimetric reaction assay 
was performed to determine the kynurenine concentration (Braun et al., 2005). Briefly, in 
order to precipitate protein, 60 µl samples were incubated with 30 µl 30% (w/v) TCA 
(trichloroacetic acid) at 50 ºC for 30 mins. Samples were then vortexed and centrifuged at 
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3000 x g for 10 minutes. A seventy five microliters volume of the upper phase was mixed 
with an equal volume of Ehrlich Reagent (2% (w/v) p-dimethyl amino benzaldehyde in 5 ml 
glacial acetic acid) in separate wells of a 96-well plate. Kynurenine was measured 
spectrophotometrically at 492 nm using a plate reader (Versa Max, Molecular Devices, 
Sunny Vale, CA, USA; Takikawa et al., 1986). The absorbance of a reagent blank was 
subtracted from sample absorbance values. 
2.2.8 Measurement of Lactate production  
Differentiated macrophages were either stimulated or not stimulated with E.coli k12-LPS 
(100 ng/ml). The supernatant from each sample was harvested and the lactate content was 
determined in a 96-well plate using an end-point colorimetric lactate assay. The lactate assay 
is based on the lactate dehydrogenase (LDH) reaction in which lactate is oxidized to pyruvate 
via the activity of LDH. Pyruvate is then decomposed by the action of hydrazine allowing the 
complete oxidation of all lactate molecules. To achieve this, NAD
+
 is provided in excess and 
the concentration of lactate in the sample is proportional to the increase in absorbance as 
NAD
+
 is reduced to NADH.  
Briefly, 6 µl samples were incubated for 1 h at 37 ºC with 268 µl freshly prepared assay 
buffer containing 0.4 M hydrazine sulphate, 0.5 M glycine (adjusted to pH 9.0 with 3 M 
KOH), 80 mM NAD
+
 and LDH (20 U/ml; Roche Diagnostics GmbH, Penzberg, Germany). 
Lactic acid was diluted in 50mM potassium phosphate buffer, pH 7.4, to create standards of 
known concentration (0-2000 µM; Figure 2.3) and absorbance was measured as function of 
lactate concentration. The absorbance was measured spectrophotometrically at 340 nm and 
lactate of unknown samples was quantified and normalised to proteins from each samples. 
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Figure 2.3 Example standard curve generated using the lactate assay. Lactate was diluted in assay 
buffer to create standards of known concentrations and absorbance was measured at 340 nm and 
plotted as a function of concentration. 
 
2.2.9 Quantitative analysis of cytokines levels 
To quantify TNF-α/IL-6 release, cell-free culture supernatants were collected and analyzed 
for cytokine secretion using sandwich enzyme-linked immunosorbent assay (ELISA) as 
previously described according to the manufacturer’s instructions. The cells were centrifuged 
3000 x g for 5 minutes and the supernatants were harvested, protocols were followed and the 
results compared to standard curves within the range 7 to 5,000 pg/ml. Briefly, 96-well 
ELISA plates (Nunc, Fisher Scientific, UK) were coated with either (4 µg/ml) of mouse anti-
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human TNF-α or (1 µg/ml) of rat anti-human IL-6 in coating buffer (PBS) followed by 
overnight incubation at 4 ºC. After this step, the plate was blocked with 2% BSA (w/v in 
PBS). Fifty microliters samples and standard of TNF-α or IL-6 were added into the plate and 
incubated overnight at 4 ºC. For cytokines measurement, biotinylated mouse anti-TNF-α at 1 
µg/ml or biotinylated rat anti-Human IL-6 at 0.5 µg/ml in 2% BSA (w/v in PBS) was applied 
to form a sandwich complex and incubated at room temperature for 3h. Additionally, (4x) 
horseradish peroxidase streptavidin conjugate (HRP) was added, followed by incubation with 
the substrate, TMB (3,3,5,5-tetramethyl benzidine). The reaction was stopped by addition of 
1.17 mM sulphuric acid. Colour development was assayed spectrophotometrically using an 
OPTI Max tunable microplate reader set to 450 nm and the results analyzed by Soft max Pro 
version 2.4.1 software (Versa Max, Molecular Devices, Sunny Vale, CA, USA).  
2.2.10 RNA extraction, reverse transcription and real time qPCR 
Total RNA was extracted from 1 x 10
6
 cultured cells, after twice washing with PBS, using a 
Gen Elute Mammalian Total RNA kit (Sigma-Aldrich, Poole, UK) with a DNase I digestion 
treatment for 15 mins according to the manufacturer’s instructions. The quantity and purity of 
RNA samples were measured at 260 nm and 280 nm using a Nano-drop Plus 
spectrophotometer (Bioscience, Cambridge Bioscience Ltd, Cambridge, UK). For RNA 
purity, A 260/280 ratio, of equal to or less than 2, was considered as optimal. To test the 
quality of RNA, the extracted RNA was run on a 1% agarose gel (Figure 2.4) as mentioned in 
section 2.2.11. Total RNA (at a concentration of 25 ng/ ml) was subsequently was reversing 
transcribed in a total reaction volume of 20 µl containing: 2.5 µM random nonamers, 10 U/µl 
reverse transcriptase (RT) and 500 µM deoxynucleotide mix. The mixture was then incubated 
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for 1h at 42 ºC, followed by an inactivation step at 50 ºC for 5 min before qPCR was 
performed.  
 
Figure 2.4 Determination of RNA integrity, using gel electrophoresis. Total RNA from each samples 
were run on 1% agarose gel and stained with Syber® Safe nucleic acid gel stain to evaluate the RNA 
integrity. The intact RNA (high quality RNA) shows two ribosomal RNA (rRNA) bands- 28S and 
18S- with one approximately double the size of the other. 
qPCR was performed to quantify specific mRNA using a SYBR® green detection kit 
according to the manufacturer’s instructions (Sigma-Aldrich, Poole, UK). The qPCR analysis 
was carried out using an Applied Biosystems Step-One Plus real-time PCR system with Step-
One
TM
 software (v2.2.2; Applied BioSystems). The cDNA product was utilized in the 
reaction mixture containing 0.4 nM of specific forward/reverse primer sets along with 0.025 
U/µl reaction of SYBR®-Green Jumpstart Taq ready mix (Sigma-Aldrich, Poole, UK) in a 
total volume of 20µl. The reactions were performed under the following thermocycling 
conditions: denaturation at 94 ºC for 1min and final elongation step at 72 ºC for 30s. To 
verify the purity of PCR products, all samples were subjected to melting curve analysis to test 
for single amplification of a specific product. The primers used for qPCR are listed in table 
2.4 (overleaf). The sequence of primers for all target genes were checked using primer 
express software (v2.2.2; Applied BioSystems). 
   Time (h)          0       4        8      12       18       24 
28S 
18S 
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Table 2.4 The primer sequences of selective genes in NAD
+
 metabolism pathway 
Target 
genes 
Sequence (5’      3’) Primer 
size 
(bp)                
Annealing 
Temperature 
(ºC) 
Product 
size 
    (bp) 
GAPDH For: CCCACTCCTCCACCTTTGAC   20 56 100 
 Rev: CTGTTGCTGTAGCCAAATTCGT 22 56  
CD38 For: GCACCACCAAGCGCTTTC 18 57 100 
 Rev:TCCCATACACTTTGGCAGTCTACA 24 56  
CD157 For: GGGAAGGCAGCATGAAAGTC 20 56 105 
 Rev: GGTCCACGCACTGTAAGAGCTT 22 57  
IDO For: GCCTGCGGGAAGCTTATG 18 56 100 
 Rev: TGGCTTGCAGGAATCAGGAT 20 57  
NMNAT For: TCATTCAATCCCATCACCAACA 22 56 105 
 Rev: AGGAGAGATGATGCCTTTGACAA 23 57  
NAMPT For: TCCGGCCCGAGATGAAT 17 57 105 
 Rev: TGCTTGTGTTGGGTGGATATTG 22 56  
 
The relative amounts of mRNA for each target transcript were normalized according to the 
expression of the house-keeping gene, glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). This gene was chosen because it was stably expressed in both M1-like and M2-
like differentiated macrophages. The values were expressed, using the formula 2
-ΔΔCt
, as fold 
differences between the stimulated and non-stimulated differentiated cells, and also relative 
to the value at zero time points of THP-1 cells (Livak and Schmittgen, 2001).  
 59 
 
 
Figure 2.5 Schematic diagram depicting the basic steps of the gene transcription process using real 
time quantitative PCR (RT qPCR) analysis. The mRNA was extracted from the sample, the integrity 
of the sample was confirmed using gel electrophoresis, before reverse transcription and finally qPCR 
were performed. The product was tested for purity using melting curve analysis.  
 
2. 2.11 Agarose gel electrophoresis for RNA analysis  
Agarose (0.4 g) was dissolved in 40 ml of1 x TAE buffer which was prepared by mixing 9.68 
g Tris, 2.28 ml glacial acetic acid and 4 ml of 0.5 M EDTA (made up to 200 ml distilled 
water and adjusted to pH 8. The agarose was melted by microwaving for approximately 1-2 
mins until boiling and then cooled down by swirling the flask in a cold water bath at 
temperature (4 ºC). Four microliters of 10,000 x SYBR® Safe nucleic acid gel stain was 
added to the melted agarose before being poured (about 40 ml) into a tank has buffer in it and 
fitted with 12 well combs. The gel was left to set at room temperature. The gel was covered 
with 1x TAE running buffer in an electrophoresis. Samples were diluted appropriately with 
loading buffer: containing 25 mg Bromophenol Blue, 3 ml glycerol and 7 ml water. Finally, 
samples were loaded into wells on gel and the gel was run at 80-150V until the dye front had 
travelled approximately 75-80% along the gel. 
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2. 2.12 Characterisation of the bioenergetic flux in differentiated macrophages  
The cells were seeded at density 40,000 cell/well and differentiated in XF24 (extracellular 
flux 24) cell culture plate and incubated with LPS- k12 (100 ng/ml) or with medium alone 
(control). After the indicated times, the cells were washed twice with medium. The medium 
was removed from each well and replaced with fresh 650 µl glucose-free Krebs-Ringer buffer 
(KRH) containing 135 mM NaCl, 1 mM HEPES, 0.5 mM MgCl2, 1.5 mM CaCl2, 0.5 mM 
NaH2PO4, 2 mM glutamine and 0.1% w/v BSA, followed by adjustment to pH 7.4 with 0.5 
mMsodium phosphate and incubated at 37 °C for 30min. To characterise the bioenergetics 
flux in differentiated macrophages, a Seahorse extracellular flux analyser was used (Seahorse 
Bioscience, USA). This system is a fully integrated 24-well instrument that measures in real 
time the changes in oxygen uptake (oxygen consumption rate, OCR) and proton (extracellular 
acidification rate, ECAR) in the media surrounding adherent cells. ECAR and OCR were 
measured using disposable assay kits that contain an XF24 cell culture plate and a solid state 
sensor cartridge, embedded with 24 dual fluorescent biosensors (detecting O2 and pH). Each 
sensor cartridge is also equipped with four drug delivery chambers per well for injecting test 
agents into wells during an assay. All the test drugs were prepared at appropriate 
concentrations in the assay buffer. Prior to performing XF24 analysis, the sensor cartridge 
was loaded with 75 µl of test drugs (oligomycin, retonone/antimycin or 2-deoxy glucose). 
While the sensor cartridge was calibrated the cell plate was incubated in a 37 ºC non-CO2 
incubator for 30 mins, in order to allow medium temperature and pH to reach equilibrium, 
before the assay started. After calibration, the cartridge was placed over the plate that 
contained cells and then transferred to a temperature-controlled 37 ºC seahorse analyser. The 
plate was then subjected to an equilibration step for 10 mins. The ECAR and OCR baseline 
(before compounds addition) were measured during 3-4 measurement cycles, each consisting 
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of a mixing step of 1mins, 2 mins incubation and finally a measuring time of 3min. After the 
base line measurement, testing drugs were injected into each well to the final working 
concentration. The first injection was glucose (1mM) and glucose induced-stimulation ECAR 
or OCR were measured. The second injection was oligomycin (1µM) to inhibit ATP 
mitochondrial production, with the increase in ECAR after this point representing the 
capacity of cells to increase glycolysis to maintain ATP production. Finally, 100mM 2-DG 
(2-deoxy glucose) or a mixture of rotenone/antimycin (1 µM/2 µM, respectively) was added 
to inhibit glycolysis or complex I and III to correct non-acidification or non-mitochondrial 
respiration rate, respectively. OCR was expressed as picomoles per minute (pmols/ min) and 
ECAR as milli-pH per minute (mpH/ min). 
2.2.13 Scanning electron microscopy 
Cells were seeded on 12 mm glass coverslips in six-well plates and incubated with PMA 
(25ng/ ml) or Vitamin D3 (10nM) to generate M1-like and M2-like macrophages as described 
in section 2.2.2. Non-differentiated THP-1 cells were used as a control. The cells were 
initially fixed in 2.5% (v/v) glutaraldehyde (Agar scientific, Stansted, UK) in pH 7.2, 0.1 M 
sodium cacodylate buffer for 2 h. The coverslip was washed four times with 0.1 M 
cacodylate buffer at pH 7.2 for 10 mins each time. After the washing step, coverslips were 
then alcohol dehydrated in a graded ethanol series (v/v) in water (30%, 50%, 70%, 90% and 
100%) for 15 mins each time. Finally, coverslips were then critically point dried in an 
Emitech k850 critical point drier before being placed on aluminium stubs (Agar scientific, 
Stansted, UK) with a carbon infiltrated minitab also known a ‘black spot’ (Agar scientific, 
Stansted, UK). This was followed by sputter coating with gold/palladium using an Emitech 
K550 (Quorum Technologies, Laughton, UK) gold sputter coating unit. The stubs were then 
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examined using a JEOL JSM 6610 LV scanning electron microscope (SEM) using a 
appropriate magnifications to produce the desired images. 
2.2.14 Statistical analysis 
Statistical calculations were performed using Statgraphics Centurion XVI (Stat Point 
Technologies, Inc.) and Minitab 17 Statistical Software. All data were tested for normality 
using the Anderson-Darling test (with P < 0.05 indicating that the data were non-normal). 
Levene’s test was used to check that there were no significant differences in variance 
between each group (P < 0.05 indicated a significant difference in variance between groups). 
For normally distributed data, significant differences were determined using one way 
ANOVA followed by Tukey’s test while the non-parametric ranking (Kruskal-Wallis) test 
was performed when data were non-normally distributed. To further investigate the main 
effects, Bonferroni tests were carried out as post hoc multiple comparison tests for normal 
and non-normal data, respectively. Data were reported as means ± standard error (SE) for 
triplicate samples from three separate experiments unless otherwise indicated. Differences 
were considered significant if P < 0.05.  
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Figure 2.6 General schematic diagrams summarizing the experimental design and the assays carried 
out during this study. THP-1 cells were differentiated into M1-like and M2-like macrophages using 25 
ng/ml PMA and 10 nM vitamin D3 respectively. The morphological changes were determined using 
SEM technique as mentioned in section 2.2.13. After stimulation with LPS, the cells were lysed and 
assayed for NAD
+
, protein and kynurenine. The cells free supernatant was used for ELISA, lactate 
and extracellular kynurenine. Finally, bioenergetics flux was determined in viable cells free medium.  
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CHAPTER 3 
NAD
+
 HOMEOSTASIS PROFILE IN PRO-
INFLAMMATORY (M1-LIKE) AND ANTI- 
INFLAMMATORY (M2-LIKE) 
MACROPHAGES 
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3.1 Introduction 
It is widely accepted that there is a close link between metabolic activity (energy status) of 
immune cells and their ability to mount appropriate immune responses (Hotamisligil and 
Erbay, 2008). In particular, classically activated, pro-inflammatory (M1) macrophages obtain 
their energy largely through glycolysis to support rapid immune responses whereas 
alternatively activated; anti-inflammatory (M2) macrophages rely mainly on oxidative 
phosphorylation to support long term-immune functions such as wound healing and tissue 
repair (Galvan-Pena and O'Neill, 2014). NAD(H) is considered to be crucial as a co-factor to 
maintain redox balance such that flux through glycolysis can continue. Besides its role as a 
co-factor, NAD
+
 is required for a broad range of metabolic pathways. Indeed, NAD
+
 is also 
involved in a number of signalling processes including calcium signalling and gene 
transcriptional regulation (Schreiber et al., 2006; Malavasi et al., 2008; Koch-Nolte et al., 
2009). In particular, regulation of gene expression by the NAD
+
-dependent enzymes, sirtuins, 
has been shown to play a critical role in modulating of the synthesis of the pro-inflammatory 
cytokine, TNF-α (van Gool et al., 2009). Conversely, it has been shown that TNF-α itself is 
able to modulate intracellular NAD
+
 levels by regulating the expression of selective NAD
+
 
homeostatic enzymes, probably via a form of feedback regulation, in a model of primary 
murine macrophages (Iqbal and Zaidi, 2006). In response to TNF-α, these cells have been 
shown to upregulate the expression of NAMPT, IDO, CD38 and CD157 (Mehta et al., 1996; 
Okuyama et al., 1996; Musso et al., 2001; Nua et al., 2002; Rongvaux et al., 2003; Iqbal and 
Zaidi, 2006). Among the NAD
+
 homeostasis enzymes, CD157 and CD38 have shown 
contrasting expression patterns on immune cells where CD157 is expressed in mature 
monocytes whereas CD38 is expressed on macrophages suggesting an important role in cell 
maturation and differentiation (Okuyama et al., 1996; Frasca et al., 2006). In macrophage and 
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monocytic cell lines, the induction of CD38 expression, has been shown to increase their 
antigen presenting ability and the ability to secrete pro-inflammatory cytokines (Funaro et al., 
1990; Lund et al., 1995). Furthermore, LPS has also been shown to mediate the expression of 
NAMPT (nicotinamide phosphoribosyl transferase, a key enzyme in the NAD
+
 recycling 
pathway) in activated monocytes and macrophages. Indeed, inhibition of NAMPT by FK866, 
also called APO866 or WK175; (E-N-[4-(1-benzoyl piperidine)-4-yl) butyl] acrylamide-3-
pryridin-3-yl), which is a non-competitive inhibitor NAMPT, led to the increase in 
intracellular NAD
+
 being blocked in macrophages (Hasmann and Schemainda, 2003). The 
upregulation of NAMPT expression was interpreted as a physiological response to provide 
adequate intracellular NAD
+
 levels for optimal TNF-α production in activated macrophages 
(van Gool et al., 2009). However, despite these interesting observations and the intrinsic link 
between NAD
+
 and immune regulation, the potential roles of NAD
+
 homeostasis in 
macrophages and their relationship to the cell phenotype effector functions is not yet 
completely understood. Understanding NAD
+
 synthesis/consumption in macrophages is 
important to underline and develop potential effective treatment strategies in the context of 
tumours. Tumour microenvironments are composed of tumour cells as well as other 
infiltrated immune cells including circulating monocytes and macrophages that are recruited 
by tumours. While recruiting, M2 cells are polarized resulting in promotion of tumour 
progression (Chanmee et al., 2014). Therefore, a recent focus in the switch from M2 
polarization (pro-tumour) into M1 polarization (anti-tumour) has been suggested as a better 
pharmaceutical strategy for targeting tumours (Chanmee et al., 2014). Indeed, it has recently 
been shown that polarization from an M2 to an M1 phenotype suppressed mammary tumour 
growth and angiogenesis in vivo (Zhang et al., 2013; Foey, 2015). To understand more about 
and NAD
+ 
levels in macrophages, we have investigated NAD
+
 homeostasis using THP-1 cell 
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line-derived M1-like MΦs and M2-like MΦs. The results showed that NAD+ levels differ 
markedly between M1-like and M2-like macrophages with M1s having much higher basal 
levels. Also, both phenotypes display differential expression profile of selective NAD
+
-
homeostasis enzymes in the resting state as well as in the activated state. This could suggest 
that NAD
+
 homeostasis enzyme expression and activity as an additional tool in 
discriminating macrophage maturation and differentiation. 
3.2 Results 
3.2.1 M1-like and M2-like macrophage subsets differ in their morphology and 
the ability to secrete cytokines in response to LPS stimulation 
The links between TNF-α and NAD+ levels are well documented. This link might represent a 
novel regulatory mechanism controlling TNF-α synthesis by the cells of the immune system. 
In order to investigate this link further, we made use of the differentiation of THP-1, a 
monocytic cell line. THP-1 cells have become commonly used for the study of macrophage 
differentiation and immune responses due to (i) the similarity with blood primary monocyte 
cells, (ii) the difficulty in obtaining primary cells from patient blood and (iii) the fact that 
phenotypically, these cells are more stable than primary monocytes/ macrophages since it has 
been reported that THP-1 minimizes the genetic variation in the phenotype (Cousins et al., 
2003; Rogers et al, 2003). We investigated whether THP-1 can be used as a model to 
generate cells with characteristics of M1-like and M2-like macrophages (MФs) by using 
PMA and vitamin D3, respectively. To verify whether THP-1 was useful model for 
differentiated macrophages, both the pro-inflammatory TNF-α release and the release of 
regulatory IL-6 was measured following differentiation. The morphology of the generated 
macrophages was investigated using scanning electron microscopy (SEM), as described in 
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section 2.2.13. SEM images of resting cells showed clear differences between PMA-
differentiated (M1-like) THP-1 MФs in comparison to vitamin D3– differentiated (M2-like) 
THP-1 MФs and non-differentiated THP-1 cells. M1-like MФs became adherent and changed 
their morphology to become more flat, amoeboid in shape and developed long pseudopodia 
extensions resembling classically activated MΦs in their appearance (Figure 3.1). Also, PMA 
caused the cells to become attached to the cell culture plate, requiring trypsin treatment to 
remove them. In contrast, non-differentiated THP-1s maintained their shape and did not 
adhere to the culture plate surface. Similarly, there were no appreciable differences in the 
external morphology of M2-like cells, which stayed rounded and spherical in shape, although 
the cells developed a ruffled membrane and increased their size relative to untreated THP-1s 
(Figure 3.1). Given that macrophage heterogeneity is influenced by differentiation state, we 
investigated potential differences in immune responses, particularly in cytokine production 
between the two subsets. Differentiated macrophages were stimulated with 
lipopolysaccharide (LPS) and both TNF-α and IL-6 secretion was measured. LPS, an outer 
membrane component of Gram negative bacteria, is known to mediate monocyte and 
macrophage activation (Meng and Lowell, 1997). As expected, M1-like released TNF-α, but 
little IL-6 while the opposite was true for M2-like cells (Figure 3.2 A, B). Significant 
increases in TNF-α levels started soon after stimulation (4 h, P = 0.007) compared to the 
control (unstimulated) and peaked at 8 h (P = 0.004) before declining after 24 h (P = 0.07) as 
shown in figure 3.2 A. In contrast, M2-like MФs released TNF-α after 4 h of LPS 
stimulation, but 10-fold lower than that secreted by M1s as in figure 3.2 A. M2-like MФs 
showed significantly increased IL-6 levels during LPS stimulation compared to M1-like cells 
with the magnitude 8-fold lower than that of the M2-like cells. Indeed, IL-6 levels increased 
within 4 h (P = 0.03) compared to the control (unstimulated) cells, peaking at 8 h (p = 0.001), 
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after which time they started to decline during the stimulation period (24 h). However, IL-6 
release in M1-like cells was within the range of unstimulated levels of that for M2-like cells 
during LPS stimulation (Figure 3.2 B). Neither of the differentiated non-stimulated subsets 
released any detectable cytokines into the culture medium without LPS stimulation. In 
addition, non-differentiated, stimulated THP-1s released a detectable amount of TNF-α after 
4 h (data not shown) under LPS challenge. Taken together, the data suggests that PMA-
differentiated THP-1 exhibited M1-like characteristic due the changes in morphology and 
TNF-α secretion whereas differentiation with vitamin D3 induces less morphological changes 
and TNF-α secretion. Therefore, our observations suggest that THP1-derived macrophages 
differentiated by PMA or vitamin D3 could be a useful strategy for generating a reliable 
model of differentiated macrophages to study macrophage immune responses. 
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Figure 3.1 Scanning electron micrographs showing the morphological changes of differentiated 
macrophages compared to non-differentiated THP-1 cells. THP-1 cells were differentiated with either 
25 ng/ml PMA or 10 nM vitamin D3. Scale bars=1 and 10 µm. 
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Figure 3.2 LPS stimulation induces differential cytokine secretion profiles in M1-like and M2-like 
MФs. THP-1 cells were differentiated into M1-like and M2-like macrophages using either PMA (25 
ng/ml) or vitamin D3 (10nM), respectively. Differentiated cells were then stimulated with LPS-K12 
(100 ng/ml). Cytokine production is expressed in pg/10
6 cells for (A) TNFα and (B) IL-6. Data are the 
mean ± SE of three biological experiments, n=3-4. The data were analysed by two-way ANOVA with 
Bonferroni test. Significant differences in cytokine production between activated M1 and M2 MΦs 
are indicated as *P < 0.05, **P< 0.01, ***P < 0.001. 
10µm 
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3.2.2 The association between LPS stimulation and NAD
+
 levels in differentiated 
macrophages 
The link between NAD
+
 metabolism and inflammation is well established in macrophages. 
To test this link further, we first investigated NAD
+ 
levels in resting macrophages and 
compared to THP-1 cells (control) prior stimulation with LPS. Our data show that M1-like 
MΦs display significantly higher basal NAD+ levels (P= 0.0001; Figure 3.3 A) compared to 
resting M2-like
 MΦs and control THP-1s (P = 0.004). Importantly, we observed no 
significant differences in NAD
+
 levels between M2-like MΦs and the control cells. It is 
known that LPS induces TNF-α release in a TLR4-dependent manner and to understand 
whether NAD
+
 is also involved, the NAD
+
 levels were measured in both subsets during LPS 
stimulation. While LPS caused a significant increase in NAD
+
 levels in M1-like MΦs (P = 
0.0001; Figure 3.3 A) it failed to affect NAD
+
 levels in both THP-1 and M2-like MΦs with 
both stimulated and non-stimulated cells showing similar levels of NAD
+ 
throughout the 
experiment (Figure 3.3 A). Upon stimulation with LPS, M1-like MΦs showed a large 
biphasic increase in intracellular NAD
+
 levels with a significant distinct peak after 30 min (P 
= 0.0001) followed by a second significant but lower peak at 4 h (P = 0.001) that remained 
high and lasted for several hours, starting to return to unstimulated levels at 24 h (Figure 3.3 
B). M1-like stimulated with LPS for 4 h significantly increased NAD
+
 compared to non-
stimulated M1-like macrophages (0 h, P = 0.002 and 4 h, P = 0.0002). These results suggest 
that LPS affects NAD
+
 levels differently in the two subsets with NAD
+
 levels being 
associated with LPS stimulation only in M1-like MΦs, suggesting that M1-like MΦs might 
be characterised by NAD
+
 changes. Also, these observations could suggest that NAD
+
 levels 
might have a critical role for LPS mediated TLR4-induced signalling pathways in pro-
inflammatory M1-like cells. 
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Figure 3.3 LPS stimulation increases NAD
+
 levels in pro-inflammatory M1-like macrophages. 
Differentiated macrophages were induced by incubation with PMA and vitamin D3 prior to 
stimulation with LPS. Pellets were harvested at intervals for NAD
+
 analysis using NAD
+
 cycling 
assay (A) Differential profile of basal NAD
+
 levels in differentiated and non-differentiated (control) 
cells. NAD
+
 levels increased in M1-like cells (B), while it was not affected in M2-like macrophages 
under LPS challenge (C). Data shown are mean ± SE of three biological experiments (n = 3). Results 
are significantly different (*P < 0.05, **P < 0.01, ***P < 0.001) when analysed by two-way and one 
way ANOVA followed by post hoc multiple pairwise Bonferroni comparisons compared to the 
control.  
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3.2.3 Differential profiles of NAD
+
 homeostasis in resting macrophages 
We showed that NAD
+
 levels clearly differ between M1-like and M2-like MФs during LPS 
stimulation, therefore we were interested whether these two subsets differ in the way they 
perform NAD
+
 production. To achieve this, both subsets were treated with either FK866, an 
inhibitor of NAD
+
 synthesis (via inhibition of NAMPTase), nicotinamide (a dietary NAD
+
 
precursor) or quinolate (an NAD
+
 precursor formed via the IDO pathway; Figure 3.4). The 
concentrations used in this study were chosen based on preliminary experiments and the 
literature (Grant and Kapoor, 1998; Busso et al., 2008; Bowlby et al., 2012). THP-1 cells 
were incubated over 24h with a range of different agents (Figure 3.4 A, B, C). The FK866 
treatment was able to significantly decrease NAD
+
 levels within the range 1-1000 nM at 
different times (P = 0.001). However, 100 nM FK866 at 2 h was chosen for all experiments 
because we were interested in early NAD
+
 response. Indeed, this concentration is commonly 
used for NAMPT inhibition (Busso et al., 2008; Bowlby et al., 2012). Also, differentiated 
MФs were incubated with nicotinamide and quinolate (10-300 µM) for up to 3 days (Figure 
3.4 B, C). Both nicotinamide and quinolate significantly increased NAD
+
 levels at 300 µM 
after 24 h (P = 0.001), therefore, this concentration was chosen for the other experiments. It 
has been reported that higher micromolar concentrations of nicotinamide and quinolate 
caused increases in NAD
+
 generation (Grant and Kapoor, 1998). Interestingly, FK866 caused 
a drop in NAD
+
 levels in M2-like MФs (Figure 3.5 B), while it conversely caused an NAD+ 
increase in M1-like MФs (Figure 3.5 A). M1-like MФs were able to gradually and 
significantly increase NAD
+
 levels (P = 0.02) within 4 h of FK866 treatment, reaching 
maximum levels after 12 h (p = 0.0014). In M2-like cells, the decrease was not significant 
and occurred within 2 h of FK866 treatment, continuing steadily during the entire 
experiment. This might suggest that the NAD
+
 consumption rate is high in M2-like MФs as 
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FK866 blocks NAD
+
 recycling while the opposite is true for M1-like MФs. Coupled with 
this, NAD
+
 synthesis from the NAD
+
 precursor nicotinamide was high in M1-like cells after 
24 h treatment but low in M2-like cells (Figure 3.5 C), again supporting the rapid change in 
NAD
+
 levels in M1-like cells. M1s were able to significantly increase NAD
+
 levels by almost 
45% after nicotinamide treatment compared to the control (P = 0.01). In contrast, 
nicotinamide treatment failed to induce a significant increase in NAD
+
 generation in M2-like 
MΦs. These data fit well with observations showing that M1-like MФs are able to rapidly 
increase their NAD
+
 levels while M2-like are not. This might support the assumption 
suggesting that NAD
+
 recycling is low in M2-like cells compared to M1-like cells. On the 
other hand, quinolate treatment did not induce significant changes in either subset (Figure 3.5 
D). Collectively, these observations might suggest that the two phenotypes differ in the way 
they handle NAD
+
 homeostasis, highlighting that this might be phenotype-specific. 
Therefore, the gene expression of selected regulators of NAD
+ 
homeostatic enzymes (IDO, 
NAMPT, CD38, CD157 and NMNAT) was investigated to further understand differences 
between the two subsets. 
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Figure 3.4 The effect of FK866, nicotinamide (NAM) and giunolate (QUN) on NAD
+
 levels in 
undifferentiated THP-1 cells over time. THP-1 cells were incubated with (A) FK866 (0.1-1000 nM), 
(B) nicotinamide (10-1000) µM for 1-3 days and finally with (C) quinolate (10-300) µM for 1-3 days. 
Data shown are mean ± SE of three replicate samples (n = 3). Results are significantly different (*P< 
0.05, **P < 0.01, ***P < 0.001) analysed by one way ANOVA followed by Bonferroni post hoc test 
compared to the control. 
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Figure 3.5  Resting macrophages exhibit differential profiles of NAD
+
 levels. Differentiated MФs 
were incubated with 100 nM FK866 and then the NAD
+
 content was measured in unit of pmol/10
6
 
cells in (A) M1-like MФs and (B) M2-like MФs over 24 h. Differentiated MФs were incubated with 
300 µM nicotinamide for 1-3 days and NAD
+ 
levels were measured in (C) M1- and M2-like MФs. 
Similarly, 300 µM was chosen and differentiated MФs were incubated for the same time and NAD+ 
levels were measured in (D) M1- and M2-like cells. Data shown are mean ± SE of three separate 
experiments (n = 3). Results are significantly different (*P < 0.05, **P < 0.01, ***P < 0.001) when 
data were analysed by one way and two way ANOVA followed by Bonferroni post hoc test compared 
to the control. 
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3.2.4 Macrophage differentiation induces gene expression of selected NAD
+
 
homeostatic enzymes 
We have shown that NAD
+
 status clearly differs in both subsets in resting and activated 
states. To address these differences in NAD
+
 levels between the two phenotypes, we 
investigated the gene expression profile of some key regulators for NAD
+
 homeostasis, using 
RT-qPCR, compared to expression in the monocytic progenitor THP-1 cell line (Figure 3.6). 
In this analysis, the mRNA expression levels of IDO, NAMPT, CD38, CD157 and NMNAT 
were determined. Upon differentiation with PMA or vitamin D3, however, both subsets 
showed a significant increase in IDO expression compared to THP-1 (P = 0.03; Figure 3.6 
C). Indeed, IDO expression showed the significant highest fold change among the analysed 
enzyme genes. The NADase CD38, which mediates NAD
+
 degradation and can generate 
cADPR, NAADP
+
 and ADP-ribose (Lee, 2006; Howard et al., 1993), was significantly 
(upregulated in M1-like cells (P = 0.02; Figure 3.6 A) and down-regulated in M2-like cells 
(Figure 3.6 B), while the opposite was true for CD157, a homologue of CD38 (Ferrero and 
Malavasi, 1997). Finally, NMNAT (nicotinamide mononucleotide adenylyl transferase), 
which catalyses the final step in NAD
+
 biosynthesis (Magni et al., 1999), was slightly 
upregulated in both subsets (Figure 3.6 C), while NAMPT was significantly  upregulated 
only in M1-like cells (P = 0.04; Figure 3.6 B). These data indicate that NAD
+
 homeostasis 
enzyme expression changes clearly during differentiation state and this might confirm 
previous observations showing the difference of NAD
+ 
levels between differentiated and 
undifferentiated THP-1 cells. The findings from the current study might suggest that the 
enzymes involved in NAD
+ 
metabolism might be associated with macrophage differentiation 
and activation.  
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Figure 3.6 The expression of NAD
+
 homeostasis enzyme genes in both macrophage subsets in the 
resting state. The expression of genes relating to the activity of selected enzymes of NAD metabolism 
were analysed in (A) M1-like (B) M2-like and (C) M1/M2-like MФs. Data shown are mean ± SE of 
three separate experiments (n = 3-4). The data were analysed by one way ANOVA followed by 
Bonferroni test, *P < 0.05. 
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3.2.5 LPS-induces differential gene expression profile of human M1-like versus 
M2-like differentiation 
We wanted to assess whether LPS stimulation could affect the expression of some key 
regulators of NAD
+
 homeostasis over 24 h. In M1-like cells, LPS stimulation caused a 
significant increase in IDO mRNA, with a maximal expression after 12 h (P = 0.02) during 
LPS stimulation and with smaller increases in CD38, CD157 and NAMPT expression within 
4 h of the stimulation while NMNAT expression was unaffected (Figure 3.7 A). Despite LPS 
not being able to stimulate NAD
+
 changes in M2-like cells, LPS stimulation caused 
upregulation of all genes examined except CD157. We observed a similar but significant 
increase in IDO after 4 h of stimulation (P = 0.01). NAMPT expression was significantly 
increased within 4 h (p = 0.02) and maintained a rise for the entire stimulation time unlike 
M1s, where NAMPT reached its maximum expression after 4 h before declining back to 
almost unstimulated levels after 24 h (Figure 3.7 A, B). On the other hand, NMNAT reached 
its maximal expression after 24 h of LPS stimulation (P = 0.017). Surprisingly, the expression 
of CD157 was largely unaffected. The current results suggest that NAD
+
 homeostasis 
enzymes are highly sensitive to LPS stimulation highlighting important immune regulatory 
role for NAD
+
 and its metabolism in differentiated macrophages. 
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Figure 3.7 The kinetic expression profiles of NAD
+
 homeostasis enzymes in (A) M1-like MФs and 
(B) M2-like MФs during LPS stimulation. Differentiated cells were stimulated with LPS (100ng/ml) 
and the gene expression levels measured using RT-qPCR. . Data shown are mean ± SE of three 
separate experiments (n = 3-4). The data were analysed by one way ANOVA plus Bonferroni post hoc 
test *P < 0.05. 
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3.3 Discussion 
The tight link between metabolic activity and cellular phenotype is well established, with 
anti-inflammatory macrophages (M2s) relying on oxidative phosphorylation for energy 
production, the pro-inflammatory (M1) macrophages relying primarily on glycolysis 
(Galvan-Pena and O'Neill, 2014). NAD(H) is necessary for glycolysis, thus it was thought 
that investigating NAD
+ 
levels might be useful in order to understand more about the 
metabolism and immune responses in macrophages. Therefore, we decided to investigate 
NAD
+
 and the NAD
+
 homeostasis profile in macrophages during LPS stimulation using THP-
1 derived macrophage differentiation as a study model. THP-1 cells can be differentiated into 
macrophage-like cells using PMA and vitamin D3 and differentiated macrophages were 
characterised by observing both morphological changes as well as TNF-α and IL-6 secretion. 
As described previously, and as we show here, PMA treatment induces clear changes in cell 
morphology, as cells start to adhere to culture plates, developing long pseudopodial 
extensions and becoming comparable to differentiated macrophage subsets (Traore et al., 
2005; Schwende et al., 1996; Daigneault et al., 2010). On the other hand, vitamin D3 
treatment did not greatly affect the morphology of THP-1 as the cells remained spherical and 
non-adherent although they only increased in size. The observed changes in morphology 
were supported by the observation of distinct cytokine profiles. In keeping with others, we 
also have shown that TNF-α and IL-6 secretion differ greatly between M1-like cells and M2-
like cells with M1-like cells showing a larger increase in TNF-α release but not IL-6, while 
M2-like cells display larger increase in IL-6 but only a little of TNF-α (Schwende et al., 
1996; Daigneault et al., 2010). These results suggest that M2-like might resemble M2b 
features on the sliding sale of macrophage polarization (Figure 1.1) due to TNF-α and IL-6 
secretion. 
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In addition, the results showed that PMA, treatment caused a drop in THP-1 proliferation 
whereas vitamin D3 did not. PMA is well known to activate protein kinases (PKCs), in PMA-
treated THP-1 cells (Schwende et al., 1996), which has been shown to induce cell cycle arrest 
in a ROS-dependent manner during both G0-G1 and G2 phases (Traore et al., 2005). In M1-
like cells, TNF-α increases in response to LPS since ROS is known to regulate TNF-α 
expression in NF-kB-dependent manner (Collart et al., 1990; Shakhov et al., 1990; Trede et 
al., 1995). The NF-B accumulation is induced in cytoplasm of M1-like cells, allowing rapid 
secretion of pro-inflammatory TNF-α in response to LPS stimulation (Takashiba et al., 1999). 
This might explain, at least in part, the large increase in TNF-α secretion by M1-like. This is 
possibly occurring due to the fact that PMA induces metalloproteinases (MMP-9) that are 
required for TNF-α release (Ismair et al., 1998). However, MMP-9 expression was shown to 
be inhibited by vitamin D3 in primary macrophages (Coussens et al., 2009) following 
inflammatory signals which might partially explain the differential trend in TNF-α response 
in M1-like but not in M2-like cells (Mohler et al., 1994; Gearing et al., 1994; McGeehan et 
al., 1994). One possible explanation is that vitamin D3 may be able to suppress the expression 
and protein of TLR2 and TLR4 in human monocytes in a time- and a dose-dependent manner 
resulting in hypo-responsive towards pathogens (Sadeghi et al., 2006). In contrast, PMA has 
been shown to enhance TLR2 responses suggesting important role in macrophages 
differentiation (Daigneault et al., 2010). Enhancement of TNF-α secretion by macrophages 
during monocytes differentiation is well established (Gessani et al., 1993).  
It seems that both NF-B and MMP induction by PMA treatment caused an increase in TNF-
α release in M1-like MФs. Vitamin D3 treatment, on the other hand, showed an opposing 
effect on IL-6 release in response to LPS challenge. The data in this study seems to be in line 
with other works (Daigneault et al. 2010; Foey and Crean, 2013, Hmama et al., 1999) 
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showing that vitamin D3 was capable of increasing IL-6 release following LPS stimulation. 
Indeed, vitamin D3 has been shown to support HL-60 and U937 cells towards 
monocyte/macrophage differentiation but not into granulocytes. This is mediated either via 
induction of alpha-naphthyl acetate esterase activity, a typical marker of monocyte-
macrophages or via receptor-mediated monocytic maturation (Tanaka, et al., 1983; 
Mangelsdorf, 1984; Collins, 1987). It is important to note that IL-6 secretion is not only 
known to mediate pro-inflammatory responses via recruiting mononuclear cells and 
inhibiting Treg. proliferation but is also implicated in the anti-inflammatory response via 
activation of STAT3-mediated signalling pathways (Scheller et al., 2011). STAT3 has 
recently emerged as a vital mediator for M2 differentiation (Chávez-Galán et al., 2015). In 
addition, macrophage stimulation with IL-6 led to downregulated IDO expression which 
might explain the reason as to why M2s display low IDO expression compared to M1s in 
both the resting and activated states (Figure 3.6). Thus, it appears likely that IL-6 secretion 
might support the M2 phenotype versus M1 phenotype. 
There were some differences between macrophages and THP-1 derived differentiated 
macrophages with respect to pattern expression of certain genes. For instance, while both 
apolipoprotein-E and MMP 9 are induced in primary macrophages and M1-like cells, the 
induction of IL-1β is conversely upregulated in M1-like MФs but not in primary 
macrophages (Kohro et al., 2004) suggesting that caution must be taken in interpreting results 
when experiments are done with THP-1 under different conditions. However, collectively, 
the results from this study and the previous research that we referred to in this section seem to 
provide further evidence suggesting that THP-1 is a reliable and suitable model to generate 
cells that might be very close to pro-inflammatory M1-like or anti- inflammatory M2-like 
MФs. It has been reported that NAD+ homeostasis plays a pivotal role in transcriptional 
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modulation of pro-inflammatory cytokines produced by immune cells. For example, NAD
+
-
mediated sirtuin activity has been shown to modulate the production of the pro-inflammatory 
cytokine, TNF-α in pro-inflammatory MФs (van Gool et al., 2009). In the current study, it 
has been demonstrated that NAD
+ 
levels differ significantly between differentiated and non-
differentiated MФs with pro-inflammatory M1-like MФs having higher basal NAD+ levels, 
suggesting that NAD
+
 are pro-inflammatory (Figure 3.3 A). It seems that M1-like MФs 
exhibit higher NAD
+
 synthesis rates than M2-like MФs. This was confirmed by the increase 
observed in NAD
+
 levels after nicotinamide application in M1-like compared to M2-like 
(Figure 3.5 C). This might account for the upregulation in NAMPT expression we observed 
in resting M1-like MФs compared to THP-1 and M2-like MФs (Figure 3.6 A) whereby both 
cells display similar NAMPT expression. This might explain why both cells show similar 
NAD
+
 levels as in Figure 3.3 A. Indeed, NAMPT is the rate limiting enzyme in the NAD
+
 
recycling pathway (Revollo et al., 2004) and this pathway is the most active of the three 
known pathways that lead to NAD
+
 synthesis; the others being the de novo IDO pathway 
(Magni et al., 2004) and the nicotinamide riboside kinase (NRK) pathway (Bieganowski and 
Brenner, 2004). The increases in NAMPT in M1-like MФs would suggest that the cells are 
priming themselves for NAD
+
 production. The induction of NAMPT expression has 
previously been shown in primary murine macrophages (Iqbal and Zaidi, 2006). The increase 
in NAMPT expression might be linked to the findings showing that M1-like MФs are mainly 
glycolytic (Vazquez et al., 2010; Galvan-Pena and O'Neill, 2014) and thus high NAD
+
 levels 
are required to maintain glycolytic activity. In contrast, M2-like MФs were not able to alter 
NAD
+
 levels under same the same conditions suggesting that M2-like MФs exhibit low 
NAD
+
 synthesis capacity compared to M1-like. This complemented the results showing 
NAD
+
 production was not affected by both NAM and quinolate treatment. Furthermore, we 
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observed an opposite effect on NAD
+
 levels between the two subsets. In M2-like MФs, 
FK866 treatment decreased the levels of NAD
+
 over time as it would be expected due to 
inhibition of NAD
+
 synthesis suggesting that M2-like MФs might have high NAD+ 
consumption rate but low synthesis capacity as M2-like failed to increase NAD
+ 
after NAM 
and quinolate application. In contrast, FK866 treatment gradually increased NAD
+
 levels in 
M1-like MФs (Figure 3.5 A). It is not exactly clear as to how this increase might occur. 
However, we can speculate that these rather contradictory results may be explained as the 
NAD
+
 generation might occur partially via NAMPT recycling pathway as it has been shown 
in different results that NADH oxidation via NADPH mechanism could be another source for 
NAD
+ 
production in M1-like cells (see Chapter 4). Additionally, it is also possible that the 
increase in NAD
+
 levels, observed in M1-like, could be related to the impact of NAD
+
-
consuming enzymes on NAD
+
 turnover resulting in NAM accumulation. Indeed, the 
treatment with NAM has been shown to block SIRT-dependent de-acylation and ADP-
dependent PARP activity can be inhibited in micromolar range of non-competitive inhibitor 
NAM (Clark et al., 1971; Shall, 1983; Szabo and Dawson, 1998; Hageman and Stierum, 
2001, Sanders et al., 2007). For example, NAM can inhibit deacetylation reactions through 
interference with the reaction intermediate via a base exchange reaction to reproduce NAD
+
 
at the expense of protein deacetylation reaction (Sanders et al., 2007). The NAD
+
-consuming 
enzymes are regulated by NAD
+
; therefore it has been suggested that NAD
+
/NAM plays a 
critical role in linking and thus modulating the activity of NAD
+
-requiring enzymes 
(reviewed in Hassa and Hottiger, 2008). For instance, limiting NAD
+
 by
 
ADP-PARP activity 
might indirectly led to modulate CD38-depedent mono-ribosylation and SIRT-dependent 
deacetylation activity (reviewed in Hassa and Hottiger, 2008). Indeed, these proteins have 
been shown to be highly up-regulated in activated macrophages and this seems to be 
 87 
 
associated with NAD
+
 catabolism and also the consequence liberation of NAM as end-
product of the process (Paine et al., 1982; Liu et al., 2012). Therefore, treatment with FK866 
resulted in decreased NAD
+
 depletion in a neuronal model due to inhibition SIRT1 activity, 
one the main NAD
+
-consuming enzymes (reviewed in Hassa and Hottiger, 2008). Reduction 
in NAD
+
 depletion has also been reported in neuronal model following FK866 treatment as a 
result of inhibiting PARP1 activity, another of the main NAD
+
-consuming enzymes 
(reviewed in Hassa and Hottiger, 2008). These data indicate that both subsets have 
differential profile of NAD
+
 homeostasis and it is likely that these differences might be 
physiologically relevant. Taken into consideration the differential profile of NAD
+
 
homeostasis, pharmacological approach has been taken to investigate the source of NAD
+
 
levels in macrophages during stimulation (see Chapter 4). 
The intracellular NAD
+
 concentration is often reported to be in the high micromolar range 
(Hasmann and Schemainda, 2003; Houtkooper et al., 2010). The increase in NAD
+
 levels has 
been reported previously in a model of human leukaemia cells such as the HL-60 and THP-1 
cell lines (Baranowska-Bosiacka et al., 2005), suggesting an important role for NAD
+
 in cell 
maturation and proliferation. We also show here increase in NAD
+
 levels whereby M1-like 
MФs exhibit significant high NAD+ levels that are even higher than that for THP-1 cells. It is 
not clear as to why this important increase occurs. A possible explanation is that 
macrophages are known to induce ROS production as part of a defence mechanism, which 
induces PARP activity mediated by DNA damage which is thought to be one of the NAD
+
-
consuming activities in cells (Rodriguez-Vargas et al., 2012; Hassa and Hottiger, 2008; 
Altmeyer and Hottiger, 2009). As a result, PARPs might partially deplete intracellular NAD
+
 
levels, thus promoting the fast recycling of NAD
+
 either de novo or from salvage pathways to 
maintain cellular viability or to support the activity of other NAD
+
-consuming enzymes 
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(Berger, 1985; Skidmore et al., 1979). For instance, PARP-1 binds to the nuclear NAD
+
 
synthase, NMNAT-1 (the enzyme that catalyses NAD
+
 synthesis from nicotinamide 
mononucleotide (NMN) replenishing NAD
+
 and providing sufficient NAD
+
 for
 
PARP-1), 
SIRT1, as well as the main NAD
+
-consumer, CD38 ( Aksoy et al., 2006b; Berger et al. 2007; 
Zhang et al. 2009). Interestingly, M1-like cells showed higher levels of the NADase CD38, 
which might reflect high turnover (Figure 3.6 A). This might explain, at least in part, the 
observed increase in NAD
+ 
content
 
that is frequently followed by a steady drop within 1 to 2 
h of the initial rise before the second rise that start at 4h (Figure 3.3 B). These data might 
agree with evidence suggesting that the half-life of NAD
+
 is short (estimated to be around 1 
to 2 h), forcing the cells to continuously replenish NAD
+
 to restore NAD
+
 balance inside the 
cells (Elliott and Rechsteiner, 1975; Rechsteiner et al., 1976; Williams et al., 1985; Berger, 
1985). In fact, there is evidence showing CD38 as an early differentiation marker (Frasca et 
al., 2006). However, M2-like cells displayed higher expression of CD157, the CD38 
homologue, NADase and the converse of CD38. These findings are in agreement with the 
results obtained by Hussain et al. (2000), who showed that CD157 expression was 
upregulated in vitamin D3-differentiated myeloid cells and conversely downregulated with 
PMA treatment from the same cells. Although there are differences in some genes between 
primary macrophages and M1/M2-like MФs (Kohro et al., 2004), the differential regulation 
of CD157 and CD38 for the two subsets may reflect a similarity to in vitro monocyte and 
macrophages. Indeed, the induction of CD157 expression was shown on myeloid precursors 
as the cells differentiate towards more mature monocytes/macrophages (Kizaki et al., 1991; 
Okuyama et al., 1996; Hussain et al., 2000). In addition, the ability of M1-like cells to 
promote NAD
+
 level increases could occur due to the increase in volume of cells caused by 
PMA treatment, as it has previously been reported that NAD
+
 amount production is 
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associated with an increase in cell volume (Williams et al., 1985). The results from the 
current study show that extracellular application of quinolate had no effect on NAD
+
 
generation in M1-like MФs. It is somewhat surprising there was no increase in NAD+ 
production after quinolate application, although IDO expression was upregulated in both 
subsets suggesting that IDO might not be involved in NAD
+ 
generation in resting state. It is 
not quite clear as to why this occurs. However, it could be that the concentration of quinolate 
used here was not enough to affect IDO activity or that IDO/kynurenine might be not 
efficient under the experimental conditions employed. Given the differences in NAD
+
 levels 
and NAD
+
 homeostasis gene expression, the NAD
+
 changes were investigated during LPS 
stimulation in both subsets. M1-like MФ exposure to LPS stimulation led to significantly 
increasing NAD
+
 levels (Figure 3.3 B). NAD
+
 levels display a biphasic response with a rapid 
peak within 50 minutes followed by a sustained rise that lasted for longer during the 
stimulation. There exists some evidence of the involvement of LPS in NAD(P)H oxidase 
activation (Remer et al., 2003), in a TLR4 dependent manner (oxidative burst) which 
catalyses the NAD
+
 oxidation from NAD(P)H (Riebel et al., 2002). The sustained rise in 
NAD
+
 levels also suggests that NAD
+
 synthesis occurs as it would be expected that the cell 
would return the redox balance after the oxidative burst relatively rapidly so as to maintain 
the NAD
+
/NADH ratio. Given that classical activation (M1s) induces glycolysis to support 
fast and rapid response while M2s (alternative) utilize oxidative metabolism to support the 
long phase response (Vazquez et al., 2010; Galvan-Pena and O'Neill, 2014)our data could 
suggest a critical role for the NAD
+
 increase in the rapid response reflected by the initial rise 
that end with a drop after 24 h to allow the second and long phase of the response, 
highlighting important role for NAD
+
 levels in cells phenotype effector function. Indeed, it 
has been shown that NAD
+
 behaves like pro-inflammatory cytokine, recruiting granulocytes 
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at the site of inflammation (Bruzzone et al., 2006). Together, these findings suggest that LPS 
affects NAD
+
 homeostasis differently in the two phenotypes with pro-inflammatory M1-like 
cells are characterized by changes in NAD
+
 while anti-inflammatory M2-like MФs are not. 
Also, the gene expression of NAD
+
 homeostasis enzymes was investigated during LPS 
stimulation in both subsets. The greatest increase in expression, compared to parent THP-1 
cells, was in IDO in both phenotypes and it might be expected that the de novo pathway 
would, thus, be the biggest contributor to NAD
+
 levels. However, this pathway is known to 
contribute little to the intracellular NAD
+
 pools with as little as 1 in 60 molecules of NAD
+
 
being derived from tryptophan (Horwitt et al., 1956). The IDO has been shown to play a key 
role in mediating the flux between pro- and anti-inflammatory cytokines production (Pilotte 
et al., 2012). It seems that the increase in IDO expression is to regulate macrophage immune 
function in the second phase of the response.  
In M1-like cells, mRNA expression of all enzymes except NMNAT increased significantly 
within 4h of LPS stimulation with the largest effects on IDO and CD38. In agreement with 
this, it was found that LPS was able to induce increase in IDO and CD38 expression in NF-
kB-dependent manner (Fedele et al., 2004; Jung et al., 2007). It is likely that the TNF-α 
released during the experiment is partially responsible for the expression observed and thus 
why the results largely follow the same trend (Figure 3.7 A) This assumption seems to be in 
line with Iqbal and Zaidi (2006) who revealed that TNF-α application to macrophages 
increased the expression of the same enzymes. M2-like MФs, that secreted a lesser amount of 
TNF-α, showed subtle differences in expression profiles of the enzymes. While IDO and 
CD38 both significantly increased, CD157 remained unchanged in M2-like (Figure 3.7 B). 
Most striking was the differential regulation of NMNAT and NAMPT mRNA expression. 
While we have been unable to measure long-term effects after LPS stimulation due to 
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limitations in the cell model, it is tempting to postulate that changes in NAD
+
 homeostasis 
caused by these changes in gene expression, might contribute to changes in cell phenotype 
and immune function post-infection. It is tempting to speculate that the change in NAD
+ 
homeostasis gene expression might be required for the initial phase of response which takes 
few hours to day since the genes expression results seem to follow the same trend of TNF-α. 
Therefore, future work must be directed to investigate the NAD
+ 
homeostasis in the 
macrophage during the second phase of response. 
In conclusion, the current findings have shown that pro-inflammatory M1-like cells were 
subject to significant NAD
+ 
changes compared to anti-inflammatory M2-like MФs. The 
intracellular NAD
+ 
levels increased with NAM and FK866 in M1-like MФs unlike M2-like 
MФs suggesting a differential profile of NAD+ synthesis/consumption rate between the two 
subsets. Therefore, on the basis of the obtained results, it seems that the two subsets clearly 
differ in the way that they perform NAD
+
 homeostasis and this may reflect different needs for 
NAD
+
. Additionally, both subsets differ in the expression profiles of a number of NAD
+
 
homeostasis enzymes in both basal and activated state. We have shown that expression of 
CD38 and CD157 are differentially regulated in resting and activated state for both subsets. 
This could add to list of molecules that discriminate between M1-like and M2-like MФs (as 
illustrated in Figure 3.8). The current findings might open the door for pharmacological 
approach by which we would be able to regulate the immune function for primary MФs. 
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Figure 3.8 Schematic diagram depicting the differences in NAD
+
 homeostasis and cytokine 
production between M1-like and M2-like MФs during LPS stimulation. M1-like cells displayed 
higher levels of NAD
+
 and TNF-α compared to M2-like cells which displayed high levels of IL-6 in 
response to LPS. These are also observed by others (Daigneault et al., 2010; Foey and Crean, 2013). 
M1-like MФs increase the expression of CD38, CD157, NAMPT and NMNAT which might reflect 
the unusual changes in NAD
+
 levels. On the other hand, M2-like cells increase the expression of 
NAMPT, CD38 but not CD157 and NMNAT in response to LPS challenge compared to M1-like cells. 
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CHAPTER 4 
PHARMACOLOGICAL MODULATION OF 
NAD
+
 LEVELS CONTROLS TNF-α 
SECRETION IN DIFFERENTIATED 
MACROPHAGES 
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4.1 Introduction 
TNF-α is mainly produced by proteolytic cleavage of a larger protein by macrophages which 
play a pivotal role in both innate immunity and adaptive immunity upon inflammation 
induction (Grivennikov et al., 2005; Classen et al., 2009). TNF-α is critically involved in a 
variety of inflammatory effects (Hehlgans and Pfeffer, 2005). Despite TNF-α being crucial 
for macrophage immune function and host defence (Parameswaran and Patial, 2010), 
excessive production of TNF-α can lead to pro-inflammatory cascades resulting in a 
potentially fatal cytokine storm (Finlay and McFadden, 2006) leading to damage of the host. 
Therefore, a regulatory system must have evolved to dampen the damaging impact of TNF-α 
in such conditions. TNF-α synthesis is initially triggered by LPS-induced TLR4 signalling 
resulting on activation of the MAPKs (ERK 1, 2), P38, JNKs pathways along with the 
transcription factors NF-B and AP-1 (Sanghera et al., 1996; Tsushima and Mori, 2001; 
Beutler and Rietschel, 2003; Karin, 2009). TNF-α is produced as a 26 kDa pro-form, which is 
membrane associated (mTNF-α) and which either stays on the cell surface or can be 
processed to release a 17 kDa soluble product (sTNF-α) via proteolytic cleavage referred to 
as ectodomain shedding (Beutler and Cerami, 1989; Moss et al., 1997; Peschon et al., 1998). 
This process is defined as the proteolytic cleavage of a wide range of transmembrane 
proteins, such as TNF-α, to release an extracellular domain from the cells (Peschon et al., 
1998). The shedding is induced by PMA in a PKC-dependent manner (Nakada-Tsukui et al., 
1999). Indeed, PKC mediates the shedding of a number of membrane proteins including pro-
TNF-α, pro-TGF-β, CD14, CD16, CD44, IL-6 and the receptors for TNFα (Bazil, 1995; 
Hooper et al., 1997; Peschon et al., 1998). Several studies have shown that the shedding 
process is mediated by a disintegrin and metalloproteinases (ADAM) family such as TNF-α 
converting enzyme (TACE) in several cell line systems (Black et al., 1997; Reddy et al., 
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2000; Peschon et al., 1998). Indeed, ADAM 10 has been shown to cleave TNF-α and its 
receptor in THP-1 (Rosendahl et al., 1997), whereas ADAM 17 has been shown to be a 
sheddase of TNF-α and its receptor in macrophages and neutrophils (Bell et al., 2007). 
However, there is evidence that, rather than ADAM, serine proteases are also involved in the 
shedding of TNF-α (Kim et al., 1993; Nakada-Tsukui et al., 1999). Interestingly, since TNF-
α is a fatty acylated protein (Stevenson et al., 1993) it is believed that TNF-α can also be shed 
by SIRT6 via removal of the fatty acyl group (Jiang et al., 2013). This is perhaps not 
surprising because SIRT6 plays a crucial role in the regulation of TNF-α synthesis via 
intracellular NAD
+
. Indeed, a key role has been shown for NAD
+
 in the positive control of 
TNF-α transcription, via the de-acylation of the Rel A/p65 subunit of NF-kB, in an NAD+-
sirtuin dependent manner and thus the reduction in NAD
+
 levels or SIRT6 knock out blocks 
synthesis of TNF-α (van Gool et al., 2009). Sirtuins comprise a family of seven conserved 
members (SIRT1 to 7) that use NAD
+
 (Heltweg et al., 2006) to regulate multiple biological 
processes from gene transcription/translation (Vaquero et al., 2004) to cell differentiation 
(Fulco et al., 2003). Sirtuin-dependent acetylation has been shown to modulates the immune 
response via its substrate NAD
+
 (Magni et al., 2004) and its sensitivity to NAD
+
/NADH ratio 
(Picard et al., 2004; Yeung et al., 2004). It has recently been shown that pharmacological 
inhibition of sirtuins caused a reduction in secretion of selective inflammatory cytokines 
including IL-6 and TNF-α due to blockage of NF-B activity and IBa phosphorylation in 
J774 macrophages (Fernandes et al., 2012). Besides the sirtuins, the inflammatory responses 
can be also regulated via NADPH oxidase which mediates reactive oxygen species (ROS) 
production and oxidative burst (Chiarugi et al., 2012). NADPH oxidase has been shown to 
regulate the NF-B signalling pathway and the consequence production of pro-inflammatory 
TNFα (Kaul and Forman, 1996). Despite the well-established link between NAD+ and TNF-
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α, there is still a need to elucidate the mechanisms that mediate how NAD+ levels and TNF-α 
are linked and whether pharmacological NAD
+
 manipulation can modulate macrophage 
inflammatory responses, in particular, TNF-α.. An interest in the pharmacological modulation 
of NAD
+
 levels to regulate pro-inflammatory responses. In particular, focus has grown on the 
modulation of NAD
+
 homeostasis as a way of decreasing NAD
+
 levels, reducing the activity 
of NAD
+
-dependent immune function. Indeed, the inhibition of NAMPT-mediated NAD
+
 
generation by FK866 blocked the increase of NAD
+
 content and inhibited LPS-mediated 
TNF-α secretion in THP-1 cells, human monocytes and macrophages (van Gool et al., 2009; 
Schilling et al., 2012). In addition, in the light of the role of de novo NAD
+
 synthesis in 
maintaining NAD
+
 levels, Braidly and his team (2011) have investigated the pharmacological 
inhibition of IDO activity using an IDO inhibitor, 1D-MT (1D-methyl tryptophan), with the 
ability to decrease NAD
+
 levels, highlighting the importance of IDO activity in sustaining 
NAD
+
 availibity during inflammation. Despite the role of IDO in NAD
+
 production, IDO is 
known for its role in immune suppression and therefore 1D-MT-mediated IDO inhibition led 
to blockage of host-mediated immunosuppression and enhanced antitumour immunity in 
dendritic cells (Hou et al., 2007). We show here that NAD
+ 
levels are correlated with TNF-α 
secretion in pro-inflammatory M1-like but not in anti-inflammatory M2-like cells during LPS 
stimulation. Also, we found that NAD
+
 is produced partially via NADH oxidation and 
partially via the NAD
+
 recycling pathway suggesting that the mechanism linking NAD
+
 and 
TNF-α is complex and requires a combination of pathways. 
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4.2 Results 
4.2.1 Toxicity assessment of inhibitors 
We performed pharmacological inhibition to elucidate how NAD
+ 
modulation controls TNF-
α responses using a number of specific inhibitors includes DPI (diphenylene iodonium), a 
competitive inhibitor for NADPH oxidase, 1-MT (1-methyl tryptophan, a competitive 
inhibitor of IDO (indole amine 2,3-dioxygenase), FK866, an inhibitor of NAMPT and 
sirtinol, a sirtuin inhibitor (Table 4.1). We initially sought to test the toxicity of inhibitors 
used in this study in order to select a non-toxic concentration and thus to exclude non-specific 
cellular toxicity. The inhibitor concentrations were chosen according to the literature and 
primary optimization. Thus, the MTT assay was performed on differentiated cells following 
incubation with different concentrations of the inhibitors used in our study (Figure 4.1). 
Although, the MTT assay showed reduction in viability with DPI after 12 h, the trypan blue 
assay did not show any reduction in cell viability before 18 h. This is because the MTT assay 
is based on the activity of dehydrogenases, which might be already affected by DPI 
treatment. The remaining inhibitors had no toxic impact on the cells under the experimental 
conditions (Figure 4.1) and this was confirmed by the trypan blue assay. It has been shown 
that DPI is able to block NADPH oxidase activity at 100 µM (Riganti et al., 2004), so we 
used this concentration because we wanted to achieve sufficient inhibition. In addition, our 
rationale is that we were interested in the very early stages of the LPS response. It has been 
reported that the inhibition of NAMPT activity was achieved with 100 nM (Hasmann and 
Schemainda, 2003; Billington et al., 2008), while IDO inhibition was achieved with 1-MT at 
200 µM for 2 h according to Opitz et al. (2011a) and sirtuin inhibition with 25 µM sirtinol for 
24 h according to Fernandes et al. (2012). 
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Table 4.1 The chemical structure and solvents used for the inhibitors used in this study 
 
 
 
Inhibitors Action Solvents Chemical Structures 
1-methyl-L-
Tryptophan (1-
MT) 
 
FK866 
(APO866, 
Daporinad ) 
 
 
DPI ( Diphenyl 
iodonium 
chloride) 
 
Sirtinol  2-[(2                   
Hydroxynaphtha
len-1-
ylmethylene) 
amino]-N-
(1phenethyl)ben
zamide 
Competitive IDO 
inhibitor 
 
 
Non-competitive 
inhibitor 
 
 
Uncompetitive 
inhibitors of 
flavoenzyme 
 
inhibitor of sirtuin 
family members 
 
0.1 N NaOH to give 
200µM final 
concentration 
 
DMSO (dimethyl 
sulfoxide) to give 
100nM final 
concentration 
 
DMSO (dimethyl 
sulfoxide) to give 
100 µM final 
concentration 
 
DMSO (dimethyl 
sulphoxide) to give 
25 µM final 
concentration 
 
 
 
 
 
OH
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Figure 4.1 Cell vitality was determined using the MTT assay. Differentiated cells were pre-incubated 
with 100 µM DPI, (0.5 h) or 25 µM sirtinol, (24 h) or 200 µM 1-MT, (2 h) or FK886 100 nM, (1 h) 
prior to stimulation with LPS. Results were analysed by two way ANOVA followed by the 
Bonferroni test. Significantly different results are indicated as follows: *P<0.05, **P<0.01, 
***P<0.001.  
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4.2.2 Elevated NAD
+
 levels are associated with TNF-α secretion in response to 
LPS stimulation 
The link between NAD
+
 levels and TNF-α is well established with NAD+ being shown to 
modulate TNF-α synthesis in a sirtuin-dependent manner (van Gool et al., 2009). The authors 
showed that intracellular NAD
+
 levels are required for TNF-α synthesis regulation as sirtuin 
deacetylase-6 (SIRT6) uses NAD
+
 to regulate TNF-α expression at the transcriptional level. It 
has been previously shown that TNF-α secretion is triggered by LPS stimulation in MΦs 
(Tracey and Cerami, 1994). We showed earlier (Chapter 3) that M1-like MΦs display high 
NAD
+
 levels in response to LPS challenge; therefore we reinvestigated the link between 
NAD
+
 and TNF-α and whether TNF-α release is associated with the observed changes in 
NAD
+
. To do this, we initially investigated TNF-α release in differentiated MΦs following 
stimulation with and without LPS over 24 h (Figure 4.2). As expected, M1-like MΦs showed 
significant TNF-α release, under LPS challenge, that peaked within 4 h compared to the 
control (P = 0.001) and was sustained at 8 h before decaying back to basal levels by 24 h (P = 
0.001; Figure 4.2 A). In contrast, M2-like cells secreted a relatively small but significant 
amount of TNF-α which corresponded to less than 10% of that secreted by M1-like cells 
(Figure 4.2 B). In M2-like cells, the levels of TNF-α peaked at 4 h compared to the control (P 
= 0.01) but this was short lived and TNF- α had returned to almost basal levels by 8 h. 
However, there was a lower level of TNF-α which persisted to beyond 18 h. It seems that 
TNF-α levels paralleled LPS-induced NAD+ changes in pro-inflammatory M1-like MΦs (see 
Chapter 3) while this is not the case with anti-inflammatory M2-like MΦs. In order to 
investigate this link further, differentiated macrophages were incubated with and without 
sirtinol, a well-known sirtuin inhibitor, and both NAD
+
 and TNF-α levels were measured. 
The stimulation with LPS caused a robust TNF-α release, as expected, where TNF-α reached 
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its maximum levels after 8 h while sirtinol significantly reduced TNF-α cells after 8 h in 
treated MΦs compared to non-treated MΦs (P = 0.001; Figure 4.2 C). This only occurred 
after 24 h of incubation confirming recent results (Fernandes et al., 2012). In contrast, 1 h 
pre-treatment with sirtinol surprisingly failed to reduce TNF-α release and rather significantly 
increased TNF-α to reach its maximum levels after 12 h  in treated MΦs compared to non-
treated cells (P = 0.002; Figure 4.2 D) suggesting that the effect might be at the 
transcription/translation level rather than the release levels. The incubation with sirtinol for 1 
h increased LPS-induced TNF-α release almost 3-fold higher after 12 h following LPS 
stimulation. Similarly, sirtinol was capable of increasing NAD
+
 levels, which also started to 
significantly increase after 4 h of stimulation to reach maximum levels after 12 h of LPS 
stimulation (P = 0.02; Figure 4.2 E) highlighting that NAD
+
 may cover the response phase of 
TNF-α. Together, these data might suggest that TNF-α secretion is correlated with NAD+ 
changes in M1-like cells highlighting that NAD
+
 is required for TNF-α secretion. Therefore, 
the data from this study confirm and further strengthen the existing link between NAD
+
 and 
TNF-α and thus metabolism and pro-inflammatory responses.  
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Figure 4.2 NAD
+
 levels are associated with TNF-α release in differentiated macrophages during LPS 
stimulation. LPS increases TNF-α release in M1-like cells (A) but not in M2-like macrophages (B). 
Pro-inflammatory M1-like macrophages were pre-incubated with sirtinol prior LPS stimulation (C) 
Sirtinol (25 µM, 24 h) treatment caused decrease in TNF-α release in response to LPS stimulation. 
However, incubation M1-like with 25 µM sirtinol for 1 h prior to LPS stimulation led to increase in 
both (D) TNF-α and (E) NAD+ levels over the experiment. Data shown are means ± SE of three 
separate experiments (n = 3).  Results were analysed by two way ANOVA followed by the Bonferroni 
post hoc test. Significantly different results are indicated as follows: *P<0.05, **P<0.01, ***P<0.001.  
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4.2.3 DPI treatment decreases both NAD
+
 and TNF-α levels in M1-like MΦs but 
only TNF-α in M2-like MΦs during LPS stimulation 
Given that LPS induced unusual changes in gene expression of NAD
+
 homeostasis and that 
NAD
+
 levels are correlated with TNF-α release, we decided to investigate the source of 
NAD
+
 generation and whether NAD
+
 manipulation can control TNF-α release in 
differentiated cells. NAD(P)H oxidase is required for macrophage activation because it is 
involved in TNF-α production via ROS-mediated NF-B activation (Forman, 1996 and 
Forman and Torres, 2002; Kaul). Therefore, we were interested in investigating the potential 
role of NAD(H) oxidation in NAD
+
 generation using the inhibitor DPI. DPI is a well-known 
NADPH oxidase inhibitor that covalently binds to the catalytic subunit of NOX2 enzymes 
(Cross and Jones, 1986). Indeed, it was found that DPI was capable of abolishing NAD(P)H 
oxidase-mediated ROS generation in monocytes/macrophage cells (Li and Dinauer, 1998). It 
is known that NAD(P)H oxidase (Remer et al., 2003) is activated in response to LPS in a 
TLR4-dependent manner and catalyses the oxidation of NAD(P)H to NAD(P)
+
 (Riebel et al., 
2002). It has recently been shown that NADPH plays a critical role in supporting elevated 
glycolysis, by facilitating additional NAD
+
 production in cancer cells (Lu et al., 2012).  
Differentiated macrophages were pre-incubated with 100 µM DPI for 0.5 h prior to LPS 
stimulation and both NAD
+
 and TNF-α were measured, with the results shown in figure 4.3. 
M1-like cell exposure to DPI caused an inhibition in LPS-induced TNF-α and NAD+ but only 
TNF-α in M2s as in this case, DPI might block NADPH oxidase mediated ROS-induced NF-
B activation resulted in inhibition of TNF-α release. In M1s, DPI was able to significantly 
attenuate both the initial NAD
+
 peak (P = 0.023) and the sustained rise caused by LPS (P = 
0.014) suggesting that one source of the NAD
+
 is the oxidation of NADH during the 
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respiratory burst as might be expected (Figure 4.3 A). The decrease was 80% and 50% for the 
initial peak and the sustained rise, respectively, in comparison to the control. However, 
NAD
+
 levels were not affected by DPI treatment in M2-like cells in response to LPS 
challenge. Most striking was the effect of the DPI treatment on TNF-α release. In fact, DPI 
was able to almost completely abolish TNF-α secretion although a small amount was secreted 
over 8-24 h but significantly less than in the absence of DPI (Figure 4.3 C, D). Indeed, 
incubation of M1-like MФs with DPI caused a significant reduction in TNF-α release 
compared to stimulated non-treated macrophages (4 h, P = 0.001). In M2-like MФs, however, 
TNF-α release was significantly impaired (4 h, p = 0.014) whereas NAD+ levels were not 
affected under the same conditions. These data might indicate that the TNF-α response is 
independent of NAD
+
 in M2-like MФs. This is consistent with data showing that M2-like 
MФs secreted a lower amount of TNF-α and showed a modest change in NAD+ generation 
(Chapter 3). Taken together, our data suggested that NAD
+
 generation might occur partially 
via NADH oxidation and that NAD
+
 might regulate TNF-α release via a DPI-dependent 
mechanism in M1-like MФs which further strengthen the link between NAD+ and TNF-α. 
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Figure 4.3 DPI treatment blocks LPS-induced NAD
+
 levels and TNF-α release in differentiated 
macrophages. The cells were incubated in the presence or absence of 100 µM, 0.5 h DPI prior LPS 
challenge. Incubation of M1-like MФs with DPI led to inhibited NAD+ levels (B) and TNF-α (C) 
while in M2-like cells it did not affect NAD
+
 levels (C) but did affect TNF-α levels (D) during LPS 
stimulation. Data shown are mean ± SE of separate experiments in triplicate (n = 3-4). Results were 
analysed by two way ANOVA followed by the Bonferroni post hoc test, and significant results are 
indicated as follows:*P < 0.05, **P < 0.01, ***P < 0.001.  
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4.2.4 FK866 stops the increase of both NAD
+
 and TNF-α release in M1-like but 
not in M2-like macrophages in response to LPS challenge 
In mammalian cells, NAD
+ 
is resynthesized preferentially by NAMPT, using nicotinamide, a 
by-product of the enzymatic cleavage of NAD
+
, the rate limiting step for NAD
 
salvage 
pathways. Since we have shown earlier the upregulation of NAMPT expression (Chapter 3) 
and considering the importance of the salvage pathway, we next decided to investigate the 
impact of NAMPT blockage on NAD
+
 recycling and TNF-α secretion by using FK866, an 
inhibitor of NAMPT. It has been recently reported that monocytes rely on this pathway to 
mount an appropriate inflammatory response, in particular, TNF-α (Schilling et al., 2012). 
Therefore, we made use of FK866, an inhibitor of NAMPT, to investigate the impact of the 
salvage pathway blockage on TNF-α release in order to test whether lowering NAD+ levels 
by FK866 might alter TNF-α response in differentiated macrophages. To acheive this, 
differentiated macrophages were pre-incubated with 100 nM FK866 for 1 h prior to 
stimulation with LPS, versus control cells.  
As seen in figure 4.4 A, incubation of M1-like MФs with FK866 resulted in the significant 
decrease in NAD
+
 levels by 40% and 70% for both the initial (1 h, P = 0.02) and sustained 
rise (4 h, P = 0.014), respectively, with the greatest effect over the longer term. To investigate 
whether the decrease in NAD
+
 level was correlated with TNF-α, we measured TNF-α release 
under the same experimental conditions to verify whether FK88-mediated NAD
+
 inhibition 
could negatively affect TNF-α release. TNF-α did still increase, but FK866 was able to 
significantly reduce the amount released (Figure 4.4 B). FK866 significantly inhibited LPS-
induced TNF-α release in time-dependent manner (8 h, P = 0.023). TNF-α was decreased by 
40% in M1-like MФs compared to the control.  
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In M2-like MФs, however, FK866 caused both NAD+ and TNF-α to decrease slightly but not 
significantly after 4 h of LPS stimulation (Figure 4.4 C, D). In M1-like MФs, it seems that 
FK88 mediated-NAD
+
 inhibition modulates LPS-induced TNF-α secretion suggesting that 
both are correlated. These data could also suggest NAD
+
 re-generation via NAMPT, at least 
in part, plays an important in identifying the link between NAD
+
 and pro-inflammatory TNF-
α response suggesting that NAD+ might be required for TNF-α release. 
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Figure 4.4 FK866 inhibits LPS-induces NAD
+
 levels and TNF-α release in pro-inflammatory 
differentiated (M1-like) macrophages and not in anti-inflammatory (M2-like) macrophages. 
Differentiated macrophages pre-incubated with and without 100nM FK866 (1h) prior LPS stimulation 
for the indicated time points. Cells were then harvested for NAD determination and supernatant were 
collected, from the same sample, for TNF-α measurement. FK866 treatment reduced in time 
dependent manner (A) NAD
+
 levels and (B) TNF-α in M1-like while it did not affect (C) NAD+ levels 
and (D) TNF-α in M2-like under LPS challenge. Data shown are means ± SE of three separate 
experiments (n = 3). Results were analysed by two way ANOVA followed by the Bonferroni post hoc 
test. Significantly different results are indicated as follows:*P < 0.05, **P < 0.01, *** P < 0.001). 
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4.2.5 Inhibition of IDO with 1-MT attenuates NAD
+
 levels but does not affect 
TNF-α release in differentiated macrophages during stimulation 
The IDO pathway, also known as the IDO-kynurenine pathway, is reported to play an 
important role in de novo NAD
+
 generation via the oxidation of the essential amino acid 
tryptophan (Mellor and Munn, 1999; Orabona et al., 2006). Given the involvement of IDO in 
NAD
+
 supply as suggested by Grant and Kapoor (2003) and the remarkable upregulation in 
IDO expression which we observed previously (chapter 3), we decided to investigate the 
impact of IDO inhibition on LPS-induced TNF-α and NAD+ levels in differentiated MФs. To 
verify this role, we blocked the enzymatic activity of IDO using the IDO inhibitor, 1D-methyl 
tryptophan (1D-MT). Differentiated macrophages were pre-incubated in the presence and 
absence of 200 µM for 2 h prior stimulation with LPS, and both NAD and TNF-α were 
measured (Figure 4.5). While 1-MT was able to significantly decrease intracellular NAD
+
 
levels, it did not affect TNF-α responses (Figure 4.5 A, B). Interestingly, 1-MT also inhibited 
the initial rise of NAD
+
 with a longer effect on the sustained rise in M1-like MФs. In M1-like 
MФs, the decrease in NAD+ levels in stimulated cells treated with 1-MT was 40% (1 h, P = 
0.01) and 60% (4 h, P = 0.001) for the initial and sustained rise, respectively. On the other 
hand, when M2-like cells were incubated with 1-MT, both NAD
+
 and TNF-α levels were 
slightly but not significantly affected under the same conditions (Figure 4.5 C, D). These data 
could suggest that the IDO inhibition largely affects NAD
+
 generation in M1-like MФs and it 
does not affect LPS-induced TNF-α production. 
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Figure 4.5 1-MT (1-methyl tryptophan) pre-treatment for LPS stimulated pro-inflammatory (M1-like) 
differentiated macrophages reduced NAD
+
 levels but not TNF-α release while anti-inflammatory 
(M2-like) macrophages were not affected. After differentiation, macrophages were stimulated with 
LPS post-incubation with and without 200 µM 1-MT (2 h). 1-MT treatment reduced in time-
dependent manner (A) NAD
+
 levels but not TNF-α (B) in M1-like cells while it did not affect (C) 
NAD
+
 levels and (D) TNF-α in M2-like MФs. Data shown are means ± SE of three separate 
experiments (n = 3). Results were analysed by two way ANOVA followed by the Bonferroni post hoc 
test. Significantly different results are indicated as follows:*P < 0.05, **P < 0.01, *** P < 0.001). 
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4.2.6 Determination of IDO-kynurenine pathway (IDO-KP) activity in 
differentiated macrophage-like subsets 
It is known that IDO catalyses the conversion of tryptophan, via the IDO-kynurenine 
pathway, into number of immune regulatory metabolites collectively known as kynurenines 
before ultimately NAD
+
 formation (Munn et al., 1998). Given that 1-MT inhibits IDO 
activity mediated NAD
+ 
production and to further verify the activity of IDO, we next decided 
to investigate the effect of 1-MT on kynurenine pathway in both macrophage subsets. 
Differentiated macrophages were pre-incubated with 200 µM 1-MT prior stimulation with 
LPS and extracellular kynurenine was measured (Figure 4.6). While 1-MT was able to 
significantly decrease NAD
+
 levels, surprisingly, it caused a slight but not significant increase 
in extracellular kynurenine formation in M1-like MФs (Figure 4.6 B). We observed no effect 
on kynurenine levels in 1-MT treated M1-like MФs in the early stages of LPS stimulation as 
the levels were comparable to those measured in cells without 1-MT but reached levels even 
higher than those without treatment and started to increase slightly but not significantly after 
18 h and 24 h of LPS stimulation. On the other hand, 1-MT treatment did not affect 
kynurenine levels in M2-like MФs. Also, kynurenine consumption rate was quantified in cell 
lysate from both phenotypes after the indicated times (Figure 4.6 C). Both subsets displayed a 
very low consumption rate of kynurenine (Figure 4.6 D). These data, collectively, suggest 
that kynurenine metabolism might be regulated by different pathway in M1-like MФs and 
could also suggest that 1-MT has partial effect on kynurenine metabolism. 
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Figure 4.6 The 1-MT treatment does not affect kynurenine formation during LPS stimulation in 
differentiated macrophages. (A) The linearity of kynurenine standards using the Ehrlich assay. The 
kynurenine was dissolved in 0.5 M HCl and serial dilutions were prepared. The effect of 1-MT 
treatment on extracellular kynurenine levels in (B) M1-like and (C) M2-like cells during LPS 
stimulation is also shown. After differentiation, macrophages were incubated with kynurenine and the 
rate of kynurenine consumption was measured. (D) The kynurenine consumption in resting 
macrophages. Data shown are means ± SE of four separate experiments (n = 3-4). Results were 
analysed by two way ANOVA followed by the Bonferroni test. Significantly different results are 
indicated as follows:*P < 0.05, **P < 0.01, *** P < 0.001). 
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4.3 Discussion 
It is becoming clear that there is a close relationship between NAD
+
 metabolism and 
inflammatory responses in innate immune cells, in particular, in macrophages (van Gool et 
al., 2009). One of the best studied links is that between NAD(H) and TNF-α with NAD(H) 
levels known to regulate TNF-α synthesis (van Gool et al., 2009) and conversely TNF-α 
levels are known to regulate expression of NAD(H) homeostasis enzymes (Iqbal and Zaidi, 
2006). This study was designed to understand how pharmacological manipulation of NAD
+
 
homeostasis can control TNF-α release by macrophages. Our data show that LPS stimulation 
of M1-like macrophages caused significant changes (Chapter 3) in NAD
+
 levels while in M2-
like cells this was not the case. Also, we demonstrated that TNF-α level also increased in pro-
inflammatory M1-like MФs suggesting that they might be linked. Therefore, to understand 
more about this link, we investigated the unusual NAD
+ 
changes and the source of the LPS-
induced changes as well as the link to TNF-α release in both subsets. LPS stimulation of 
differentiated cells was performed in the presence of DPI (commonly used to inhibit NADPH 
oxidase), FK866 (a NAMPT inhibitor) or 1D-MT (an IDO inhibitor) and sirtinol (a sirtuin 
inhibitor). We demonstrate that both DPI and FK866 are also able to inhibit the observed 
initial and the sustained rise in M1-like MФs (Figures 3 B and 4 A). This decrease might be 
caused, in part, via direct and indirect inhibition of the NADPH oxidase by DPI and FK866 
treatment, respectively. Indeed, it has been recently shown that DPI and FK866 treatment was 
able to inhibit oxidative burst through inhibition of NAD(P)H activity (Malam et al., 2011; 
Lu et al., 2012).  
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The current results might suggest that NAD
+
 levels are lowered as consequence of inhibition 
of NADPH oxidase mediated NADH oxidation via DPI suggesting NADH oxidation as an 
important source of NAD
+
 production as well as NAMPT-mediated NAD
+
 recycling. In 
addition, our results show that the decrease in NAD
+
 production following FK866 and DPI 
was correlated with a reduction in TNF-α levels in M1-like but not in M2-like MФs (Figure 
3, 4). Since TNF-α is required for LPS-induced IDO activity in the THP-1 model (Fujigaki et 
al., 2001) and considering the role of IDO in NAD
+
 production, one might speculate that 1D-
MT mediated inhibition of NAD
+
-dependent IDO activity could affect TNF-α release from 
THP-1-derived macrophages. Interestingly, we observed no effect of IDO inhibition on TNF-
α release and this could be explained, in part, by the fact that IDO contributes only a little to 
the intracellular NAD
+
 pool as 1 NAD
+
 molecule out of 60 molecules comes from this 
pathway. These assumptions are supported by Grant and Kapoor (2003), who showed that 
IDO activity functions to maintain NAD
+
 levels during inflammation. M2-like MФs, 
however, display only a small TNF-α increase after 4 h of LPS stimulation and clearly this 
was not linked to NAD
+
 in M2-like MФs (Figure 4.2 B). It seems that NAD+ levels are 
correlated with TNF-α secretion in M1-like cells and not in M2-like cells, confirming the 
existing link between NAD
+
 and macrophage inflammatory responses, in particular the TNF-
α response. We initially investigated the link between NAD+ and TNF-α in our model via 
using sirtinol, a sirtuin inhibitor. The role of sirtuins and NAD
+
 dependent
 
mediated cytokine 
production is well established (Landry et al., 2000a; Jackson and Denu, 2002; van Gool et al., 
2009). Our data confirmed previous findings showing that synthesis of TNF-α is sirtuin 
dependent (van Gool et al., 2009). Sirtinol treatment was able to inhibit the secretion of TNF-
α when cells pre-incubated overnight prior LPS stimulation (Figure 4.2 C). These findings are 
in accordance with a recent study showing that sirtuin inhibition blocks LPS-induced TNF-α 
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release in an NF-B-dependent manner in stimulated macrophages (Fernandes et al., 2012). 
However, pre-incubation with sirtinol for 1 h prior to stimulation led to a block in the time-
dependent decrease in TNF-α release during LPS stimulation with TNF-α levels not 
decreasing in 24 h as in the control (Figure 4.2 D). It is perhaps not surprising that TNF-α 
release is modulated by a sirtuin inhibitor as TNF-α synthesis was shown to be regulated by 
NAD
+
 in SIRT6-dependent manner (van Gool et al., 2009).  
In fact, the second phase of the NAD
+
 increase, that we observed under LPS stimulation, is 
prolonged and covers the period of the TNF-α decay phase suggesting they may be correlated 
and thus that NAD
+
 levels mediate the decay phase of TNF-α. This assumption is supported 
by the results showing that NAD
+
 levels also not decreasing over 24 h after 1 h sirtinol 
treatment prior to stimulation (Figure 4.2 E). The contradictory effect of sirtinol on TNF-α in 
this study is not quite clear. Although, it is difficult to explain the discrepancy in these 
results- we could speculate that there is a counter-regulatory mechanism between sirtuin 
family members, including SIRT1 and SIRT6. It seems that TNF-α production is not only 
regulated by SIRT6 because SIRT1 has also been shown to regulate TNF-α production in 
response to LPS stimulation in monocytes (Niederer et al., 2011). In this study, the authors 
showed SIRT1 overexpression led to a modest but significant increase in LPS-induced TNF-
α secretion while inhibition or downregulation by SIRT1 siRNA caused TNF-α release to be 
halted in the same cells (Niederer et al., 2011). Also, It has recently been shown that SIRT1 
contributes to TNF-α secretion by up-regulation the expression of TLR 2, 4 (Lee et al., 2012) 
that are required for cytokine release (Andersson and Tracey, 2011). On the other hand, a 
converse relationship between SIRT1 and the capacity for TNF-α production, via the ability 
to dampen inflammatory process through inhibition of NF-B in cultured macrophages, has 
been observed previously (Shen et al., 2009). Indeed, knockdown of SIRT1 or inhibition led 
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to largely activate the JNK and IKK inflammatory pathways in a model of the mouse 
macrophage RAW264.7 cell line and in intraperitoneal macrophages resulted in augmented 
TNF-α secretion (Yoshizaki et al., 2010). In the same respect, SIRT6 has been shown to 
positively regulate TNF-α production at the transcription/translation level (van Gool et al., 
2009). Despite these findings, it has been suggested that SIRT6 exerts opposing effect on 
expression of pro-inflammatory mediators via negatively regulating the transcriptional 
activity of NF-B (Kawahara et al., 2009).  
It seems that SIRT1 and SIRT6 roles are not straightforward with regards to the TNFα 
response as they exert contradictory effects on TNFα, indicating that sirtuin’s role in this 
signalling pathway is more complex than previously thought. It is possible, therefore, that 
these findings may partially explain the observed increase in TNF-α release, following 
sirtinol treatment in the current study. This increase could be explained in part by selective 
inhibition for SIRT1 by sirtinol which has higher affinity for SIRT1 than other family 
member (Heltweg and Jung, 2002; Heltweg et al., 2006; Braidy et al., 2011) and thus sustains 
NAD
+
 availibity for SIRT6-mediated TNF-α secretion. This assumption is strongly supported 
by recent observations showing that SIRT6 enhances TNF-α secretion, in a fatty acyl 
modification mechanism, via the removal of the fatty acyl groups on K19 and K20 of TNF-α 
(Jiang et al., 2013). It is believed that TNF-α release is mediated via acyl modification since 
TNF-α is one of the fatty acylated proteins (Stevenson et al., 1993). Furthermore, TNF-α 
release is alternatively regulated by a shedding proteolytic process, rather than SIRT6-
mediated fatty acyl modification, that is mediated by a disintegrin and metalloproteinases 
including TACE in a model of human alveolar macrophages (Rosendahl et al., 1997; Moss et 
al., 1997; Armstrong et al., 2006) in a PKC-dependent manner in macrophages (Nakada-
Tsukui et al., 1999). TNF-α is initially synthesised as a precursor protein of 26 kDa which 
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can be processed by a metalloproteinases that specifically cleave the polypeptide at a site 
between the amino acid Val
76
 and Ala
77
, to a secrete a soluble TNF-α into the cell culture 
medium (Rosendahl et al., 1997). Indeed, ADAM 10 has been shown to cleave TNF-α in 
THP-1 whereas ADAM17 is required for the processing of TNF-α and its receptor in 
macrophages (Rosendahl et al., 1997; Bell et al., 2007). Furthermore, several studies revealed 
that sheddases other than ADAM are required for TNF-α release including matrix 
metalloproteinase enzymes (MMPs; Haro et al., 2000) from peritoneal macrophages due their 
ability to cleave extracellular domain of many surface-proteins. Therefore, pharmacological 
inhibition by an hydroxomic acid-based MMP inhibitor led to the blockage of TNF-α 
proteolytic shedding (McGeehan et al., 1994; Solomon et al., 1997). Given that MMP 
expression is activated in M1-like MФs via PMA, it is likely that sirtinol mediated SIRT1 
inhibition led to up-regulated MMP expression resulting in TNF-α release induction (Ismair 
et al., 1998; Wang et al., 2003). In fact, SIRT1 has been shown to negatively regulate MMP9 
expression and MMP9 promoter activation and that SIRT1 activation by small 
pharmacological activators blocks the MMP9 expression in U937 cells line suggesting a 
critical regulatory role for SIRT1 on MMP9 expression (Nakamaru et al., 2009). These 
assumptions, therefore, strongly agree with recent evidence by Shen et al. (2009) who found 
that sirtinol addition or SIRT1 knockdown by siRNA led to augmented TNF-α secretion 
suggesting the involvement of SIRT1 in impairment of TNF-α release.  
In addition, these observations are further supported by findings showing that SIRT1 deletion 
or inhibition was associated with a compensatory elevation in SIRT6 expression in 
macrophages in response to environmental stress, suggesting important immune regulatory 
roles for sirtuins in myeloid cells (Schug et al., 2010). Future work is needed to investigate 
the role of SIRT6 in regulating MMP expression in macrophages. Other possible mechanism 
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might be related to SIRT1 role mediated the reprogramming switch from glycolysis to 
oxidative metabolism in THP-1 cells line (Liu et al. 2012). It may be the case that selective 
inhibition of SIRT1 by sirtinol might block a SIRT1 mediated shift towards oxidative 
metabolism leading to increased incidence of glycolysis which is required for TNF-α release 
(Dietl et al., 2010). This assumption is supported by TNF-α increase following a 1 h 
incubation of cells with sirtinol (Figure 4.2 D). Collectively, these results further confirm the 
link between NAD
+
, the immune response and metabolism highlighting the importance of an 
immune regulatory role for NAD
+
 and thus SIRT1, 6 in macrophages. Therefore, further 
study is required to investigate the NAD
+
-sirtuin axis in M1-like MФs and whether this link 
could be useful approach for developing a therapeutic strategy for inflammation associated 
tumours. It is known that NAD(P)H oxidase activation occurred both in vitro and in vivo via 
LPS stimulation in TLR4-dependent manner during macrophage activation resulting in a 
marked increase in oxidative burst activity and the generation of reactive oxygen species 
(ROS; Kaul and Forman, 1996; Remer et al., 2003). Our data show that the increase in NAD
+
 
levels was also inhibited by blocking NADH oxidation via the flavoenzyme, NAD(P)H 
oxidase (Figure 4.3 A). This may explain, at least in part, the rapid peak that was observed in 
NAD
+
 levels as this was partially inhibited by the NAD(P)H oxidase inhibitor DPI. 
Therefore, our findings strongly agree with others showing that DPI treatment caused 
NAD(P)H oxidase (NOX) inhibition and led to lower NAD
+
 levels suggesting a critical role 
for NADPH oxidase in supporting glycolysis activity in cancer cells via providing additional 
NAD
+
 (Lu et al., 2012). Interestingly, the initial peak was also inhibited after FK866 
treatment (Figure 4.4 A). Indeed, it has been shown recently that FK866 treatment was able 
to decrease NADP(H) levels, which is required for NADPH oxidase, as well as the 
production of ROS, in a time and dose-dependent manner (Roberts et al., 2013). In line with 
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these findings, a recent study has also shown that a reduction in ROS production have been 
observed in FK866-treated monocytes (Schilling et al., 2012), highlighting the involvement 
of FK866 in the inhibition of NADPH oxidase activity.  
Additionally, we showed here that FK866 treatment limited the second NAD
+
 rise (after 4 h) 
similar to others in a model of monocytic cells (Busso et al., 2008; Schilling et al., 2012). 
These data fit nicely with previous results showing that M1-like induced NAMPT expression 
after 4 h of LPS stimulation (chapter 3). Similarly, TNF-α levels were also inhibited by both 
FK866 and DPI in M1-like MФs. The effect of DPI on TNF-α was striking (Figure 4.3 B) as 
DPI treatment mediated NAD(P)H oxidase inhibition led to almost completely knock out 
TNF-α release. Our results seem to be line with others who reported that DPI blocked 
NADPH oxidase-derived IL-6 and TNF-α release (Turchan-Cholewo et al., 2009). It is likely 
that both NAD
+
 and perhaps the free radicals generated by NAD(P)H oxidase might partially 
contribute to TNF-α secretion. These assumptions are supported by others showing that DPI 
treatment inhibited the oxidation of NAD(P)H to NAD(P)
+
 via NAD(P)H oxidase (Riebel et 
al., 2002) and it also has been shown that DPI was able to inhibit the NADPH oxidase-
mediated (oxidative burst) ROS production (Babior, 1999). The induction of ROS has 
previously been shown in neutrophils following PMA stimulation (Kobayashi et al., 1998; 
Babior, 1999). As a consequence, PMA-induced monocyte/macrophage activation caused 
ROS to activate the transcription factor (NF-B; Kaul and Forman, 1996). Therefore, it is 
perhaps not surprising that NADPH oxidase activation has been involved in NF-B-mediated 
TNF-α production (Kaul and Forman, 1996) which, in turn, catalyses ROS production via the 
activation of NADPH oxidases (Kim et al., 2007). On the other hand, the effect of FK866 on 
TNF-α release was not striking although it was able to reduce TNF-α release (Figure 4.4 B). 
These data are supported by several studies showing that FK886 inhibiting intracellular 
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NAD
+
 levels led to block LPS-induced TNF-α release in activated monocyte while we here 
show it in activated macrophages (Rongvaux et al., 2002; Busso et al., 2008; Schilling et al., 
2012). Although the mechanism that links FK866 to NAD
+ 
inhibition and the blockage in 
TNF-α release is not fully explained, there is some evidence implicating NAD+, via NAD+-
dependent enzymes, in a number of immune regulatory pathways including transcriptional 
regulation processes. In particular, the immune regulatory role for sirtuin deacetylase in 
cytokine production has been described (Ziegler, 2000; Guarente, 2006). By using NAD
+
, 
SIRT6 can control the cytokine production via acting as co-activator of NF-B during 
inflammation (Oliver et al., 1999; Bai and Virág, 2012). Therefore, FK866 treatment might 
indirectly affect SIRT activity by decreasing NAD
+
 availability resulting in alteration in the 
expression of pro-inflammatory cytokines. In agreement with this, Bruzzone et al. (2009) 
showed that the exposure of immune cells to FK866 impaired SIRT6 activity-mediated TNF-
α production. It has been consistently shown that SIRT6 blocking or knockdown affects post-
transcriptional expression of TNF-α (van Gool et al., 2009). An alternative mechanism might 
be through the blocking of NAM conversion into NAD
+
, via FK866-mediated NAMPT 
inhibition, resulting in NAM build-up which is known for its anti-inflammatory effect on pro-
inflammatory cytokine production (Ungerstedt et al, 2003). In line with this, Heine et al. 
(1995) reported that blocking of PARP activity by NAM led to inhibited LPS-initiated 
phosphorylation of p36/38 and that this was accompanied by an inhibition of TNF-α and IL-6 
mRNA as well as protein production. Furthermore, NAM displays anti-inflammatory 
properties as it has been shown to protect mice from endotoxin toxicity by preventing TNF-α 
secretion during LPS stimulation (LeClaire et al., 1996; Fukuzawa et al., 1997). Although 
M2-like cells showed a significant increase in NAMPT expression (Chapter 3) the FK866 
treatment exert slight but not significant effect on both NAD
+
 and TNF-α secretion (Figure 
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4.4 C, D). The reason for this discrepancy is not clear and thus further study is required to 
understand the mechanism which underlies these responses. However, we can postulate that 
TLRs and MMP are differentially regulated in both subsets. While PMA was shown to 
upregulate both MMP and TLR4 expression the vitamin D3 was shown to negatively regulate 
MMP and TL4, 2 expressions. Therefore, in M1-like cells, LPS induced a robust secretion of 
TNF-α which was almost completely blocked by DPI and partially inhibited by FK866, 
suggesting that NAD
+
 is also derived from a number of different syntheses and recycling 
pathways.  
Conversely, M2-like cells responded to LPS by releasing a relatively small amount of TNF-α. 
Crucially, this was not associated with any changes in NAD
+
 levels, suggesting that the 
signalling between TLR4 and TNF-α release is via a different pathway compared to M1-like 
cells. TLR4 is known to signal via different intracellular pathways, one of which is NAD(P)H 
oxidase dependent which causes the oxidative burst and ROS production (Park et al.,2004) 
and converts NADH to NAD
+
 (Riebel et al., 2002). Our data suggest that the link between 
NAD
+
 and TNF-α secretion is perhaps complex and may require both NAD+ and the activity 
of NAD(P)H oxidase and could also suggest that NAD
+ 
 is required for glycolysis to mount 
appropriate immune response. It has been recently reported that TNF-α release requires active 
glycolysis and thus, the LPS-induced increase in NAD
+
 levels suggest that this may occur in 
order to provide NAD
+
 for glycolysis perhaps to partially support TNF-α release (Dietl et al., 
2010). Therefore, further work is required to investigate the impact of NAD
+
 modulation on 
glycolysis mediated TNF-α response. The effect of 1D-MT on NAD+ was not correlated with 
TNFα release as the 1D-MT was able to significantly decrease NAD+ whereas it showed no 
effect on TNF-α response. While 1L-MT (1-levo-methyl tryptophan) was shown to inhibit 
IDO1 (Hou et al., 2007) in cancer cells, 1D-MT was shown to selectively inhibit the IDO2 
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activity (Metz et al., 2007). Whilst both isomers block tryptophan activity, the L-isomer 
exhibits a modest effect on tryptophan metabolism compared to the D-isomer which has a 
stronger, more specific effect on IDO activity (Metz et al., 2007; Hou et al., 2007). For these 
reasons, it was chosen in this study. We showed here that 1D-MT was able to decrease NAD
+
 
levels in M1-like under LPS challenge. However, it was unable to inhibit the TNF-α rise, 
suggesting that IDO activation is possibly to maintain NAD
+
 supply. Macrophage exposure 
to LPS enhances the conversion of tryptophan into NAD
+
 in macrophages via IDO activity 
(Wirthgen et al, 2014; Heyes et al., 1997) which is correlated with ROS production that 
occurs in response to PMA and LPS (Babior, 1999; Kaul and Forman, 1996). This might 
explain, at least in part, the increase in NAD
+
 production which was inhibited by 1D-MT 
treatment (Figure 4.5 A). In agreement with this, a recent report has recently shown that the 
inhibition of IDO activity was achieved following 1D-MT treatment resulted in decrease 
NAD
+
 levels (Braidy et al., 2011). In this study, the authors showed that NAD
+
 production 
was attenuated in primary astrocyte cells following 1D-MT application resulted in inhibited 
SIRT1 activation. Given that SIRT1 is known to mediate anti-inflammatory state and IDO is 
known to regulate the flux between pro- and anti-inflammatory cytokine production pathways 
(Pilotte et al., 2012), the current data might support our hypothesis suggesting that the 
inhibition of SIRT1 block anti-inflammatory response as TNF-α release was not inhibited 
after 24 h. Alternatively, IDO activity is known to critically contribute to immune-regulatory 
mechanism in tumour conditions. Inhibition of IDO activity might therefore block immune 
suppression and conversely enhance effective anti-tumour immunity; this might explain, at 
least in part, the results showing that TNF-α was not affected by 1D-MT treatment (Munn 
and Mellor, 2007). 1D-MT was shown to differentially regulate IDO isoforms and that IDO1 
is upregulated with 1D-MT while IDO2 was downregulated (Opitz et al., 2011a) and this 
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might account to the decrease NAD
+ 
production
 
and TNF-α being not affected. Indeed, the 
induction of IDO1 expression by 1D-MT was interpreted to support anti-tumour activity (pro-
inflammation) in immune cells (Opitz et al., 2011a; Metz et al., 2007) and that 1D-MT 
blocks the IDO-mediated immunosuppression mechanism which might partially explain why 
TNF-α release was not affected. In addition, it has previously been reported that IDO 
expression induction is associated with L-isomer but not with D-isomer (Lob et al., 2008). 
These findings might support the superior-anti tumour activity of D-isomer (Opitz et al., 
2011a; Hou et al., 2007). Interestingly, while 1-MT treatment inhibited NAD
+
 levels, it did 
not affect kynurenine production and it conversely caused a slight increase in the measured 
levels in M1-like MФs (Figure 4.6 B) suggesting that kynurenine production might occur 
through different pathway. The discrepancy between the effect of 1D-MT on NAD
+
 and 
kynurenine levels might be related to the induction of a compensatory mechanism that 
increases IDO expression and activity following 1D-MT treatment (Boasso et al., 2009). 
Similarly, Boasso et al. (2009) observed an increase rather than a decrease in kynurenine 
levels after 1D-MT and related the lack of 1-MT effect on kynurenine to the increase in IDO1 
mRNA expression in model was very similar to human model. Also, an increase in 
kynurenine production and IDO1 expression has been shown by Opitz et al. (2011a) who 
related this discrepancy to the superior anti-tumour activity of 1D-MT. Recent studies 
reported that human IDO2 (hIDO2) plays pivotal role in regulating hIDO1 activation 
suggesting a useful therapeutic strategy for immune regulatory disorders (Lee et al., 2014). 
Therefore, further research might be required to understand the immune-regulatory role of 
IDO isoforms in pro-inflammatory M1-like macrophages. 
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In summary, we have demonstrated that pharmacological modulation of NAD
+
 controlled 
TNF-α release. These data serve to reinforce the link between NAD+, TNF-α and 
inflammatory responses. NAD
+
 has previously been shown to have an intimate relationship 
with TNF-α at the transcriptional level and we have further confirmed this link at the release 
level by showing that sirtinol blocks the time-dependent decrease in TNF-α and NAD+ after 
LPS stimulation. It seems that lowering NAD
+ 
might have an anti-inflammatory effect on 
inflammation and thus might be a useful therapeutic tool for inflammation-associated 
cancers. Further clarification of the exact mechanisms involved will be required before 
pharmacological approaches can be tested for immunomodulatory effects. Given that TNF-α 
plays critical role in differentiation, proliferation and apoptosis (Fiers et al., 1999; Karin and 
Lin, 2002), it would be interesting to look at the NAD
+
-TNF-α axis in modulating these 
cellular events in immune cells. In addition, recent focus has shifted to the link between 
metabolism and innate immune responses, with NAD
+
 a key player both as a indication  of 
the metabolic status of a cell and as a signalling molecule. While NAD
+
 is central to the links 
between metabolism and immunology there has been precious little work on NAD
+
 
homeostasis in this context. We believe this may be an interesting avenue to pursue regarding 
different aspects of immune responses. Therefore, we investigated whether NAD
+
 
manipulation can modulate metabolic activity in our model (Chapter 5).
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Figure 4.7 The stimulation of macrophages with LPS promotes NAD
+
 level-mediated TNF-α release 
which in turns activates macrophages for its secretion. FK866 inhibits NAMPT activation resulted in 
inhibition of NAD
+
 levels and TNF-α release. NAD kinase uses NAD+ to produce NADP. NADP 
serves as substrate for NADPH oxidase activity that activates TNF-α release in an NF-B dependent 
manner. The inhibition of NADPH oxidase by DPI (an NADPH oxidase inhibitor) blocks TNF-α 
release. The secretion of TNF-α is regulated by NAD-dependent sirtuin activity. Sirtuin activation is 
inhibited by sirtinol causing a reduction in TNF-α release. 
 126 
 
 
 
 
 
CHAPTER 5 
MODULATION OF NAD
+
 LEVELS 
MODULATES GLYCOLYTIC FLUX IN 
PRO-INFLAMMATORY M1-LIKE 
MACROPHAGES 
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5.1 Introduction 
Recent work has revealed the close link between metabolic state and the phenotype of 
immune cells. Indeed, classically activated, pro-inflammatory (M1) macrophages rely mainly 
on glycolysis whereas alternatively activated, anti-inflammatory (M2) macrophages utilise 
oxidative phosphorylation (Galvan-Pena and O'Neill, 2014). Despite NAD
+
 being required 
for glycolysis activity, little is known about the role of NAD
+
 homeostasis in driving the 
glycolytic phenotype in macrophages. Glycolysis is an inefficient way of generating ATP 
followed by lactate production and it has been found that tumour cells rely mainly on 
glycolysis to generate energy in a phenomenon termed as the Warburg effect (Warburg, 
1956; Van-der Heiden et al., 2009). For the glycolytic flux to be maintained in any type of 
cell, it is essential that NAD
+
 is regenerated from NADH to eliminate the imbalance in the 
redox ratio (NAD: NADH) caused by glycolysis activity (Locasale and Cantley, 2011). This 
can occur via active oxidation phosphorylation (OXPHOS) whereby the malate aspartate 
shuttle gives rise to cytosolic NAD
+
 providing a supply for mitochondrial NADH to support 
OXPHOS under normal conditions (Locasale and Cantley, 2011).  
During non-normal conditions, however, where the glucose uptake increases due to HIF-1α 
activity, this malate-aspartate shuttle gets saturated and thus is no longer able to replenish 
cytosolic NAD
+
. Therefore, NAD
+
 can be alternatively regenerated via LDH which catalyses 
the conversion of pyruvate into lactate (Locasale and Cantley, 2011). LDH overexpression 
has been shown to maintain high levels of glycolysis via increased NAD
+
 regeneration 
supporting the Warburg effect in cells. It is now recognised that glycolysis is induced in 
classically activated (M1) macrophages upon activation which helps to increase a glucose 
uptake as well as the conversion of pyruvate to lactate. This scenario is thought to be 
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committed in classical M1 cells due to the activity of hypoxia inducible factor 1α (HIF-1α), 
as cells are frequently exposed to hypoxic microenvironments, which have been shown to 
play a pivotal role in directing the conversion of pyruvate either to acetyl-CoA or to lactate 
(Kim et al., 2006; Papandreou et al., 2006). In fact, HIF-1α controls this mechanism via 
upregulation of the expression of LDH thus facilitating the conversion of pyruvate into 
lactate (Semenza et al., 1996) and conversely downregulation of pyruvate dehydrogenase 
(Papandreoue et al., 2006) reducing the conversion of pyruvate to acetyl-CoA. As a 
consequence, the tricarboxylic acid (TCA) cycle activity is limited in activated macrophages. 
Also, HIF-1α is known to increase glucose uptake to support glycolytic flux in activated 
macrophages through the up-regulation of glucose transporter 1 (GLUT-1; Chen et al., 2005). 
Indeed, GLUT-1 has been shown to mediate glucose metabolism and ROS production 
supporting the effector phenotype in macrophages (Freemerman et al., 2014).  
In contrast, alternatively activated (M2) macrophages are known to be regulated by OXPHOS 
(Lacy-Hulbert and Moore, 2006). Interestingly, M2 macrophages prefer to use OXPHOS 
which can be induced for longer phases during LPS stimulation (Vats et al., 2006; Rodriguez-
Prados, 2010). Stimulation of M2s with LPS decreases the expression of adenosine 
monophosphate activated protein kinase (AMPK) which supports the metabolic switch from 
glycolysis to OXPHOS (Sag et al., 2008; Krawczyk et al., 2010). AMPK promotes the switch 
towards OXPHOS via upregulating enzymes involved in mitochondrial activity (Winder et 
al., 2000) including succinate dehydrogenase (SDH) as well as proteins involved in 
mitochondrial biogenesis (Vats et al., 2006) such as peroxisome proliferator-activated 
receptor (PPAR-γ). While M2s utilize OXPHOS because this helps with their longer-term 
immune functions (Galvan-Pena and O'Neill, 2014), M1s favour glycolysis because it is 100-
times faster but less efficient than OXPHOS for faster responses and macromolecule 
 129 
 
synthesis (Figure 5.1; Pfeiffer et al., 2001). Notably, LPS stimulation also increases the 
activity of the pentose phosphate pathway (PPP) where glucose is directed at an early branch 
point in the glycolysis pathway to feed into the PPP. The PPP is essential for pentose sugar 
production, which is required for nucleotide biosynthesis (Borregaard and Herlin, 1982) as 
well as for the production of NADPH. NADPH is a critical coenzyme for NADPH oxidase-
mediated ROS production and respiratory burst (Aktan, 2004). 
Recent reports have shown that NADPH oxidase drives glycolysis activity in cancer cells by 
providing additional NAD
+
 (Lu et al., 2012). Suppression of NAD(P)H oxidase by chemical 
inhibitors or knock-down by genetic modification caused a decrease in NADH oxidation 
lowering NAD
+ 
levels leading to a decrease in cellular glycolysis (Lu et al., 2012). Moreover, 
pharmacological modulation of NAD
+
 recycling (NAMPT pathway) by FK866 led to a 
decrease in intracellular NAD(H) resulting in inhibition of glycolysis (Venter et al., 2012). 
On the other hand, inhibition of NAD
+
 de novo synthesis by 1D-MT showed the opposite 
effect on glycolytic flux and oxidative metabolism activity in human lymphocytes 
(Eleftheriadis et al., 2012).  
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Figure 5.1 Schematic diagrams depicting the bioenergetics of the metabolism in classical (M1) 
macrophages versus alternative activation (M2) macrophages. Classical M1s utilize anaerobic 
glycolysis for rapid response and to generate new nucleotides as well as pentose phosphate pathway 
(PPP)-mediated NADPH production, while alternative M2s use oxidative phosphorylation to build up 
reserves of ATP for longer-term function. 
We have shown in Chapter 3 that NAD
+
 levels increased in M1-like cells during LPS 
stimulation, so here we investigated the bioenergetics flux in stimulated M1-like cells using 
an extracellular flux analyser that depends on pH and oxygen sensors to measure ECAR 
(extracellular acidification rate) and OCR (oxygen consumption rate). We have shown here, 
that M1-like MФs increase glycolysis activity, which might support the increase in NAD+ we 
showed earlier, whereas oxidative metabolism is decreased in response to LPS stimulation 
confirming previous findings showing that classical M1s mainly rely on glycolysis for energy 
generation. Our data show that both DPI and FK866, but not 1-MT, were capable of 
decreasing glycolysis activity suggesting that NAD
+
 and thus NAD
+
 homeostasis might 
partially regulate glycolysis activity in macrophages. Given that glycolysis is required to 
support the effector phenotype, pharmacological modulation of NAD
+
 levels
 
might affect at 
least in part the macrophages metabolic phenotype and inflammatory response.  
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5.2. Results  
5.2.1 LPS-induced NAD
+
 affect the NAD
+
/NADH ratio in M1 but not in M2 MФs 
It is well established that classically activated macrophages rely mainly on glycolysis 
(Calder, 1995) for pro-inflammatory responses (Delmastro-Greenwood and Piganelli, 2013). 
In order to sustain flux through glycolysis, it is essential that macrophages maintain sufficient 
concentrations of cytoplasmic NAD
+
 and hence the NAD
+
/NADH ratio, so that glycolysis 
can continue (Newsholme, 1986). Given the unusual changes we observed earlier (Chapter 
3), we decided to try to understand more about the redox-state and the link to glycolysis in 
differentiated macrophages. Therefore, the concentration of NAD
+
 and NADH, plus the 
NAD
+
/NADH ratio, in response to LPS stimulation, was investigated in both macrophage 
subsets. Stimulation with LPS regulates NAD
+
 and NADH levels differentially in a time-
dependent manner in M1-like but not in M2-like MФs (Figure 5.2). In M1-like MФs, NAD+ 
levels showed an early peak after 0.5 h of stimulation, followed by a second sustained rise 
after 4 h, before decaying back after 24 h. However, NADH levels showed a smaller increase 
than NAD
+
 levels after 4 h in response to LPS stimulation before they decreased and stayed 
low for almost the entire period of stimulation. While NAD
+ 
levels increased (Figure 5.2 A) 
by almost 60% compared to NADH levels in M1- like MФs, in M2-like MФs both NAD+ and 
NADH levels were unaffected by LPS stimulation (Figure 5.2 B). The observed increase in 
NAD
+
 levels in M1-like cells might be due to the conversion of NADH to NAD
+
 confirming 
our hypothesis that NADH oxidation might be another source of NAD
+
 generation (Chapter 
4) and thus sustain the intracellular redox ratio. This assumption was supported by 
NAD
+
/NADH ratio results that showed a similar pattern to that of NAD
+
 levels after LPS 
stimulation in M1-like cells only (Figure 5.2 C) with ratio of almost twice as high as that in 
M2-like cells. In these cells, the NAD
+
/NADH ratio was not affected by LPS stimulation. 
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Figure 5.2 LPS stimulation regulates NAD
+
, NADH and NAD
+
/NADH ratio differentially in M1- and 
M2-like macrophages. Differentiated macrophages were stimulated with 100 ng ml
-1
 LPS-K12 for the 
indicated time periods and intracellular NAD
+
/NADH was measured. (A) LPS increases NAD
+
 levels 
in M1-like MФs in a time-dependent manner. (B) LPS does not affect NAD+ levels in M2-like MФs. 
(C) LPS stimulation increases NAD
+
/NADH ratio in M1-like but not in M2-like MФs. Data are 
means ± SE from three independent experiments performed in triplicate. 
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5.2.2 LPS enhances ECAR but not OCR in M1-like macrophages 
We suspected that the increase in NAD
+
 and the subsequent increase in redox-balance might 
lead to distinct glycolytic activity. Therefore, a Seahorse X24 extracellular flux analyser was 
used to test the metabolic profile in differentiated macrophages (see Chapter 2, section 
2.2.12). We decided to continue the current study with the main focus being on M1-like MФs 
because of the limitation of using only M2-like cells for the Seahorse protocol, as M2-like 
cells do not adhere [see chapter 3] to the Seahorse plate.  
The ECAR and OCR were measured after the sequential additions of specific inhibitors 
(Figure 5.3 A, B) including 2-deoxy glucose (an inhibitor of glycolysis), oligomycin (ATP 
synthase inhibitor), rotenone (complex I inhibitor) and antimycin A (complex III inhibitor). 
ECAR measures glycolysis independently of oxygen. To test whether glucose affects ECAR 
and OCR, glucose was added and both ECAR and OCR were measured (Figure 5.3 C, D). 
The increase in ECAR, after glucose addition, reflects the glycolysis rate (see Figure 5.3 A, 
B).  
After oligomycin (an inhibitor of mitochondrial ATP synthase) is injected, the additional 
increase in ECAR is used to calculate maximum glycolytic flux. The treatment with 
oligomycin caused the cells to augment their glycolysis flux to make ATP because of the loss 
in mitochondrial ATP production and so restore cellular ATP homeostasis (Wu et al., 2007). 
However, the injection of 2-DG completely shuts down glycolysis and thus might provide 
additional information about the non-glycolytic acidification. We demonstrated that LPS 
significantly increased all ECAR parameters including maximum glycolytic flux (P = 0.03), 
glycolysis rate (p = 0.012) and glycolysis reserve (p = 0.02) while it significantly decreased 
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(p = 0.018) non-glycolytic ECAR in M1s compared to the resting state (Figure 5.3 E). On the 
other hand, OCR measures oxygen devoted to generate ATP from mitochondrial respiration. 
The measurement after glucose addition represents glucose-stimulated respiration whereas 
oligomycin injection allows calculation of the oxygen used for mitochondrial ATP synthesis. 
The injection of the two inhibitors, rotenone and antimycin A, inhibited the electron flux 
through ETC as well as the TCA cycle and thus provided data about the non-mitochondrial 
oxygen consumption. Our data show that all OCR parameters (coupling efficiency, 
respiration rate and reserve) as well as non-mitochondrial OCR were not affected by LPS 
stimulation (Figure 5.3 F). These data might suggest that glycolysis accounts for the majority 
of the ECAR observed in macrophages post-stimulation with LPS.  
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Figure 5.3 LPS stimulation of macrophages promotes ECAR induction but not OCR in M1-like MФs. 
Differentiated MФs were checked for OCR and ECAR with or without 100 ng/ml LPS (the later 
representing the control). OCR is expressed as the absolute rate in pmol/min, while ECAR is 
expressed in mpH/ min. Both ECAR and OCR were measured after sequential interferences with 
specific inhibitors, using Seahorse XF-24 extracellular flux technology, for glycolysis and respiration, 
respectively. (A) and (B) provide an overview of ECAR and OCR measurement, respectively. The 
baseline refers to ECAR and OCR in the saturation state prior to inhibitor injection. The glycolysis 
and respiration activity was obtained after glucose injection whereas 100 mM 2-DG, an inhibitor of 
glycolysis, was added to correct for non-glycolytic acidification. After inhibition with oligomycin 
(Oligo, 1 µM), an inhibitor of mitochondrial ATP production, maximum glycolysis and coupling 
efficiency (CE) were obtained. LPS stimulation increases ECAR (C) while it decreases OCR (D) in 
M1-like MФs. LPS increases ECAR (E) but not OCR parameters (F). The data are averaged means ± 
SE from 3-4 wells of a single XF24 microplate. Each set of data was measured in triplicates. The data 
were analysed by one way ANOVA followed by the Bonferroni post hoc test and significant 
differences are indicated as *P < 0.05, **P < 0.01, ***P < 0.001.  
A) 
B) 
A) 
A) 
B) 
A) 
B) 
A) B) 
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5.2.3 LPS stimulation increases glycolytic flux and glycolysis capacity in M1-like 
macrophages 
It has recently been reported that exposure of macrophages to LPS leads to a switch from 
mainly OXPHOS to predominantly glycolysis activity for energy production (Krawczyk et 
al., 2010; Galvan-Pena and O'Neill, 2014). As expected, M1-like cells showed clear 
glycolysis activity in response to LPS activation whereas mitochondrial respiration was not 
affected in M1s. When glucose was added to the M1-like MФs the cells exhibited a clear 
increase in ECAR which was inhibited after 2-DG injection eliminating the glucose effect on 
ECAR.  
The results show that glycolytic capacity, glycolysis rate and glycolytic reserve significantly 
increased after 4 h (P = 0.014) reaching maximum levels after 12 h (where maximum was P = 
0.02, glycolysis was P = 0.027 and reserve was P = 0.021) of LPS stimulation compared to 
the control (zero time). Meanwhile, respiration activity (coupling efficiency, CE), respiration 
rate and respiration reserve showed no sensitivity to LPS stimulation (Figure 5.4 A, B, C). 
Indeed, LPS stimulation promoted glycolytic rate and maximum glycolytic capacity 2.5 fold 
more than control samples compared to mitochondrial respiration activity. Therefore, the 
current data strongly agree with others showing that the increase observed in ECAR is 
accounted for by glycolysis activity (Winer and Wu, 2014).  
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Figure 5.4 LPS stimulation of macrophages induces glycolytic metabolism. (A) Glycolysis rate and 
(B) maximum glycolytic activity were induced by LPS exposure whereas coupling efficiency and 
respiration activity was not affected. Inhibition with rotenone/antimycin A (R/A, 1 µM/ 2 µM), 
inhibitors of complex II and III, respectively, were used to calculate reserve capacity. (C) LPS 
stimulation increases glycolytic reserve and do not affect respiratory reserve in M1-like macrophages. 
Each data point represent mean value ± SE, n = 3-4 independent experiments performed in 3-4 wells/ 
treatment. The data were analysed by one way ANOVA followed by the Bonferroni post hoc test and 
significant differences are indicated as *P < 0.05, **P< 0.01, ***P < 0.001. 
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5.2.4 LPS-induced lactate production increases in M1-like but not in M2-like 
macrophages 
Given that glycolysis increases during LPS stimulation, we measured lactate production to 
confirm that this increase is due to lactate production since the lactate reflects glycolytic 
metabolism. Accordingly, a significant increase in lactate production was observed in M1-
like MФs following LPS stimulation (P = 0.03; Figure 5.5 A). 
The lactate production increased during the early stages of stimulation before declining back 
into almost unstimulated levels after 24 h. On the other hand, LPS failed to increase lactate 
levels in M2-like MФs, suggesting that M2-like cells do not produce the majority of their 
ATP via glycolysis (Figure 5.5 B). We show here that lactate levels parallel that of ECAR 
and thus glycolysis increase in response to LPS stimulation. These findings suggest that LPS 
stimulation enhances lactate production due to glycolysis activity in M1-like MФs 
highlighting that M1-like MФs  might switch to glycolytic metabolism for energy production. 
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Figure5.5 LPS stimulation of macrophages promotes lactate production in M1-like macrophages 
during LPS stimulation. In response to LPS stimulation, lactate production was increased in M1-like 
macrophages (A) while it was not affected in M2-like macrophages (B). Each data point represents 
mean ± SE, n = 3-4 independent experiments performed in 3-4 wells/ treatment. The data were 
analysed by one way ANOVA followed by the Bonferroni post hoc test and significant differences are 
indicated as *P < 0.05, **P < 0.01, ***P < 0.001. 
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5.2.5 FK866 and DPI treatment block LPS-induced increases in the NAD
+
/NADH 
ratio in differentiated macrophages 
The conversion of pyruvate, into lactate, helps to maintain the cytoplasmic NAD
+ 
and thus
 
NAD
+
/NADH ratio needed to maintain glycolysis activity. It has been reported that SIRT can 
regulate metabolic reprogramming in MФs by sensing the changes in NAD+/NADH ratio, 
showing that NAD
+
-dependent sirtuin activity mediates the link between metabolism and 
immune response during LPS stimulation in a model of THP-1 sepsis (Liu et al., 2012). 
Therefore, we tested the impact of inhibition by DPI and FK866 on the NAD
+
/NADH ratio 
and on whether it can control flux through glycolysis in M1s during LPS stimulation.  
The NAD
+
/NADH ratio was significantly decreased with both FK866 and DPI, with DPI 
showing higher impact from the early stages of the experiment at 0.5 h, compared to the 
control (P = 0.02), for DPI and FK866 treatment, respectively (Figure 5.6 A). These data fit 
nicely with previous results showing that both the initial peak and the second peak of NAD
+
 
levels were inhibited in M1-like cells treated with DPI and FK866, respectively. It seems that 
NAD
+
 level decrease affected the redox ratio resulting in a clear decrease following 
treatment. These results showed that both DPI and FK866 treatment caused a decrease in 
NAD
+
/NADH ratio due to limitation of NAD
+ 
from NADH oxidation and the recycling 
pathway, respectively. In view of these results and the NAD
+
 availability, we suspect that 
NAD
+
 manipulation might regulate the flux through glycolysis in pro-inflammatory M1-like 
macrophages, so we next decided to investigate the glycolysis activity using the same 
inhibitors. 
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Figure 5.6 Pharmacological modulation with DPI (A) and FK866 (B) decreases the NAD
+
/NADH 
ratio in response to LPS stimulation in pro-inflammatory M1-like MФs. Differentiated M1s were pre-
incubated with DPI (100 µM) or FK866 (100 nM) for 0.5 h and 1 h, respectively, prior to LPS 
stimulation. LPS-induced NAD
+
/ NADH ratio increase is inhibited with (A) DPI and (B) FK866. 
Each data point represents mean ± SE, (n = 3) independents experiments performed in triplicate. The 
data were analysed by one way ANOVA followed by Bonferroni post-hoc test and significant 
differences are indicated as *P < 0.05, **P < 0.01, ***P < 0.001.  
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5.2.6 DPI inhibits LPS-induced glycolysis activity increase in M1-like 
macrophages 
Since we observed that NAD
+
 and the NAD
+
/NADH ratio were decreased by DPI treatment 
in M1-like cells, we suspected that blockage of NADH oxidation might affect the glycolytic 
flux during LPS stimulation and therefore DPI was used in this study. Macrophages were pre-
incubated with 100 µM DPI for 0.5 h prior to LPS stimulation. DPI treatment confirmed our 
prediction as maximum glycolysis and glycolysis rate were significantly inhibited in a time-
dependent manner after 0.5 h (where maximum was P = 0.036, glycolysis was P = 0.02 and 
reserve was P = 0.006) while coupling efficiency, respiration rate and reserve were not 
affected as shown in figure 5.7. The decrease in maximum glycolysis, glycolysis and 
glycolytic reserve decreased to less than 70%, 60% and 50%, respectively (Figure 5.7 A, B, 
C). 
These results are consistent with previous findings showing that glycolysis was inhibited by 
DPI-mediated NADPH oxidase inhibition (Liu et al., 2012). Based on our previous results 
that showed DPI treatment blocks NAD
+
 production, the observed inhibition in glycolytic 
parameters might be due to limit NAD
+
 availability via DPI-sensitive mechanism. 
Consistently, we observed no effect on the respiratory parameters and this because the latter 
is limited in M1-like macrophages and could also suggest that NAD
+ 
production is not linked 
to OXPHOS activity. 
 143 
 
 
 
Figure 5. 7 DPI treatment decreased glycolytic activity in M1-like macrophages. Differentiated cells 
were pre-incubated with DPI (100 µM) or with culture medium for 0 h and 0.5 h prior to stimulation 
with LPS. Both OCR and ECAR were measured in seeded cells after sequential addition of glucose 
(11 µM), oligomycin 1 µM), 2-DG (100 mM) and finally (rotenone/antimycin (1 µM/ 2 µM, 
respectively). The effect of DPI on LPS induced (A) max glycolytic and coupling efficiency, (B) 
glycolysis and respiration rate, (C) glycolytic and respiration reserve. In each case, +/- indicates 
addition/non-addition of DPI/LPS. Data shown are the means ± SE of (n = 3-4) independent 
experiments performed in triplicate. The data were analysed by one way ANOVA followed by the 
Bonferroni test and significant differences are indicated as *P < 0.05, **P < 0.01, ***P < 0.001.  
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5.2.7 FK866 inhibits LPS-induced glycolytic activity increase but not OXPHOS 
activity following LPS stimulation in M1-like macrophages 
Next, we decided to test the impact of FK866 treatment mediated NAD
+
 recycling on 
glycolytic flux in M1-like cells. As we observed that NAD
+ 
production and the redox ratio 
were clearly sensitive to FK866-mediated NAD
+
 inhibition, we assumed that FK866 might 
also affect glycolysis. FK866 is a well-known drug that has entered clinical trials to treat 
tumours (Hasmann and Schemainda, 2003). Venter and others (2012) have recently reported 
that FK886-mediated NAMPT inhibition attenuated glycolysis activity but it did not affect 
OXPHOS in a model of macrophages. We show a similar picture here, with glycolysis 
significantly inhibited with FK866 treatment whereas OXPHOS was not affected in M1-like 
macrophages (Figure 5.8).  
The inhibition with FK866 caused a significant decrease in maximum glycolytic (60%, P = 
0.02) and glycolysis rate (50%, P = 0.012) but it had no pronounced effect on glycolysis 
reserve suggesting that glycolysis is partially dependent on NAMPT-mediated NAD
+
 
production. Indeed, we have shown previously that FK866 treatment blocks NAD
+
 
production under LPS challenge (Chapter 4). It seems that the decrease in NAD
+
 impairs 
redox balance and tips the balance to NADH which might lead to inhibition of glycolysis 
activity. However, FK866 was not able to inhibit glycolysis in resting macrophages. This 
might fit nicely with previous results showing that NAD
+
 increases gradually after FK866 
treatment and further confirm that M1-like are glycolytic. On the other hand, FK866 
treatment does not affect respiration parameters (Figure 8 A, B and C).  
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Figure 5.8 FK866 treatment decreased LPS-induced glycolysis, but had no effect on mitochondrial 
respiration. Differentiated cells were incubated with the presence of FK866(100 nM) or with culture 
medium for 1 h prior to stimulation with LPS for 0 h and 4 h. ECAR and OCR were calculated as 
previously described in Materials and Methods (chapter 2, section 2.2.12). FK866 treatment decreases 
LPS-induced maximum glycolysis activity but not coupling efficiency (A), glycolysis and not 
respiratory rate (B) and glycolytic reserve while it does not affect respiratory reserve in macrophages 
(C). In each case, +/- indicates addition/non-addition of FK866/LPS. Data shown are the means ± SE, 
(n = 3) independent experiments performed in triplicate. The data were analysed by one way ANOVA 
followed by the Bonferroni test and significant differences are indicated as *P < 0.05, **P < 0.01, 
***P < 0.001.  
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5.2.8 1D-MT treatment does not affect LPS-induced glycolytic activity in M1-like 
macrophages 
To further investigate the link between NAD
+
 availibity and glycolysis, 1-MT has been 
used as inhibitor for IDO activity, the rate limiting step for NAD
+
 de novo pathway. It is 
well-known that IDO supports immune regulatory mechanisms through tryptophan 
depletion and/or immune regulatory metabolites produced by kynurenine pathway 
(Orabona et al., 2006; Pilotte et al., 2012). Our data show that 1-MT treatment has no 
effect on glycolysis activity (Figure 5.9) suggesting that NAD
+
 de novo synthesis plays an 
insignificant role in regulating glycolysis flux in M1-like cells. These results might be 
because NAD
+
 de novo synthesis contributes less to NAD
+
 production as only one NAD
+
 
molecule in 60 can be produced through the IDO pathway. Also, our data show that 1-MT 
treatment had no effect on respiration parameters. These observations contradict some 
other recent findings in which the investigators reported that IDO activity inhibition with 
1D-MT led to decrease glycolysis activity while conversely increased mitochondrial 
metabolism in a model of lymphocytes (Eleftheriadis et al., 2012). The contradiction in the 
results might be cell-type dependent response.  
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Figure 5.9 1D-MT treatment causes no effect on anaerobic glycolytic and mitochondrial respiration 
during LPS stimulation in differentiated macrophages. Cells were seeded in a Seahorse V7 plate and 
allowed to differentiate for 72 h prior to ECAR/ OCR measurement. Prior to stimulation with LPS, for 
0 h and 4 h, differentiated cells were pre-incubated with 1D-MT (200 µM) for 2 h. The effect of 1D-
MT treatment on LPS induce max glycolytic actvity and coupling efficiency (A), glycolysis rate and 
respiration rate (B) and finally glycolytic reserve and respiratory reserve in macrophages (C). In each 
case, +/- indicates addition/ non-addition of 1D-MT/LPS Data shown are the means ± SE, (n = 3) 
independent experiments performed in triplicate. 
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5.3 Discussion 
It is now known that classical (M1) macrophages depend strongly on glycolysis while M2s 
(alternative) are known to utilize OXPHOS for energy production. In order to achieve this, 
macrophages need to maintain the redox state (NAD
+
/ NADH ratio) and maintain sufficient 
quantities of NAD(H) in the cytoplasm (Newsholme, 1986). We have shown here that 
NAD(H) levels, at least in part, might affect glycolytic activity in pro-inflammatory 
macrophages suggesting that NAD
+
 levels and thus NAD
+
 metabolism as another factor 
influencing the regulation of energy metabolism under LPS challenge. Our results 
demonstrate that LPS stimulation increases NAD(H) levels and the NAD
+
/NADH ratio in 
differentiated macrophages (Figure 5.2). This increase might be accounted for by the 
NADPH oxidase activity as this increase was inhibited with DPI, an NADPH oxidase 
inhibitor (Figure 5.6 A). These assumptions are confirmed by a recent report in which the 
authors have shown that NAD(P)H oxidase plays a key role in supporting glycolysis by 
increasing NAD
+ 
generation in a model of cancer cells (Lu et al., 2012). In this study, the 
authors relate the decrease in NAD
+
 production to the reduction in NADH oxidation caused 
by DPI treatment leading to a decrease in glycolysis activity. Indeed, our results show that 
NADH levels follow the same trend as that observed for NAD
+
 although NADH levels were 
slightly lower but also might mean that NADH is oxidised to give rise to NAD
+
 in M1-like 
cells during LPS stimulation (Figure 5.2 A). In contrast, the NAD(H) levels and the 
NAD
+
/NADH ratio were not sensitive to DPI treatment in M2-like cells and this might be 
accounted for being NADPH oxidase role missing in this subset. Alternatively, M2-like MФs 
are known to use OXPHOS for energy production. Therefore, LPS failed to induce 
significant changes in NAD(H) levels and hence the NAD/NADH ratio in this subset (Figure 
5.2 B, C). These findings fit well with our previous data showing that DPI treatment was able 
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to block the NAD
+
 increase in M1-like but not in M2-like macrophages. The current data 
might confirm our assumptions suggesting that NADH oxidation through NADPH oxidase 
activity could be another source of NAD
+
 production in M1-like macrophages. We have 
shown here that FK866 treatment caused a decrease in redox (NAD/NADH) ratio (Figure 5.6 
B); this is in agreement with Venter et al. (2014). This could be explained in a variety of 
ways, such as (i) the cellular redox ratio was highly sensitive to FK866 inhibition in M1-like 
cells since the latter produces high levels of NAD
+ 
as we have shown previously (Chapter 3). 
(ii) The redox ratio was affected in M1-like cells because pro-inflammatory macrophages 
depend on glycolytic metabolism to produce energy (Galvan-Pena and O'Neill, 2014) and it 
is known that NAMPT-mediated NAD
+
 production supports glycolysis. Therefore NAD
+
 
levels and thus the NAD/NADH ratio were sensitive to FK866 treatment. While studying 
macrophages using the inhibitor FK866, Vento-Gerad and his colleagues (2014) also 
observed that FK866 was able to decrease NAD
+
 levels and redox ratio in a model of RAW 
264.7 macrophages. They pointed out that cells with a high metabolic activity, such as 
tumour cells, are more sensitive to FK866 treatment because these cells have high NAD
+ 
turnover. Given that NAD
+
 levels are a central link to glycolysis, we decided to evaluate 
metabolic flux in our model using Seahorse technology as we suspected that the increase in 
NAD
+
 we observed might lead to an increase in glycolysis flux in M1-like macrophages.  
The ECAR was investigated while sequentially injecting glucose, oligomycin and 2-DG 
whereas we concurrently measured OCR, replacing 2-DG with a combination of 
rotenone/antimycin. When glucose was added to cells, the ECAR showed a significant 
increase while OCR was not affected with glucose treatment. Our data are consistent with 
others showing that glucose augments ECAR and this was attributed to increased glycolysis 
activity (Winer and Wu, 2014). Oligomycin injection caused M1-like MФs to induce an 
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ECAR increase; this might be attributed to compensation for the loss of mitochondrial ATP, 
due to oligomycin treatment, via the generation of more ATP through glycolysis in order to 
maintain the required cellular ATP levels (Winer and Wu, 2014). In this study, the authors 
found that when cancer cells experience high energy demand due to loss in mitochondrial 
ATP, under hypoxic condition or exposure to oligomycin, cells maintained energy 
homeostasis by boosting glycolysis activity as an alternative mechanism to adapt and survive 
under hypoxic conditions.  
The data shows that LPS stimulation caused an induction of glycolysis parameters (maximum 
glycolytic, glycolysis rate and reserve) and conversely a down-regulation of OXPHOS 
parameters (mitochondrial capacity, respiration rate and respiration reserve) in M1-like MФs 
(Figure 5.4). Accordingly, our data show that glucose failed to increase OCR under the 
experimental conditions and this is supported by recent work (Winer and Wu, 2014). It is 
tempting to speculate that metabolic reprogramming was induced towards glycolytic activity 
by LPS stimulation, suggesting that M1-like MФs are regulated by active glycolysis and not 
OXPHOS. Accordingly, these results are in line with recent reports in which Krawczyk and 
colleagues (2010) reported that TLR-activation mediates metabolic reprogramming in 
dendritic cells (DCs) from OXPHOS to highly active glycolysis. In this pathway, NADH is 
converted back into NAD
+
 via the conversion of pyruvate to lactate (Pearce and Pearce, 
2013). Interestingly, this can occur under conditions where OXPHOS is inhibited (Locasale 
and Cantley, 2011). In fact, this reaction restores NAD
+
/NADH balance which help to 
maintain the NAD
+
 supply for glycolysis (Venter et al., 2014). NAD(H) plays a key role in 
the glycolysis pathway. For instance, it is used as a coenzyme for the GAPDH reaction that is 
mediated the flux through glycolysis (Ying, 2006). As lactate is an alternative measure of 
anaerobic glycolysis (Keuper et al., 2014), we measured lactate production. We demonstrate 
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that lactate increase paralleled glycolysis increase in response to an LPS challenge. Of note, 
TCA-mediated CO2 production can contribute to ECAR, therefore, this could be ruled out by 
observing lactate production, which served to confirm that the observed acidification (ECAR) 
was not due to TCA activity. In response to LPS stimulation, the lactate production was 
increased by 40% compared to the resting state while it was not affected in M2-like MФs in 
both the resting and the activated states (Figure 5.5 A, B). Notably, there was an argument 
that the TCA cycle activity and CO2 release might contribute to extracellular acidification rate 
(ECAR) as a result of CO2 being converted to bicarbonate (Keuper et al, 2014).We and others 
have shown that glycolysis was highly active unlike OXPHOS and this might mean that 
glycolysis pathway is the main source of lactate production (Jensen et al., 1990). Indeed, it 
was reported that if the glucose does not affect or inhibit OCR, as we showed earlier, then 
this might mean that there is no glucose- derived CO2 production (Winer and Wu, 2014). In a 
similar way to DCs and T-cells, pro-inflammatory MФs rapidly utilize glycolysis but not 
oxidative metabolism. Several possible mechanisms might be involved. For example, PMA 
has been reported to promote the induction of the phosphatidyl inositol 3'-kinase/Akt 
pathway (PI3K/Akt; Nishizuka, 1995; Busca et al., 2014) that is required for glycolysis. 
Indeed, PI3K/Akt activity has been shown to enhance TLR-induced glycolysis activity while 
monophosphate (AMP)-activated protein kinase (AMPK) has been shown to antagonise 
glycolysis (Busca et al., 2014). It has been reported that AMPK is regulated by vitamin D3 
treatment is involved in supporting oxidative metabolism in M2s (Sag et al., 2008; Wu et al., 
2015). Although the reason as to why macrophages utilize glycolysis is largely unknown, it 
has recently been speculated that using glycolysis is beneficial from the bioenergetics point 
of view. While glycolysis ability is less efficient at producing ATP than OXPHOS, it actively 
supports an immune response in immune cells because glycolysis is 100 times faster than 
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oxidative metabolism. Also, it was suggested that increased glycolytic metabolism might be 
useful in maintaining immune cell activity during inflammation where ATP production could 
also occur anaerobically. One study has reported that HIF-1α plays a crucial role for DC 
activation in inflammatory states by enhancing LPS- induced glycolysis (Jantsch et al, 2008). 
HIF-1α induces glycolysis flux in activated macrophages by mediating the expression and 
up-regulation of the glucose transporter, GLUT-1 leading to increase glucose uptake (Chen et 
al., 2005). It has been shown that GLUT-1 is translocated from the cytoplasm to the cell 
surface under energy stress, promoting rapid glucose uptake (Artemov et al., 1998; 
Rivenzon-Segal et al., 2003). Indeed, GLUT-1 mediated glucose metabolism induces ROS 
production which supports pro-inflammatory phenotypes in macrophages (Freemerman et al., 
2014). The current findings might suggest that in M1-like MФs NAD+ increases might 
partially support the glycolytic phenotype and perhaps explain why these cells are committed 
to anaerobic glycolysis. Also, the increase in glycolysis flux might be accounted for by a 
different mechanism according to Winer and Wu (2014), who suggested that inhibition of 
mitochondrial ATP synthesis by oligomycin might direct pyruvate away from TCA to lactate 
production. To investigate whether modulation of NAD
+
 availability can control glycolysis, 
we measured LPS–induced glycolytic metabolism in the presence of DPI, an NAD(P)H 
oxidase inhibitor. Interestingly, examination of glycolysis in the presence of DPI led to a 
decrease in maximum glycolysis, glycolysis rate and glycolytic reserve. The maximum 
glycolysis and glycolysis was reduced 2.5-fold in DPI-treated macrophages compared to non-
treated cells. The decrease in maximum glycolytic metabolism is perhaps due to the fact that 
DPI-mediated inhibition limits NAD
+
 availability, allowing reduction of the flux through 
glycolysis pathway. This assumption is supported by NAD
+
/NADH ratio results in which the 
ratio was inhibited by 60% after treatment with DPI. While DPI inhibition did not affect the 
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respiration rate, it was able to slightly increase the respiratory reserve. The observed increase 
in respiratory reserve was probably due to the fact that oxidative phosphorylation still occurs 
because it is necessary for functionality to compensate for the energy required for cell 
viability. Our results might suggest DPI-sensitive NAD
+ 
inhibition as a potential approach to 
control glycolysis flux in macrophages. NAD
+
 can be generated via de novo synthesis from 
tryptophan or via three salvage pathways, and NAMPT salvage is more preferable. To further 
investigate the importance of NAD
+
 availability for glycolytic metabolism, we have 
investigated NAD
+
 biosynthesis pathways by using FK866, NAMPT (salvage pathway) 
inhibitor or 1D-MT, an inhibitor for IDO (de novo pathway). We have demonstrated here that 
FK866-mediated NAD
+
 inhibition was able to attenuate glycolytic metabolism in 
differentiated macrophages. Our results seems to be in agreement with Tan and his team 
(2013), who showed that FK866-mediated NAMPT inhibition caused a reduction in 
glycolysis as a result of the inhibition in NAD
+ 
availability for the glyceraldehyde 3-
phosphate dehydrogenase enzyme. Collectively, the inhibitory effect of FK866 on aerobic 
metabolism, in macrophages, is probably due to the fact that cytoplasmic NAD
+
 levels are 
high in activated macrophages, and it has been found that the NAD
+ 
pool in cytoplasm is 
highly sensitive to FK866-mediated NAMPT inhibition (Pittelli et al., 2010). On the other 
hand, mitochondrial respiration seems to not be sensitive to FK866 inhibition. One possible 
explanation is that the mitochondrial NAD
+ 
pool is independent of NAMPT activity (Yang et 
al., 2007 and Pittelli et al., 2010). In agreement with these findings, Tan and others (2013) 
reported that mitochondrial NAD
+
 represents a small fraction of the total NAD
+
 pool, and 
therefore FK866-mediated NAMPT inhibition may only affect the cytoplasmic NAD
+
 pool 
(Pittelli et al., 2010). Together, both FK866 and DPI treatments were able to inhibit NAD
+
 
production (Chapter 4) as well as glycolytic activity with M1s not being able to boost their 
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OXPHOS activity to meet their energy demands. These findings further confirm that the ATP 
generation is glycolysis-dependent in macrophages, and suggest that NAD
+
 metabolism as a 
potential approach to pharmacologically modulate bioenergetics metabolism in pro-
inflammatory differentiated MФs. 
Finally, the glycolysis and OXPHOS profiles were also investigated using 1D-MT under LPS 
challenge. While 1D-MT-mediated IDO inhibition was able to attenuate NAD
+
 levels the 
inhibitory effect of 1D-MT on glycolytic metabolism was less pronounced. These 
observations might be due to the IDO pathway being less efficient at building up a sufficient 
cytoplasmic NAD
+
 pool to derive glycolytic activity in our model. Indeed, it has been 
reported that one in 60 molecules of NAD
+
 is derived from tryptophan pathway (Horwitt et 
al., 1956), and this could be accounted for by 1D-MT’s effect on energy production in M1-
like macrophages. The treatment with 1D-MT did not affect OXPHOS activity and this could 
be attributed to OXPHOS activity already being inhibited in M1-like macrophages. In 
contrast, a recent study has been conducted on lymphocytes in which the investigators 
showed that 1D-MT was able to induce glycolysis an increase while conversely suppressing 
oxidative metabolism (Eleftheriadis et al., 2012). These findings might be somewhat limited 
as the glycolysis profile in this study is represented by the lactate production which might be 
not sufficient as both TCA and glycolysis could contribute to lactate production. However, 
the discrepancy in the results could be accounted i several ways, namely (i) cell- dependent 
response as M1-like macrophages differ from lymphocytes since these cells are known to 
utilize both TCA and glycolysis for energy production, whereas M1s are mainly glycolytic, 
(ii) different experimental conditions were used in the two studies; we treated our cells with 
1D-MT for 2 h, while Eleftheriadis et al. (2012) incubated the cells with 1D-MT for 96 h and 
finally (iii) there may be differential expression of IDO isoforms (IDO1/IDO2) in response to 
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1D-MT treatment. Opitz and his colleagues (2011b) reported that 1D-MT was capable of 
upregulating IDO mRNA and protein expression in T cells. Further work might be required 
to investigate the counter-regulatory impact of IDO1/IDO2 isoforms on glycolysis activity in 
macrophages.  
In this study, we focussed on how NAD
+
 manipulation modulates glycolysis activity in pro-
inflammatory M1-like macrophages. The most striking findings to emerge were that 
disturbing NAD
+
 production either from NADH oxidation or from NAD
+
 recycling pathway 
caused a decrease in glycolytic metabolism in M1-like macrophages. Also, LPS stimulation 
did not affect oxidative respiration in M1-like macrophages and this might suggest a switch 
towards glycolysis activity. This switch might occur to compensate for energy demand and to 
support M1-like cell immune function, confirming previous findings (Galvan-Pena and 
O'Neill, 2014) in showing that M1 are mainly glycolytic. The impact of NAD
+
 homeostasis 
on glycolysis is not yet fully understood, therefore further study is necessary to address how 
modulation NAD
+ 
homeostasis affects glycolytic enzyme activities. The current results may 
assist in identifying pharmacological targeting for NAD
+
 homeostasis as a useful molecular 
mechanism to modulate bioenergetics metabolism and thus offer a novel approach that might 
assist in restoring metabolic disorder-associated diseases.  
 
 156 
 
 
 
Figure 5.10 Pharmacological modulation of NAD metabolism controls glycolysis metabolism in pro-
inflammatory macrophages. FK866 and DPI (but not 1-MT) inhibits LPS-induced glycolytic capacity 
by controlling the availability of NAD
+
 that is required for deriving glycolysis pathway. FK866= 
inhibitor of nicotinamide phosphoribosyl transferase (NAMPT); DPI = diphenylene iodonium, an 
inhibitor of NADPH oxidase. 1-MT= 1-methyl tryptophan, an inhibitor of IDO pathway; G6P= 
glucose-6-phosphate, G3P= glyceryl aldehyde-3-phosphate; PPP = pentose phosphate pathway. 
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CHAPTER 6 
GENERAL DISCUSSION 
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6.1 Discussion 
This study aimed to explore NAD
+ 
levels and NAD
+
 homeostasis in differentiated 
macrophages and during LPS stimulation to see whether pharmacological manipulation of 
NAD
+
 can control TNF-α release in differentiated MФs using a monocytic THP-1 cell line. 
Whilst THP-1 cells are usually non-adhesive cells that grow in suspension, THP-1 are widely 
used for macrophage differentiation as these cells can be easily differentiated into cells with 
features of MФ-like subsets. Accordingly, the macrophages used in this study were generated 
using pro-monocytic THP-1 differentiation towards macrophages (MФs) with M1-like and 
M2-like characteristics using PMA and vitamin D3, respectively (Figure 6.1). This is 
supported by the changes in cytokine secretion as TNF-α largely increased in M1-like MФs 
in addition to the gene expression profile of NAD
+
 homeostasis enzymes reflected by 
upregulation in CD38 and CD157 that are known as markers of macrophages maturation and 
activation (Frasca et al., 2006). Exploring NAD
+
 homeostasis gene expression revealed that 
M1-like MФs exhibit a differential profile in the resting state and also when stimulated with 
LPS as both CD38 and CD157 expression, well known differentiation markers, were 
upregulated in M1-like MФs while this was not the case with M2-like MФs (chapter 3). In 
support of this, it has been shown that vitamin D3 treatment was capable of upregulating 
CD157 expression. Conversely, PMA was found to downregulate CD157 expression. TNF-α 
release was also increased in M1-like MФs; this is supported by Takashiba et al., (1999) 
suggesting that PMA mediates NF-kB accumulation, metalloproteinases and TLR2/TLR4 
expression (Figure 6.1) that are required for LPS-induced TNF-α secretion. However, TNF-α 
release increased slightly for a short time in M2-like MФs and this might be explained by 
vitamin D3 treatment which was shown to negatively regulate MMPs and TLR4 expression in 
time dependent manner.  
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Several studies have shown that THP-1 cells are the most commonly used cells to study 
monocyte-macrophage immune function since THP-1 cells behave similarly to PBMCs 
(Sharif et al., 2007; Qin, 2008). Indeed, THP-1 cells synthesise and secrete MCSF, IL-8 and 
apolipoprotein E (Menju et al., 1989). Also, THP-1 is similar to primary macrophages with 
regards to LPS-induced gene expression (Verreck et al, 2006). Furthermore, THP-1 
represents a better system than PBMCs as technically speaking; THP-1 minimizes the degree 
of variability in the cell phenotype. Additionally, by following an appropriate procedure, this 
cell line can be recovered without any obvious effect on monocyte-macrophage features and 
cell viability. Using THP-1 as a model offers some advantages that it avoids the difficulties of 
obtaining sufficient quantities of human primary monocytes/macrophages. In addition, donor 
variability and accessibility are additional reasons as to why using THP-1 cells is more 
advantageous over using PBMCs. However, some differences and dissimilarities were 
observed between macrophages and THP-1 derived macrophages in that LPS stimulated the 
expression of certain genes. In fact, Kohro et al. (2004) showed that both apolipoprotein-E 
and MMP 9 are induced in primary macrophages and M1-like MФs whereas the expression 
of IL-1β is conversely upregulated between M1-like MФ and primary macrophages 
suggesting careful interpretation of the results is required before they can be generalised to 
monocytes and macrophages when experiments are done with THP-1 under different 
conditions. There is also a striking difference in the redox balance between THP-1 and 
primary monocyte as suggested recently by Carta et al (2011). The authors reported that 
THP-1 cells show large increase in anti-oxidants systems with high activity of 
cystine/cysteine cycle whereas primary monocytes display low levels of antioxidant systems 
with both cells having low amounts of ROS. Additionally, both ROS and anti-oxidants are 
induced in stimulated primary monocyte while the opposite was true in THP-1, suggesting an 
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important role for redox balance in inflammation. In a study investigating the role of redox 
balance in inflammatory response, Tassi et al. (1999) showed that anti-oxidant enzymes are 
required for regulating ROS-induced IL-1β secretion. Indeed, superoxide dismutase 1 (SOD 
1), a well know anti-oxidant enzyme, has been proven to regulate caspase-1 and consequently 
IL-1β signalling (Meissner et al., 2008). 
On the other hand, Sharif and his team (2007) showed that LPS-induced gene expression in 
THP-1 cells, but not in U937-derived macrophages, are very similar to PBMC-derived 
macrophages, suggesting that THP-1 cells have some value for the study of LPS- and NF-kB-
dependent gene expression. Taken together, it can be concluded that THP-1 cells provide a 
valid and reasonable model for the study of monocyte-macrophage differentiation, 
polarization and immune function. The current study showed that differentiated macrophages 
displayed a differential profile of NAD
+
 levels/NAD
+ 
homeostasis in the resting state and in 
response to LPS stimulation, with M1-like MФs showing higher NAD+ levels in both the 
resting and stimulated states this might suggest that NAD
+
 is pro-inflammatory and that 
NAD
+
 is required for macrophages immune function, particularly, the TNF-α response 
(chapter 3). It was hypothesised that NAD
+
 might be of high importance regarding 
characterization of both subsets. By comparing the effect of FK866 on both subsets in the 
resting state, it was found that FK866 caused a drop in NAD
+ 
levels
 
in M2-like MФs, while it 
conversely caused an increase in NAD
+ 
levels
 
in M1-like MФs. This might suggest that the 
rate of NAD
+
 consumption is high in M2-like MФs as FK866 blocks NAD+ recycling while it 
is low in M1-like MФs. These data are consistent with the observation that M1-like MФs 
significantly increase NAD
+
 while M2-like MФs do not. This is evident as NAD+ generation 
significantly increases in M1-like MФs following NAM application; this was not the case 
with M2-like MФs, again supporting the rapid increase in NAD+ levels seen in M1-like MФs. 
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Based on these observations, it can be concluded that the rate of NAD
+
 
synthesis/consumption might reflect the cellular phenotype and thus the need for a particular 
type of immune response. The study reported in chapter 4 explored the source of NAD
+
 in 
both subsets. Both DPI and FK866 decreased NAD
+
 levels in M1-like MФs but not in M2-
like MФs in response to LPS stimulation, suggesting that NAD+ is produced partially via 
NADH oxidation and partially through the NAD
+
 recycling pathway (Figure 6.1) which 
further confirmed the existence of a link between NAD
+
 and the immune response. While it 
has previously been shown that TNF-α is controlled by NAD+-dependent sirtuin activity at 
the transcription/translational level (van Gool et al., 2009), the data presented herein show 
that NAD
+
 levels seem to correlate with TNF-α secretion levels in M1-like MФs but not in 
M2-like MФs. van Gool and his team (2009) showed that intracellular NAD+, via NAMPT-
mediated NAD
+
 salvage pathway, is required for optimal TNF-α synthesis. This study was 
the first to report that NAD
+
 regulates TNF-α production in a SIRT6-dependent manner, 
suggesting a link between NAD
+
 metabolism and inflammation. However, it was not clear 
how NAD
+
 and TNF-α are linked. Therefore, we showed this link is complex as it is required 
in a combination of pathways including NAD(H) oxidation-dependent mechanisms and 
NAD
+
 salvage-dependent mechanisms suggesting that this link is even more intimate than 
first thought but this time at TNF-α secretion levels and this may also suggest that NAD+ is 
partially required for TNF-α secretion. Collectively, these results might further strengthen the 
link between NAD
+
 homeostasis, inflammation and metabolism in what it has recently 
become known as ‘immunometabolism’. The increase in NAD+ levels was supported by the 
increase in glycolysis that we showed in chapter 5 in M1-like MФs during LPS stimulation 
(Figure 6.1). In support of this, glycolysis activity is decreased when NAD
+
 availability is 
reduced by blocking either NADH oxidation or NAD
+ 
recycling in M1-like MФs (chapter 5). 
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In fact, it has been reported that glycolysis is required for TNF-α production since TNF-α 
secretion and glycolysis was inhibited by lactic acid and acidification (Dietl et al., 2010). In 
chapter 5, LPS stimulation caused an increase in glycolysis parameters (maximum glycolytic 
rate, glycolysis rate and reserve) and conversely decreases in OXPHOS parameters 
(mitochondrial capacity, respiration rate and respiration reserve) in M1-like MФs. In the 
interest of investigating NAD
+
 involvement, we used the same inhibitors for NAD
+
 
generation and glycolysis activity was explored (chapter 5). Although, the mechanism which 
mediates glycolysis increase is not yet fully understood, it is believed that the glycolysis 
pathway is induced in classically activated (M1) macrophages, resulting in lactate production 
(Figure 6.1). Indeed, M1-like MФs always exist in a hypoxic microenvironment and it has 
been shown that they are able to upregulate HIF-1α expression, which supports glycolysis 
flux via the activation of LDH-mediated conversion of pyruvate into lactate. HIF-1α 
increases glucose uptake via upregulation of GLUT-1 expression (Figure 6.1) to support 
glycolytic flux in activated macrophages. In contrast, due to AMPK induction, a switch 
towards OXPHOS occurs in M2-like (alternatively activated) MФs via the upregulation of 
enzymes involved in mitochondrial activity such as succinate dehydrogenases in addition to 
proteins involved in mitochondrial biogenesis such as PPAR-γ (Figure 6.1). Moreover, in 
chapter 5 it was also reported that glycolysis was inhibited by FK866 treatment. Clearly, the 
inhibition of NAMPT-mediated NAD
+
 recycling by FK866 caused a decrease in intracellular 
NAD(H) and the consequent inhibition in glycolysis activity. Similar to other studies, our 
data showed that NAD(P)H oxidase inhibition by DPI caused to decrease NAD
+
 levels-
mediated glycolysis activity. Together, these data might further strengthen the link between 
NAD
+
, the immune response and metabolism and suggest that NAD
+
 might be partially 
involved in TNF-α secretion. It has been reported recently that many metabolic disorders are 
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associated with inflammation. Indeed, immunometabolism is linked to numerous diseases 
such as diabetes, cardiovascular disease and some cancers (Steinberg and Schertzer et al., 
2014). The effects of immunometabolism in macrophages are well known (Steinberg and 
Schertzer et al., 2014). The immunometabolism field is an area of research which has 
recently grown, being associated with metabolic reprograming in MФs which is required for 
their immune function (O'neill et al., 2016). Therefore, it is perhaps not surprising that 
macrophages have recently been shown to play a key role in metabolic disorders (Chawla et 
al., 2011). In fact, sirtuin-mediated deacetylation has been shown to regulate the metabolic 
switch in TLR4-stimulated THP-1 (Liu et al., 2012). The authors of this study showed that 
SIRT1 uses NAD
+
 to regulate the switch from increased glycolysis, supported by HIF-1α 
mediated the up-regulation of GLUT-1, to increased oxidative metabolism, supported by 
PGC-1 α, β and CD36, highlighting a critical for NAD+ in metabolic reprogramming in MФs. 
SIRT1, via sensing NAD
+
 availability, has also been linked to a switch from early to the late 
inflammatory response via regulating TNF-α/IL-1β secretion in NF-KB dependent manner 
(Liu et al., 2011). These observations suggest that NAD
+
/sirtuin might be partially required 
for the link between metabolism and the inflammatory response. Intracellular NAD
+ 
and thus 
the NAD
+
/NADH has been implicated in range of metabolism-associated diseases including 
diabetes and obesity due to its role as co-factor in regulating metabolism and sirtuin activity, 
(Srivastava, 2016). The pathology of these diseases has also been associated with elevated 
levels of TNF-α (Swaroop et al., 2012). We showed that NAD+ levels are associated with 
elevated TNF-α secretion and that the decrease in NAD+ levels caused to decrease glycolytic 
activity. Therefore, modulation of NAD
+ 
levels might be a potential therapeutic means for 
managing MФ functions and thus metabolic diseases. Increasing evidence suggests that 
boosting NAD
+ 
levels, via precursor supplementation (NMN, NA and NR) or by inhibiting 
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NAD
+
-consuming enzymes (CD38, PARP), may have a clinically beneficial influence on 
multiple mitochondrial as well as age-associated disorders (reviewed in Srivastava, 2016). 
Studying the correlation between NAD
+ 
 and TNF-α in MФs might contribute to our 
understanding of immunometabolism which might open the door for treatment for MФs-
derive pathology of chronic diseases including rheumatoid arthritis and Crohn’s disease. 
 
Figure 6.1 Metabolic profiles differ between M1-like (classical) and M2-like (alternative) macrophages 
during LPS stimulation. In M1-like macrophages, PMA induces TLR 4, 2 expression and NAMPT activity 
resulting in TNF-α release induction being supported. TNF-α release is regulated by MMP and SIRT 1, 6 
activities which are sensitive to NAD
+
/NADH ratio. LPS also increase PPP (pentose phosphate pathway) 
mediated NADPH generation that is required for NADPH oxidase activity. This enzyme regulates 
glycolysis via providing additional NAD
+
. Moreover, HIF-1α increases glucose uptake to support 
glycolysis activity in classical M1s. In M2-like macrophages, TLRs are down-regulated by vitamin D3 
resulting in decrease TNF-α release. Similarly, MMP expression is downregulated in vitamin D3 -treated 
cells. In addition, treatment with vitamin D3 leads to upregulated AMPK which is required to drive 
mitochondrial activity in M2s (alternative) via up-regulation of PPAR-γ.  
 165 
 
6.2 Future work 
TNF-α production is implicated in numerous autoimmune and inflammatory diseases 
including rheumatoid arthritis and Crohn’s disease. TNF-α is mainly produced by 
macrophages and therefore it is perhaps not surprising that macrophage-derived TNF-α can 
be deleterious to health. Therefore, given their role in a wide range of diseases, targeting 
macrophage responses, specifically TNF-α secretion, might be beneficial for therapeutic 
intervention.  
Modulation of macrophage responses via the NAD
+
 homeostasis pathway, by lowering 
NAD
+
 levels, might represent an exciting therapeutic aspect for treating a number of chronic 
inflammatory diseases. It was recently shown that manipulating NAD
+
 levels has a potential 
therapeutic impact on metabolic associated disorders (Mouchiroud et al., 2013). Since 
NAD(H) plays important role in regulating metabolic pathways, changes in NAD
+
 levels 
have emerged as a powerful therapeutic tool for metabolic-related conditions via sirtuin 
activity (reviewed in Hall et al., 2013). In addition, NAD(H) has also been linked to pro-
inflammatory TNF-α production via sirtuin activity in MФs (van Gool et al., 2009). We have 
recently shown that pro-inflammatory MФs display unusual changes in NAD+ levels 
suggesting that NAD
+
 levels are pro-inflammatory. The results from this study revealed that 
lowering NAD
+
 levels, by modulating NAD
+
 homeostasis, limited TNF-α secretion in a time- 
dependent manner in pro-inflammatory MФs, highlighting a potential therapeutic tool for the 
treatment of MФs-derive inflammatory pathologies. Notably, the link between pro-
inflammatory MФs and chronic disease, including Crohn’s disease (CD) and rheumatoid 
arthritis (RA), has been known for some time (Kinne et al., 2000; Grip et al., 2003). Indeed, 
pro-inflammatory MФs have the ability to contribute to the pathology of RA via the 
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production of a plethora of inflammatory mediators including pro-inflammatory cytokines 
(IL-6, IL-8, IL-18, IL-1β and TNF-α) and matrix metalloproteinases (MMP-1 and MMP-3; 
reviewed in Kinne et al., 2000). It is also worth noting that, MФs derive cytokine production 
results in Th1/Th17 axis that produces IL-17/IL-15 which, in turn, supports MФ activation, 
resulting in a positive feedback loop and thus sustaining the severity of the diseases (Mcinnes 
et al., 1997; Aarvak et al., 1999). 
The M1 pro-inflammatory cytokine, TNF-α, has been shown to have primary role in the 
pathology of RA via ROS production (Miesel et al., 1996) as well as stimulation of MMP-1, -
2, -3 secretion mediated articular destruction (reviewed in Maruotti et al, 2007). Similarly, 
IL-1β secretion is responsible for the synovial destruction in RA by inhibiting proteoglycan 
synthesis and degradation proteoglycan (von den Hoff et al., 1995) and the secretion of 
MMP-1 and MMP-3 (Arend et al., 1998). Therefore, manipulating NAD
+
 homeostasis might 
offer a conventional anti-cytokine therapy towards TNF-α/IL-1β, produced by pro-
inflammatory M1s, for the treatment of M1-mediated RA. Since NAD
+
 levels are limiting for 
sirtuin activity which is required for TNF-α secretion, lowering its levels, either via NADH-
oxidation or NAD
+
-salvage dependent mechanism as we have shown previously, might offer 
a powerful therapy for treatment of RA or any inflammation-related disease. In fact, over 
expression of SIRT1 led to increase TNF-α secretion in rheumatoid arthritis synovium, as 
was found by Niederer et al. (2011). The authors found that SIRT1 is constitutively up-
regulated in synovial tissue and thus SIRT1 silencing via siRNA or inhibition of enzymatic 
activity via SIRT inhibitors decreased LPS-induced TNF-α in monocyte freshly isolated from 
RA synovial tissue. In fact, blockage of TNF-α, via antibody neutralisation treatment, has 
been proven to inhibit collagen-mediated arthritis and supress inflammation in human/murine 
arthritis (Schadlich et al., 1999) suggesting a critical role for this cytokine in progression of 
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RA. Indeed, it has been hypothesised that therapeutic targeting of TNF-α has major 
importance for RA as TNF-α inhibition inhibited pro-inflammatory cytokines including IL-1, 
suggesting that RA might be TNF-α dependent (Feldmann et al., 1996). In addition, M1s are 
also responsible for RA via the chemokines secretion including CXCL13, also known as B 
cell-attracting chemokine 1 (BCA-1), which is constitutively expressed in RA tissue, 
suggesting a pathogenic role (Carlsen et al., 2004). The chemokine signalling is controlled by 
CD38, which has been shown to regulate chemotaxis signalling to CCL2, CCL19, CCL21, 
and CXCL12 in immature and mature DCs highlighting a regulatory role for CD38 on 
adaptive immunity by controlling DCs trafficking (Partida-Sanchez et al., 2004). We have 
shown that M1s largely express CD38 in both the activated and the resting state. As CD38 
acts one of the main NAD
+
 consuming enzymes, its manipulation via lowering NAD
+
 levels 
might offer a powerful therapeutic means for regulating MФ trafficking and consequently 
adaptive immunity. Given that NAD
+
 levels are associated with TNF-α response in pro-
inflammatory MФs and that NAD+ levels are required for NAD+-dependent (sirtuin/CD38) 
activity, lowering its levels is a promising therapeutic regimen for anti-macrophage function 
which can also involve in regulation of adaptive immunity as a treatment for chronic 
diseases, in particular, RA. It is reported that NAD
+
 levels differ between M1-like (pro-
inflammatory) and M2-like (anti-inflammatory) macrophages. What is now needed is further 
systematic characterisation of NAD
+ 
homeostasis during macrophage differentiation. 
Therefore, it would be of interest to explore similar studies to those reported in this thesis on 
naturally occurring M1s, M2s and the sliding scale of functionally polarized subsets (M2a, 
M2b and M2c). Glycolysis is required for M1s (classical activation) and this was inhibited in 
this study in the FK866-mediated NAD
+
 recycling mechanism and in the DPI-mediated 
NADH oxidation mechanism. To expand this, it would be of interest to explore NAD
+
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therapeutic targeting on bioenergetics metabolism mediated M1 polarization. Recent work 
has shown that metabolic reprogramming is essential for M1-like and M2-like polarization 
and activation (Haschemi et al., 2012). In a similar context, further work needs to be done to 
establish whether manipulation of NAD
+ 
homeostasis could modulate macrophage 
differentiation and maturation. The results in this study showed that the trend of NAD
+
 
homeostasis gene expression was similar to that of TNF-α response, suggesting that both 
might be correlated. The next step would be to explore the role of NAD
+
 homeostasis gene 
expression over longer time points and whether this can contribute to endotoxin tolerance in 
macrophages. A recent report has shown that elevation of NAD
+ 
and sirtuin is required for 
epigenetic reprogramming during endotoxin tolerance in a model of human sepsis (Liu et al., 
2011). More research is needed to truly understand the role of NAD
+
 and thus NAD
+ 
homeostasis in TAMs and whether NAD
+
 targeting would be of interest for anti-cancer 
therapies. For example, a switch in polarization between M1s and M2s, via boosting NAD
+
 
levels activates sirtuin-mediated metabolic reprogramming, might be a useful tool for anti-
cancer therapy. According to the results reported in chapter 4, NAD
+ 
increases after 1h 
sirtinol treatment which further confirm the contradictory effect of sirtuin on pro-/anti-
inflammatory responses and raise the importance of the NAD
+
-sirtuin axis in treating 
inflammation-associated tumour conditions. It has recently been shown that sirtuin 1, 6 
activity are linked to metabolism reprogramming in activated macrophages (Liu et al., 2012). 
Since NAD
+ 
is a central link between metabolism and inflammation, the NAD
+
-sirtuin axis 
may be critical for coupling metabolism reprogramming to the immune response. It would be 
worthwhile to further investigate this link and to understand this process and whether it could 
be useful for a potential pharmaceutical strategy that may target immune function in 
macrophages. Given the data show that NAD
+ 
levels are not decreasing after 1h sirtinol 
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treatment, it is tempting to investigate the effect of NAD
+
 on TNF-α gene expression during 
the experimental studies. Our data might shed light on the importance of intracellular 
NAD(H) changes in supporting the energetic profile to mount an effective immune response 
in MФs. A recent study has revealed the importance of glycolysis metabolism in pro-
inflammatory cytokine signalling (Delmastro-Greenwood and Piganelli, 2013). Given that 
NAD
+ 
sensing by sirtuin activity is critical in linking inflammatory response and metabolic 
reprogramming (Liu et al., 2012), further studies need to be carried out in order to investigate 
NAD
+
 and glycolysis and formulate a useful strategy to modulate macrophage polarization 
and inflammatory immune functions such as cytokine production, phagocytosis and 
migration, etc. We found both CD38 and CD157 display differential expression between M1-
like and M2-like MФs. It would be of interest to explore expression and over-expression of 
those proteins in reverting M1/M2 polarization in TAMs, which are known to play a pivotal 
role in linking inflammatory response to tumours and are characterised by M2 polarisation-
mediated tumour progression. Thus, it would be interesting to assess the effect of CD157 and 
CD38 overexpression in reprogramming M1/M2 polarisation to hopefully provide anti-
tumour treatment. Furthermore, it would be interesting to know the effect of CD38 on TNF-α 
response in both subsets. One way to expand our knowledge on this enzyme would be to 
silence its expression by using small interfering RNA (siRNA). Also, further work regarding 
the impact of CD38 deletion macrophages or inhibition in both in vivo and in vitro model on 
macrophages differentiation, migration and polarization would be beneficial. NAD
+
 was 
reported to achieve immune regulatory function. For instance, it was reported that NAD
+
 can 
function occasionally as a cytokine and that this occurs when the secretion of NAD
+
 increases 
intracellular calcium in neighbouring cells resulting in an increase in their proliferation. In 
addition, CD38 is reported to be functionally involved in IL-12 induction in human 
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monocyte-derived DCs (Fedele et al., 2004). It perhaps not surprising that CD38 is 
implicated in immune regulation since CD38 is known to regulate the metabolism of adenine 
based-second messenger mediated calcium signalling (Fliegert et al., 2007). Therefore, future 
work should be directed towards understanding the role of CD38 in LPS-induced expression 
and the release of TNF-α in vivo and in vitro in macrophages. Additionally, we observed in 
this study that FK866 induced NAD
+
 rises or inhibited NAD
+
 turnover in M1-like but not in 
M2-like (chapter 3) macrophages suggesting a fundamental difference in NAD
+
 homeostasis 
between the two subsets. Further research is required as to how this occurs and also further 
research needs to be carried out in order to understand whether the differences in NAD
+
 
homeostasis are related to the effector phenotype. This might open the door for 
pharmacological studies to achieve the switch between subsets M1-like to M2-like 
macrophages which might be useful for treating diseases that have been associated with one 
phenotype or another. Finally, according to results reported in chapter 4, the inhibition of 
IDO by 1D-MT decreased LPS-induced NAD
+
 levels while it failed to affect the kynurenine 
pathway. In fact, IDO exists in two isoforms; IDO1 represents the classical form that is 
involved in the kynurenine pathway in addition to possessing anti-tumour activity. The two 
isoforms have been shown to display counter-regulatory roles in different inflammatory 
settings, mediating the flux between pathways that lead to pro-/anti-inflammatory cytokine 
production (Opitz et al., 2011a; Pilotte et al., 2012), understanding the cooperation between 
IDO1 and IDO2 could be useful strategy in order to characterise macrophage polarisation and 
thus further work is required to address this issue. Also, the opposing effect of IDO on 
glycolysis has been recently reported (Eleftheriadis et al., 2012). Therefore, future work may 
seek to understand the NAD
+
-IDO axis on glycolysis in primary macrophages. 
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